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Abstract 50 
Limitation of functional ability is a major feature of Huntington’s disease (HD). The 51 
International Parkinson and Movement Disorder Society (MDS) commissioned the appraisal 52 
of the use and clinimetric properties of clinical measures of functional ability that have been 53 
applied in HD studies and trials to date, to make recommendations regarding their use based 54 
on standardized criteria. After a systematic literature search, we included a total of 29 clinical 55 
measures grouped into two categories: 1) performance*based measures (e.g., balance, 56 
walking, reaching/grasping), and 2) rating scales. Three performance*based measures are 57 
rated as “recommended”: the Tinetti Mobility Test for screening of fall risk and for severity 58 
assessment of mobility in patients with manifest HD (up to stage III); the Berg Balance Scale 59 
for severity of balance impairment; and the Six*Minute Walk Test for assessment of walking 60 
endurance (severity) in HD subjects with preserved ambulation. No rating scale targeting 61 
functional ability reached a “recommended” status, either for screening or severity 62 
measurement.  63 
 64 
The main challenges identified in this review include applying widely accepted conceptual 65 
frameworks to the identified measures, the lack of validation of clinical measures to detect 66 
change over time, and absence of validated measures for upper limb function. Furthermore, 67 
measures of capacity or ability to perform activities of daily living had ceiling effects in 68 
people with early and pre*manifest HD. We recommend that the MDS prioritize the 69 
development of new scales that capture small but meaningful changes in function over time 70 
for outcome assessment in clinical trials, particularly in earlier stages of HD.  71 
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Introduction 72 
The ability to perform daily life activities depends on the integration of motor, cognitive and 73 
behavioral functioning. These domains are progressively impaired in Huntington’s disease 74 
(HD). A measure of functional ability based on key life activities is thus an attractive outcome 75 
in clinical studies, namely for treatment trials.  A single measure pertinent to patient overall 76 
function would be useful to capture changes occurring simultaneously in the different 77 
symptom domains in HD. Further, functional ability measures are valued as an outcome for 78 
drug development by regulatory agencies.
1
 79 
 80 
There is a need to identify and critically appraise the measurement properties of clinical 81 
measures currently used to capture functional ability in people with HD to inform optimal 82 
application in clinical research. The scope of this review is directed towards physical function 83 
and included a wide spectrum of clinical measures from those capturing motor tasks such as 84 
walking and balance ability, to those assessing the ability to perform activities of daily living 85 
(ADL).  86 
 87 
The current review aims to provide recommendations and identify gaps in the use and 88 
validation of these functional measures that have been used in HD studies and trials to date. 89 
Such information will inform the field, identifying where additional testing of measurement 90 
properties or development of new measures may be required. 91 
 92 
METHODS 93 
We followed the methodology proposed by the MDS Committee on Rating Scales 94 
Development described elsewhere,
2
  and includes i) Organization and Critique Process, ii) 95 
Selection of Scales, iii) Inclusion/Exclusion for Review, iv) Criteria for Rating Scales 96 
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Recommendation (Table 1). For selection of measures, the keywords selected for this review 97 
were “Huntington*” OR ”Westphal variant” OR “juvenile Huntington*”, and the terms 98 
“scale” OR “questionnaire” OR “index” OR “measure” as well as keywords: “function”, 99 
“activit* daily li*”, “capacity”, “*ability”, “impairment”. Manuscripts published before 100 
October 17, 2016 were retrieved using the above search strategy and thoroughly screened by 101 
the chair of the sub*committee (T.A.M.) to ascertain which clinical measure had been used in 102 
each study. To aid our categorization of clinical measures in this review, we applied a widely 103 
accepted classification of the health components of functioning and disability: The 104 
International Classification of Functioning, Disability and Health (ICF).
3
 The ICF defines: 1) 105 
impairments or problems in body function or structure such as a significant deviation or loss, 106 
2) activity or the execution of a task, 3) and participation or involvement in a life situation.
3
 107 
By consensus, we included clinical measures in this review that captured a) activity or the 108 
execution of a task or tasks, and b) participation or involvement in a life situation. 109 
 110 
Identified Clinical Measures and Their Utilization in Clinical Research 111 
A total of 47 potentially relevant clinical measures were identified. After screening for 112 
exclusion criteria with abstract screening and in*depth review, a total of 29 measures were 113 
included and divided in performance*based measures defined as functional assessments based 114 
on the live performance of a task (e.g., balance, walking, reaching/grasping) (n=17) and rating 115 
scales (n=12) capturing the assessment of various aspects of functional ability based on recall. 116 
(See 	
	
	 for more details) 117 
 118 
Critique of Measures of Functional Ability  119 
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We provide a summary description of the performance*based measures and rating scales 120 
classified as “recommended” or “suggested”. See 	
	
	 for a full 121 
description of all clinical measures included for full review, including those that were 122 
included in the “suggested 		” or “listed” categories. 123 
1) Performancebased measures 124 
“RECOMMENDED” 125 
Tinetti Mobility Test (TMT) 126 
The TMT is a 16*item clinician*administered performance measure, which consists of balance 127 
and gait subscales that measure static and dynamic balance. It was originally developed to 128 
measure balance and screen for risk of falls in the elderly,
4
 but has been used in other patient 129 
populations.
4
 During the 10*15 minute test, patients perform a series of balance and walking 130 
tasks and are rated on a 0*2 scale based on qualitative assessment of performance.
4
 The TMT 131 
has been used in several studies in HD and demonstrates good test*retest reliability in early*, 132 
mid*, and late stage HD (ICC = 0.8*0.9).
5, 6
 Higher scores in the TMT correlated positively 133 
with spatio*temporal measures of gait (e.g., velocity r=0.68; stride length r=0.74), with higher 134 
scores of the UHDRS*FAS (r=0.44) and UHDRS*TFC (r=0.42) and lower scores of the 135 
UHDRS*Total Motor Score (TMS) (r=*0.59).
5, 7, 8
 The TMT has demonstrated responsiveness 136 
in the context of interventional studies, including an intensive rehabilitation intervention 137 
program in patients with HD stages I–III (pre= 15.97, post=20.79, p<0.001), 
9
 and off* (17.09 138 
± 4.04) and on*tetrabenazine (19.91 ± 3.53, p<0.02) study of manifest HD patients. 
10
 139 
However, there was no significant change in the TMT following a video*based balance 140 
training program.
11
 A cut*off score of 21 has 74% sensitivity and 60% specificity in 141 
identifying fallers in HD.
5
 142 
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Recommendation: The TMT is “recommended” for assessment of mobility in patients with 143 
manifest HD (up to stage III) and “recommended” for screening for risk of  falls . 144 
 145 
The Berg Balance Scale (BBS) 146 
The BBS is a performance measure consisting of 14 subtests of various activities related to 147 
balance that takes 10 to 15 minutes to complete. These activities include static postures (e.g., 148 
sitting, standing), transitions (e.g., sitting to standing, transferring between chairs), and 149 
challenging positions (e.g., standing with eyes closed). Quality of performance for each item 150 
is scored using a 4*point scale, with higher scores indicating better balance, and a possible 151 
maximum score of 56. Although originally developed to measure balance in older people, the 152 
BBS has been widely used in HD, although it has limited applicability in non*ambulatory HD 153 
due to the nature of the activities.
6, 12*19
 The available clinimetric data show that it has good 154 
test*retest reliability in both pre*manifest (ICC=0.86) and manifest HD (ICC=0.96).
6
 A 155 
minimal detectable change (MDC) of 5 in people with manifest HD has been reported.
6
 156 
Convergent validity has been reported between the BBS and the HD*ADL (r= *0.47), UHDRS 157 
TFC (r=0.60
19
 and r=0.43
7
),  UHDRS*FAS (r=0.48)
7
, and UHDRS*TMS (r= *0.55).
7
 158 
Sensitivity to change following treatment withdrawal (tetrabenazine) was reported in a small 159 
open*label cohort.
14
 A cut*off score of 40 was used as a cut*off to predict being a “faller” for 160 
a plotted probability of  60%.
86
 161 
Recommendation: The BBS is “recommended” for assessing severity of balance impairment 162 
in ambulatory HD. The BBS is “suggested” for screening for fall risk, as no sensitivity or 163 
specificity data for falls have been reported. 164 
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 165 
The SixMinute Walk Test 166 
The Six*Minute Walk test measures how many meters an individual can walk in 6 minutes. 
20, 
167 
21
 Two practice tests are recommended, but not always carried out.
22, 23
 It has been applied as 168 
a measure of endurance in neurological conditions, in contrast to shorter walk tests that 169 
generally measure velocity of walking speed.
6
 It has been used in patients with pre*manifest 170 
and manifest HD, although it cannot be used for those who are non*ambulatory. Excellent 171 
test*retest reliability data have been reported in pre*manifest (ICC = 0.98) and manifest HD 172 
(IC=0.94; early and late HD = 0.97, and mid*stage HD=0.86).
6, 24
 It is unclear how values 173 
discriminate among pre* and manifest HD severity levels as there is an overlap of the 95% 174 
confidence interval (CI) around mean values in both groups. On the other hand, values may 175 
separate pre* and early manifest HD from mid* to late stage HD.
6
 Low correlations have been 176 
reported between the Six*Minute Walk Test and the UHDRS*FAS,
7
 but higher correlations 177 
are not expected due to the limited overlap of the measure constructs. The MDC has been 178 
reported to be 39.2 meters for pre*manifest HD and 86.6 meters for manifest HD (range: 56.6 179 
to 126.1 meters).
6
 180 
Recommendation: The Six*Minute Walk test is “recommended” for the assessment of 181 
walking endurance (severity) across HD severity. 182 
 183 
“SUGGESTED”  184 
Timed ‘up and go’ Test (TUG)185 
The TUG is a simple and quick (<3 minutes) to use test that assesses mobility, balance and 186 
risk of falls. Although not specifically developed for use in HD, it has been used in pre*187 
manifest and manifest HD to measure severity and screen for risk of falls.
13, 25
 The TUG 188 
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measures the time it takes for a patient to rise from a chair, walk three meters, turn around, 189 
walk back to the chair, and sit down. One practice test is recommended before scoring the 190 
test.
25
 Mean scores for patients with manifest HD range from 9*17 seconds 
6, 19
 and a cut*off 191 
score of  14 seconds has been reported to predict being a “faller” for a plotted probability of  192 
60%.
13
 Test*retest reliability in HD has been shown to be excellent (ICC = 0.93 [pre*manifest 193 
HD], 0.96 [manifest HD]) and the MDC has been reported to be 1.34 seconds in pre*manifest 194 
HD and 2.98 seconds in manifest HD.
6
 The TUG was not statistically significantly correlated 195 
with the UHDRS*TMS or the UHDRS*TFC and correlated weakly with the UHDRS*FAS (r= 196 
*0.33, p<0.01).
7
 Pre*post scores improved by an average of 1.3 seconds following training in a 197 
non*controlled study, that follow within the MDC.
26
 The TUG can be used in early to mid*198 
stages of HD, but not in pre*manifest or late stage HD, and it appears to be sensitive to 199 
disease progression, but does not discriminate between disease subtypes.
6, 19, 27
 200 
Recommendation: The TUG is “suggested” for assessing severity of balance and mobility, 201 
and “suggested” for screening for fall risk. There is no sensitivity or specificity data for the 202 
reported cut*off point. Construct validity needs further assessment. 203 
 204 
The TenMeter Walk Test 205 
The Ten*Meter Walk test is a quick and easy performance*based measure that assesses 206 
walking speed. The score is based on the mean of two tests. The test has been used in pre*207 
manifest and manifest HD with varying walking speeds: self*paced
6, 7, 24
 and fast*paced.
6, 17, 24
 208 
Test*retest reliability has been shown to be good in both pre*manifest and manifest HD for the 209 
self*paced version.
6
 For the self*paced version there was no correlation with the UHDRS*210 
TMS, a weak correlation was reported with the UHDRS*FAS (r=0.35, p<0.01) and none with 211 
the UHDRS*TFC.
7
 The fast*paced version of the test has been shown to be sensitive to 212 
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change following a rehabilitation program intervention in mild to moderate manifest HD 213 
(improvement of 0.27 m/s).
17
 Following a 12*week community*based exercise program there 214 
was no significant change for either the self* or fast*paced versions.
24
 215 
Recommendation: The Ten*Meter walk test is “suggested” for assessing walking speed in 216 
manifest HD. The vast majority of the clinimetric data sustaining this recommendation was 217 
obtained using the self*paced version. 218 
 219 
Four Square Step Test (FSST) 220 
The FSST is a 5*10 minute test of dynamic balance. The FSST clinically assesses a patient’s 221 
ability to step over canes positioned in a cross shape in three directions in a set sequence: 222 
forward, sideways, and backwards. The test was not specifically developed for use in HD, but 223 
has been used in three studies in HD, and some clinimetric data are available in pre* and 224 
manifest HD.
6, 8, 11
 Test*retest reliability has been reported to be excellent in pre*manifest HD 225 
(ICC=0.91), and good in manifest HD (ICC=0.78).
6
 The MDC is higher in manifest HD 226 
(15.2) than in pre*manifest HD (1.9).
6
 Moderate to high correlation has been shown between 227 
the FSST and the ABC (Pearson correlations: –0.57; p<0.05); the Tinetti Mobility Test 228 
(Pearson correlations: –0.67, p<0.01), and gait velocity (Pearson correlations: –0.69, 229 
p<0.01).
8
 The FSST has not been shown to be sensitive to change in one exercise study.
11
 230 
Recommendation: The FSST is “suggested” for assessing dynamic balance in HD  231 
 232 
Mini Balance Evaluation Systems Test (MiniBESTest) 233 
The Mini*BESTest is a 14*item measure of dynamic balance. Derived from the Balance 234 
Evaluation Systems Test (BESTest), factor analysis was used for item reduction to include 235 
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dynamic balance only, and to improve clinical utilization.
28
 Administered in 10*15 minutes, 236 
the Mini*BESTest evaluates domains of postural control. Each question is rated from normal 237 
to severe and scored between 0 and 2, for a maximum total score of 28 points. The test was 238 
not specifically developed for HD, and has not been assessed comprehensively across stages 239 
of HD. The test is not applicable to non*ambulatory patients.
29
 Convergent validity has been 240 
shown between the Mini*BESTest and the ABC (r
2
=0.45), UHDRS*TFC (r
2
=0.75) and 241 
UHDRS*TMS (r
2
=0.68).
29
  242 
Recommendation: The Mini*BESTest is “suggested” for assessing severity of balance 243 
impairment in HD, as it has been used in only one study with a very small sample size across 244 
HD severity with a partial clinimetric assessment. 245 
 246 
Physical Performance Test (PPT) 247 
The PPT is a ten*minute test, which assesses multiple domains of physical function using 248 
observed performance of tasks that simulate activities of daily living (ADL) of various 249 
degrees of difficulty (writing, eating, dressing, walking, and climbing stairs).
30
 Each activity 250 
is timed and rated from 0*4, a higher score indicating better physical performance. The test 251 
was not specifically developed for use in HD, but some of its clinimetric properties have been 252 
assessed in both pre* and manifest HD. Good test*retest reliability has been recorded in pre*253 
manifest HD (ICC = 0.76) and excellent reliability in manifest HD (ICC=0.95). The MDC 254 
was 3 points for pre*manifest HD and 5 points for manifest HD respectively.
6
 Convergent 255 
validity has been reported in manifest HD between the PPT and the UHDRS*TMS (r = *0.41 256 
n=63, p<0.01), the UHDRS*FAS (r = 0.59, p<0.01); and the UHDRS*TFC (r= 0.48, 257 
p<0.05).
7
A ceiling effect has been reported in pre*manifest HD.
6
 It has also been shown to be 258 
valid in patients with cognitive impairment.
31
 259 
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Recommendation: The PPT is “suggested” for assessing severity of impairment of physical 260 
function in performance of tasks that simulate activities of daily living.  261 
 262 
Sixcondition Romberg test  263 
The six*condition Romberg test is a 5*minute easy to administer performance*based measure 264 
of balance developed in the context of myelopathies and neuropathies with an associated 265 
sensory dysfunction. The amount of time the patient maintains the position without loss of 266 
balance for 6 standard conditions is recorded, for a maximum score of 180 seconds. Higher 267 
scores indicate better balance. The test has been used in some HD studies 
6, 10
 and the 268 
clinimetric data available document good test*retest reliability in both pre*manifest 269 
(ICC=0.73) and manifest HD (ICC=0.89).
6
 The six*condition Romberg test is a valid tool that 270 
can be used across all stages of HD provided that the patient is ambulatory as it is likely to 271 
have floor effects in non*ambulatory patients.
6
 It has not been shown to be sensitive to change 272 
in treatment.
10
 People with pre*manifest HD (158.8±22.2) have higher scores (better 273 
performance) than those with manifest HD (70.0±41.1).
6
 274 
Recommendation: The Six*Condition Romberg Test is “suggested” for assessing severity of 275 
balance impairment in HD 276 
 277 
2) Rating Scales 278 
 279 
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 “SUGGESTED”: 280 
The Unified Huntington's Disease Rating Scale (UHDRS)  Total Functional Capacity 281 
(TFC) 282 
The UHDRS*TFC is part of a multi*component rating scale originally designed to 283 
prospectively evaluate all patients with HD and individuals at risk for HD.
34
 It assesses 284 
capacity as opposed to actual performance, and consists of a 5*item interview between a 285 
clinician, and the patient and a person familiar with the patient’s functioning. It takes < 5 286 
minutes to complete and covers basic activities of living: occupation, handling finances, 287 
domestic responsibilities, ADLs such as eating, dressing, bathing, and level of care (home or 288 
facility).  A higher score indicates better functional capacity. The UHDRS*TFC has been used 289 
in pre*manifest and manifest HD populations in multiple observational studies and 290 
randomized controlled trials.
34*51
 The TFC total score can be categorized into Shoulson and 291 
Fahn HD stages.
35
 There is evidence of excellent inter*rater reliability, but only for a modified 292 
version of the UHDRS*TFC that is filled by patient or the caregiver (ICC = 0.96, 95% CI: 293 
0.92, 0.98).
52
 Data from multiple studies suggest good convergent validity with other 294 
components of the UHDRS assessing the functional domain and quality of life, and good 295 
divergent validity with motor disability, cognitive deficits and behavioral problems.
19, 29, 34, 53*
296 
60
 Extensive data from multiple observational studies and clinical trials suggest sensitivity to 297 
change over time.
34*51, 61*70
 There appears to be a ceiling effect for early stage HD and a floor 298 
effect for late stage HD.
41
 299 
Recommendation: The UHDRS*TFC is “suggested” for assessing severity of limitation in 300 
functional capacity in HD, because it lacks core clinimetric data, namely, test*retest reliability 301 
and internal consistency to reach a “recommended” status. 302 
 303 
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The UHDRS  Functional Assessment Scale (FAS) 304 
The UHDRS*FAS is an extensively*used checklist that is also part of the UHDRS. It is a 305 
clinician*administered questionnaire with 25 items which screen an individual’s capacity to 306 
complete specific tasks, enables the clinician to assess severity, and make longitudinal 307 
assessments.  The questionnaire takes 5*10 minutes to complete. It is considered an extension 308 
of the TFC and is more detailed in certain tasks.
34
 A total score is obtained by giving 1 point 309 
to all “yes” replies, and a higher score indicates better functioning.
34
 It has been used in 310 
multiple observational studies and randomized controlled trials in manifest HD populations.34, 311 
39, 43, 48, 49, 61, 62, 64, 68, 70-72 The UHDRS*FAS has been shown to have high internal consistency 312 
(Cronbach's α = 0.95).
34
 There are no available data on test*retest reliability or inter*rater 313 
reliability. Good convergent validity with other components of the UHDRS has been shown, 314 
as well as with motor disability, cogniti e and behavioral deficits.
34, 54, 58, 73, 74
 The UHDRS*315 
FAS has been shown to be sensitive to change over time in several studies.
34, 39, 42, 43, 48, 49, 61, 62, 
316 
64, 68, 70, 71, 75
 317 
Recommendation: The UHDRS*FAS is “suggested” for assessing severity of limitation in 318 
functional capacity in HD, because it lacks core clinimetric data, namely, test*retest or inter*319 
rater reliability data. 320 
 321 
The UHDRSIndependence Scale (IS) 322 
The UHDRS*IS is a clinician*rated tool which assesses the actual reduction of functional 323 
ability.
76
 It is rated from 100 (no special care needed) to 0 (tube*fed, total bed care) and takes 324 
approximately 5 minutes to complete. It has been used in many observational and randomized 325 
controlled trials in manifest HD populations.
34, 41*44, 46, 48*50, 61, 62, 64, 68, 70
 The clinimetric data 326 
available show that the UHDRS*IS has moderate inter*rater reliability but in a modified 327 
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version that compares caregiver report with patient self*report (ICC = 0.71, 95% CI: 0.48, 328 
0.85). 
59
 Good correlation with other components of the UHDRS, as well as motor disability, 329 
cognitive and behavioral deficits has been shown in various studies.
34, 54, 58, 59, 73, 76*79
 Data 330 
from clinical trials suggest sensitivity of the UHDRS*IS to change over time and across 331 
disease stages.
35, 41
 332 
Recommendation: The UHDRS*IS is “suggested” for assessing severity of limitation in 333 
functional ability in HD, because reliability data are missing, including test*retest, inter*rater 334 
(for clinicians) and internal consistency. 335 
 336 
HD Activities of Daily Living (HDADL) 17item 337 
The HD*ADL Scale, which was developed to be used specifically in HD, was modeled after 338 
the Scale for Instrumental Activities of Daily Living.
80
 It is a 17*item informant*completed 339 
instrument on which the informant rates the HD patient’s ability to perform specific activities, 340 
covering the domains of personal care, household care, work and money, social relationships, 341 
and communication. For each item, the patient is rated on a 4*point scale, from normal to 342 
severely limited. The total score of the HD*ADL scale ranges from 0 (normal) to 51 (maximal 343 
limitation). 
53
 With exception of one study,
19
 the scale has not been used outside the John 344 
Hopkins group who developed it. Clinimetric testing show that the HD*ADL has good 345 
internal consistency (α = 0.91*0.96).
53
 Principal Component Analysis showed that four factors 346 
account for 72*74% of the total variance.
53
 Convergent validity has been shown between the 347 
total score of the HD*ADL and the UHDRS*TFC (r= *0.89, p < 0.001), as well as all factors 348 
except for the domain “family relationships”.
53
 Multiple correlations have been reported with 349 
measures of cognitive impairment or disease duration.
53, 81, 82
 The HD*ADL failed to show 350 
differences in treatment compared to placebo.
83, 84
 351 
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Recommendation: The HD*ADL is “suggested” for assessing severity of limitation in ADL, 352 
because studies of the scale’s clinimetric properties are lacking, namely for any type of 353 
reliability. 354 
 355 
ActivitySpecific Balance Scale (ABC) 356 
The ABC is a patient*completed scale that measures balance confidence and fear of falling.  357 
The ABC can take anywhere between 6 and 30 minutes to complete depending on the patient. 358 
Although it is a self*administered scale, a face*to*face interview is recommended.
85
 Patients 359 
rate their balance confidence on a visual analogue scale ranging from 0 to 100 for each of 16 360 
tasks, with higher scores indicating greater confidence and lower fall risk. The ABC has been 361 
widely used in HD,
8, 17, 29
 including a modified ABC*UK version adapted for British culture,
86
 362 
but normative cut*off scores have not been established. The clinimetric data available show 363 
that the ABC has good test*retest reliability (ICC = 0.74 95% CI: 0.58, 1.0),
8
 the MDC has 364 
been reported to be 27.33.
8
 There is good convergent validity with the Mini*BESTest,
29
 and 365 
the modified ABC*UK can distinguish between non*fallers and fallers in HD (mean score: 366 
77.5 vs. 47.9).
86
 While the ABC has been shown to be sensitive to change in one study (after a 367 
9*month multidisciplinary rehabilitation program),
87
 no change was reported in two other 368 
studies.
8, 17
 369 
Recommendation: The ABC is “suggested” for assessing level of self*reported balance 370 
confidence in HD. The use of the ABC is challenged since the lack of insight is a feature of 371 
HD. 372 
 373 
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Rivermead Mobility Index (RMI) 374 
The RMI is an extension of the Rivermead Motor Assessment Gross Function Scale that 375 
assesses functional mobility and was initially developed for stroke. The RMI consists of 14 376 
questions about a patient’s ability to perform a wide range of activities, from turning over in 377 
bed to running, and one observation (standing for 10 seconds without any aid). Questions are 378 
answered as “able” (1 point) or “unable” (0 points) and summed to produce a total score, with 379 
a higher score reflecting better mobility.
88
 Test*retest reliability has been reported in HD (ICC 380 
in pre*manifest HD= 0.81; ICC in manifest HD = 0.94).
6
 A MDC of 2 points has been 381 
reported in manifest HD; ceiling effects are present in pre*manifest HD.
6
 There are no cut*off 382 
scores established in HD, which limits its use as a screening tool in HD. 383 
Recommendation: The RMI is “suggested” for the assessment of severity of restriction of 384 
mobility 385 
 386 
Discussion 387 
The current critique focuses on performance*based measures and rating scales assessing 388 
functional ability in HD. In the process of developing the protocol for the review, we found a 389 
variety of scale constructs and other instruments that could be associated with various aspects 390 
of function ability. We used the ICF
3
 as a conceptual framework related with function to 391 
guide us in the inclusion or exclusion of rating scales based on the adequacy of their 392 
constructs. Nevertheless, we realize that the measures included in this review represent a wide 393 
variety of concepts that apply across the components of the ICF. Many of these measures 394 
included multiple ICF components, raising challenges for conceptual clarity and subsequent 395 
evaluation of validity. For example, balance can be seen as a sheer impairment but it can 396 
overlap with activity/function, depending how it is captured in a given clinical measure. 397 
Page 19 of 253 Movement Disorders Clinical Practice
For Review
 O
nly
19 
 
Considering these aspects, we decided to be inclusive and included balance measures in this 398 
review. Ultimately, there is a need for clear definitions for future measures to better enable 399 
validation and application in HD populations. 400 
We identified and included a range of performance*based measures. We provide a 401 
“recommended” level of recommendation for both screening purposes related to balance, gait 402 
and/or risk of falling, and measurement of severity of impairment of specific motor tasks. 403 
There were however no “recommended” performance*based measures covering upper limb 404 
function. It is also important to emphasize that the majority of these performance measures 405 
were only used in ambulatory HD populations.  406 
We did not identify a rating scale that met the criteria for “recommended”. If further testing of 407 
the measurement properties is conducted, we agreed that UHDRS sub*scales related with 408 
function (TFC, FAS and IS) are in a good position to reach the higher level of 409 
recommendation in the future due to their widespread use, specific development in HD and 410 
known initial clinimetric development. For each one of these scales, important shortcomings 411 
in terms of clinimetric development were identified, namely incomplete reliability testing, 412 
which precluded a “recommended” level of recommendation. In addition, these scales have 413 
limiting ceiling effects that make them unattractive for use in earlier stages of HD. For 414 
example, the use of these UHDRS subscales in a clinical trial conducted with the purpose of 415 
capturing a disease*modifying effect in an ideal HD subgroup of individuals with a high level 416 
of functional ability would be performed at the cost of a prohibitively long trial duration to 417 
capture a meaningful change. Rating scales such as Functional Rating Scale Task force for 418 
pre*Huntington Disease 2 (FuRST*pHD)
89, 90
 are currently being developed and are expected 419 
to fill this gap in the future.  420 
The assessment of functional ability as a clinical outcome is deemed essential for therapeutic 421 
approval by regulatory agencies such as the FDA.1 In this regulatory context, it is important to 422 
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emphasize that there was no recommendation for the purpose of measuring change over time 423 
in individuals or groups of subjects in either a pure observational study or in an interventional 424 
context. In fact, formal testing for responsiveness was missing in all the included rating 425 
scales, and important measures of reliability such as test*retest had not been evaluated in 426 
many cases. Along the same lines, there is a need to assess the validity of each rating scale in 427 
different subgroups of patients with HD, as these data are presently lacking for most of the 428 
measures. The knowledge about responsiveness and its variation in important patient 429 
subgroups can determine sample size requirements and help with the interpretation of clinical 430 
trial results, respectively.1 431 
Looking towards the future, the committee concludes that there are well*validated 432 
performance*based measures that capture motor tasks such as walking or balance, but further 433 
clinimetric development is required for performance*based measures that capture other 434 
aspects of physical function such as upper limb function. For rating scales, including those 435 
evaluating activities of daily living, we are cannot endorse an existing scale at a 436 
“recommended” level and encourage the MDS to prioritize the development of such 437 
instruments for clinical care and research purposes. Further validation of HD*specific scales 438 
such as the UHDRS*TFC are warranted, as is the development of new scales designed to have 439 
greater sensitivity in capturing function in HD subgroups who have a relatively well 440 
preserved functional ability as measured by currently available rating scales.  441 
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	
	


 

			
 Rehabilitation Evaluation (Hall and Baker)1 
 The Leisure Time Exercise Questionnaire by Godin and Shephard 2 
 World Health Organization Disability Assessment Schedule (	
		
)  
  !	"#!#$	#%	&#
'
	#%
$'

#%!	#
 Physical Disability Scale and the Independence Scale3 
 Shoulson,Fahn Disability Scale for HD4 
 HD functional capacity scale3 
 (	#$	#)
 Work limitation questionnaire5 
 Scales for Outcomes in Parkinson’s Disease–Psychosocial (SCOPA,PS)6 
 Parkinson’s Problem Schedule (PPS)7 
 Global Assessment of Functioning (GAF)8 
 Endicott Work Productivity Scale (EWPS)9 
 Belastungsfragebogen Parkinson kurzversion (BELA,P,k)10 
 The World Health Organization Health and Work Performance Questionnaire (HPQ)11 
 	*+#
	

	#%
!

,
 Posturography using a force plate (FP)12 
 GAITRite mat13 
 Step Watch Step Activity Monitor (SAM)14 
 Sensory Organization Test 15 
 	

 Functional Rating Scale Taskforce for pre,Huntington Disease (FuRST,pHD)16
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2#		###	*		2/2	
	 
3
#	# 
	"+
+#!	"
4
Yes.  
Various versions exist, with variations for both the name of the test and scoring 
method, e.g., 16,item, 28,point version of the POMA 
(see http://www.rehabmeasures.org/Lists/RehabMeasures/DispForm.aspx?ID=1039) 
!*#567"#"7

4 The 16,item version. 

		8+
		
		Balance and gait maneuvers used during daily activities. 
The TMT was developed as a measure to screen older adults for balance and gait 
impairments and to be easy to use, reliable and sensitive to significant changes. 
 
The TMT includes balance and gait subscales (9 items for balance , POMA,B; 7 items 
for gait , POMA,G) that measure static and dynamic balance. The test quantitatively 
ranks gait deviations. Participants are asked to perform a series of functional tasks. 
 
The total maximum score is 28 points, where higher scores indicate better 
performance. The maximum scores is 16 for the gait subscale, and 12 for the balance 
subscale. 
 
(See http://www.rehabmeasures.org/Lists/RehabMeasures/DispForm.aspx?ID=1039) 
 
	!!*	8#%4
N/A. 
 
	!+#	*!*	8#%4
NOTE, the scores are made according to descriptors of the performance of tasks, and 
reflect different degrees of severity (personal judgment). 
Each item of the TMT is scored using a scale of 0 to 1 or 2; 0 – better performance, 1 
or 2, worse performance. 
(See http://www.rehabmeasures.org/Lists/RehabMeasures/DispForm.aspx?ID=1039) 
 
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	"#	!	"
##		
#!*#
+#


%
4
Discrete steps (0, 1, 2). 
(See http://www.rehabmeasures.org/Lists/RehabMeasures/DispForm.aspx?ID=1039) 


93	#	
	#	
10,15 minutes. 
(See http://www.rehabmeasures.org/Lists/RehabMeasures/DispForm.aspx?ID=1039) 
 
 
	#	6
%#+6###

Clinician. 
(See http://www.rehabmeasures.org/Lists/RehabMeasures/DispForm.aspx?ID=1039) 
!###
0
	6#	
##%!
#
	#
#4
No. 
 
*#%"	#
#4 Public domain. 
$7
	"
	
#
7#	4 http://www.rehabmeasures.org/Lists/RehabMeasures/DispForm.aspx?ID=1039 
$
	"
#"#	"
%
%4 Not formally. 
3
	#

3		+
##	*
 
*!#	%
	#
8	# No process for item generation and/or reduction identified.
1
 
3-
+
##	*   
	"#	!	"
+#!!		
!	"#!#
#4
Yes, gait and balance items.
1
 
	"
"
+#*7#%"		7

	!
	"
##	

7"#"	!	"

#
	+4
No, the scale is specific for aspects of balance and gait.
1
 
#			
	##	
	"

	#	8
%#+
4
Current state. 
:"
	#	"	#!
3%3;#%	"
	
7<=4
N/A. 
3 
 	
+#	*6#
%#!
	"
#4
Severity of balance impairment, screen for risk of falls. 
	"
	0!!4!$6!0$ Yes. 
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$
	# Cut,off for falls (definition: 	
				): fallers vs. vs. non,fallers: cut,off = 21, with sensitivity of 
74% and specificity of 60%.
2
 
3	
##	*   
	"%	"!	"

#
	4 Yes (personal judgment). 
	"
#%#	###		#	
	#	8
	


#
4
No (personal judgment). 
	"
#%#	##
	#%
"4 No (personal judgment). 
	"	#
#
	!#
$

	#4
Yes (personal judgment). 
	"

#

$#
	
%4
	"$	
%#7"#"	"
#	

#
4
Applicable for early and mid,stage but not for non,ambulatory patients.  
Questionable sensitivity in very early or pre,manifest HD (personal judgment). 
3$
	"#
#!#
*+!
#$*84
No.
1
 
3!*		"
+6"
	"
*#
$*%	"	"
	"+4
N/A. 
 !
 
	"##0*"	#	##$4 Yes. 

3'#
##	*
 
>	
 Assessed in HD. 
	
#	* Not assessed in HD. 
2	0		#
##	*
#$: 
n = 20, TFC Stages 1–3, ICC = 0.83; 95% CI (0.7; 1.0).
 
 
3
 

n = 11 (Pre,manifest HD) and n=64 (Manifest HD) 
2, 4
 
1. Pre,manifest HD: ICC=0.92 
2. Manifest HD: ICC=0.91: 
 early stage (TFC=11–13) , ICC= 0.98 
 middle stage (TFC=7–9) , ICC= 0.96 
 late stage (TFC<=6) , ICC= 0.80 
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	0
	#
##	* Not assessed in HD. 
3?
##	*#$   
+3	
 Assessed in HD. 
#	#+
##	*
*
#7#	"%0
	


No gold standard available. 
		+
##	*   
-
	

*# Not assessed in HD 
+%	+
##	*
 
1) n=20 (Manifest HD):  
a. Correlated with spatio,temporal measures of gait and other clinical 
measures:
3
 
Pearson correlations: 

	#0	

 Forward walking:Velocity, 0.68; Stride length, 
0.74; Swing percent, 0.34; Double support percent, –0.54; Base of support, –
0.58; CV step time, –0.83; CV stride length, –0.88; CV swing time, –0.82.
3
 
Backward walking:Velocity, 0.68; Stride length, 0.74; Swing percent, 0.52; 
Double support percent, –0.64; Base of support, –0.40; CV step time, –0.67; 
CV stride length, –0.73; CV swing time, –0.41. 
	#+#	#0#!#1

!#
r =0.50. 
-
	2	r = , 0.67. 
 
2) n=11 (Pre,manifest HD) and n=64 (Manifest HD): TMT 
% UHDRS,FAS 
(r=0.44), TMT 
%UHDRS,TFC (r=0.42). TMT 
% UHDRS,Total Motor Score 
(TMS): r=,0.59.
5

3) n=78, manifest HD: lower scores of the TMT correlated with higher scores of 
the UHDRS,TMS (r= ,0.75, p< 0.0001);
2, 3


	 Correlation signs are correct given direction of measures. 
#+%	+
##	* – 
.+
##%>	%

!!
*6
@%	

– 
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	
	
A
#B
##	*   
"7	+
#
	
*	
%!$4
Usually not for late stage HD as where many patients are non,ambulatory (personal 
judgment).  
 
Validation studies
2,4
 were completed in pre,manifest, manifest HD including late stage 
HD (worse reliability).
4
 
"7	+
##
*
	#7#	"	#

#%#!#
	%#	#+#
#	4
No. 
'#+		"
%+	##	"		 
	
		#	#+	"
%"
%+
	#		
		4
Yes.  
N=40, manifest HD, non,randomized study, with no control group, of an inpatient 
rehabilitation program. After a three,week period of treatment there was a significant 
average improvement in the TMT (4.7, p<0.001).
6
  
N=11, manifest HD, Open label study of on, and off,tetrabenazine, significant average 
improvement in the TMT (t = 4.20, p = 0.002).
7
  
N=18, manifest HD, not shown to detect change after a supervised video game  
balance training program that improved some spatio,temporal measures of gait.
8
  
		
##	*
$
	"##
##
*#	
	"
%

##
##
*+
	#	
#!!

4
No. 
NOTE: Minimum Detectable Change (MDC) has been calculated ranging from 1 
(premanifest) to 5 (late stage, TFC≤6). 
3, 4
 
-
##%!!	
Floor effects (not suitable for administration in non,ambulatory individuals; Ceiling 
effects, not sensitive to differences in pre,manifest and healthy controls. (personal 
judgment) 
#	#	#
n=11 (Pre,manifest HD) and n=64 (Manifest HD), mean (SD): 
2, 4
 
 Pre,manifest HD:  28 (0.7) 
 Manifest HD: 22 (5) 
 early stage (TFC=11–13) , 24 (5) 
 middle stage (TFC=7–9) , 22 (4) 
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 late stage (TFC<=6) , 21 (4) 
Fallers (n = 34) vs. Non,fallers (n = 60): 17.24 +/, 5.61 
%21.37 +/, 4.85. 
2

"#
+
	
%
Quick and easy to administer, includes balance and gait sections, fairly well validated 
in HD, requires some subjective rating of movement performance. 
#
+
	
% Questionable sensitivity to detect change due to low quality of study design. 
 
"
'!#%!#<!!
3
'!
	!%
#	


#
	#	7#	"

#!	$6	$	
%3
  
 
 
 
	
 
 
1. Tinetti ME, Williams TF, Mayewski R. Fall risk index for elderly patients based on number of chronic disabilities. 
1986;80:429,34. 
2. Kloos AD, Kegelmeyer DA, Young GS, Kostyk SK. Fall risk assessment using the Tinetti mobility test in individuals with Huntington's 
disease. 
	2010;25:2838,44. 
3. Kloos AD, Fritz NE, Kostyk SK, Young GS, Kegelmeyer DA. Clinimetric properties of the Tinetti Mobility Test, Four Square Step Test, 
Activities,specific Balance Confidence Scale, and spatiotemporal gait measures in individuals with Huntington's disease. !#	
2014;40:647,51. 
4. Quinn L, Khalil H, Dawes H, Fritz NE, Kegelmeyer D, Kloos AD$% Reliability and minimal detectable change of physical 
performance measures in individuals with pre,manifest and manifest Huntington disease. #*	2013;93:942,56. 
5. Busse M, Quinn L, Khalil H, McEwan K. Optimising mobility outcome measures in Huntington's disease. 2014;3:175,
88. 
6. Zinzi P, Salmaso D, De Grandis R, Graziani G, Maceroni S, Bentivoglio A$% Effects of an intensive rehabilitation programme on 
patients with Huntington's disease: a pilot study. '(2007;21:603,13. 
7. Kegelmeyer DA, Kloos AD, Fritz NE, Fiumedora MM, White SE, Kostyk SK. Impact of tetrabenazine on gait and functional mobility in 
individuals with Huntington's disease. 	2014;347:219,23. 
Page 57 of 253 Movement Disorders Clinical Practice
For Review Only
 11
8. Kloos AD, Fritz NE, Kostyk SK, Young GS, Kegelmeyer DA. Video game play (Dance Dance Revolution) as a potential exercise 
therapy in Huntington's disease: a controlled clinical trial. 	(2013;27:972,82. 
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	
	
 
 
 
1%1


11
3
#	# 
	"+
+#!	"
4 No. 
!*#567"#"7

4 Not applicable. 

		8+
		
The BBS was designed to assess static balance and fall risk in adult populations. 
 
The BBS entails 14 subtests of various activities related to balance control. Subtests 
include static postures (e.g., sitting, standing), transitions (e.g., sitting to standing, 
transferring between chairs), and challenging positions (e.g., standing with eyes 
closed).  
 
Quality of performance for each item is scored using a 4,point scale, with higher scores 
indicating better balance. The maximum possible score is 56. 
 
http://www.rehabmeasures.org/Lists/RehabMeasures/DispForm.aspx?ID=888 
 
	!!*	8#%4 N/A 
	!+#	*!*	8#%4 N/A 
 
	"#	!	"
##		
#!*#
+#


%
4
Discrete steps, 4,point scale. 


93	#	
	#	
10,15 minutes (personal judgment). 
15,20 minutes  
http://www.rehabmeasures.org/Lists/RehabMeasures/DispForm.aspx?ID=888 
 
 
	#	6
%#+6###
 Clinician. 
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http://www.rehabmeasures.org/Lists/RehabMeasures/DispForm.aspx?ID=888 
!###
0
	6#	
##%!
#
	#
#4
Not required. 
http://www.rehabmeasures.org/Lists/RehabMeasures/DispForm.aspx?ID=888 
 
*#%"	#
#4
Public domain. 
http://www.rehabmeasures.org/Lists/RehabMeasures/DispForm.aspx?ID=888 
$7
	"
	
#
7#	4 Multiple sources. For example: www.aahf.info/pdf/Berg_Balance_Scale.pdf 
$
	"
#"#	"
%
%4 No. 
3
	#

3		+
##	*
 
*!#	%
	#
8	# – 
3-
+
##	*   
	"#	!	"
+#!!		
!	"#!#
#4
Y s, the scale covers items across the balance domain. 
	"
"
+#*7#%"		7

	!
	"
##	

7"#"	!	"

#
	+4
No (personal judgment).  
#			
	##	
	"

	#	8
%#+
4
Current state. 
:"
	#	"	#!
3%3;#%	"
	
7<=4
Current state. 
3 
 	
+#	*6#
%#!
	"
#4
Severity. 
	"
	0!!4!$6!0$
Yes. For cut,off of BBS≤40 / Predicted probability for being a “faller” was virtually 
60%. “Fallers” ≥1 fall in the previous 12 months.
1
  
3	
##	*   
	"%	"!	"

#
	4 Yes (personal judgment). 
	"
#%#	###		#	
	#	8
	


#
4
No (personal judgment). 
	"
#%#	##
	#%
"4 Generally, no. Some of the qualifiers for the ratings (safely, easily) can be considered 
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inherently subjective (personal judgment). 
	"	#
#
	!#
$

	#4
Yes (personal judgment). 
	"

#

$#
	
%4
	"$	
%#7"#"	"
#	

#
4
Not applicable for non,ambulatory HD (personal judgment). 
3$
	"#
#!#
*+!
#$*84
No. 
3!*		"
+6"
	"
*#
$*%	"	"
	"+4
N/A  
 !
 
	"##0*"	#	##$4 Yes. 

3'#
##	*
 
>	
 Assessed in HD.
2
 
	
#	* , 
2	0		#
##	*
n = 11 (Pre,manifest HD) and n=64 (Manifest HD) 
2
 
1. Pre,manifest HD: ICC=0.86 
2. Manifest HD: ICC=0.96: 
 early stage (TFC=11–13) , ICC= 0.90. 
 middle stage (TFC=7–9) , ICC= 0.91. 
 late stage (TFC<=6) , ICC= 0.97. 
	0
	#
##	* , 
3?
##	*#$   
+3	
 Assessed in HD.
1,3
 
.+
##%>	% , 
#	#+
##	*
*
#7#	"%0
	


  
		+
##	*   
-
	

*# Not assessed. 
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+%	+
##	*
1) n=64 (Manifest HD), BBS 
% UHDRS,TFC (r = 0.60, p<0.01).3The BBS and 
the “Timed UP and GO” have been reported to have high correlations between 
them. 
4
 
2) n=11 (Pre,manifest HD) and n=64 (Manifest HD): BBS 
% UHDRS,FAS 
(r=0.48), BBS 
%UHDRS,TFC (r=0.43). BBS 
% UHDRS,Total Motor Score 
(TMS): r=,0.55. 
5
 
 
1) n=64 (Manifest HD): 
BBS 
% measures of quantitative gait: falls (r=,0.48, p<0.01) and fall risk 
(coefficients of variation for stride length (n.s), step time (r=,0.47, p<0.05), 
various balance measures (n.s).
3
 

	 Correlation signs are correct given direction of measures. 
#+%	+
##	*
1) n=64 (Manifest HD): 
            BBS 
% HD,ADL (r = , 0.48, p<0.01).  
.+
##%>	%

!!
*6
@%	

	
	
Good test,retest reliability. Reasonable construct validity testing. 
A
#B
##	*   
"7	+
#
	
*	
%!$4 Not suitable for non,ambulatory HD (personal judgment). 
"7	+
##
*
	#7#	"	#

#%#!#
	%#	#+#
#	4
No (personal judgment). 
'#+		"
%+	##	"		 
	
		#	#+	"
%"
%+
	#		
		4
Withdrawal of tetrabenazine resulted in significant reduction of BBS scores in a 
manifest HD cohort (n=10), with no change in cognitive or behavioral measures.
6
 
 
Manifest HD, mean group change in response to a 1,year rehabilitation 
multidisciplinary Program intervention = +1.0 (p<0.03).
7
 
 
Randomized Trial of structured home,based exercise 
% usual care: early to moderate 
HD with walking or balance difficulties, n=25: Mean difference: 5.4 (95% CI: 1.0, 9.9, 
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p=0.01). 
8
 
 
Manifest HD with chorea, n=11. 
9
 
Non,significant change in response to tetrabenazine: mean (SD) off: 48.8 ± 6 
and on drug 49.8 ± 7.5 (n.s.). Same trial n.s. change for Timed 25 Foot Walk Test. 
		
##	*
$
	"##
##
*#	
	"
%

##
##
*+
	#	
#!!

4
No. 
 
NOTE: MDC = 5.
2
 
-
##%!!	
Susceptible to ceiling effect
2
 and floor effect (not able to administer in non,ambulatory 
individuals) (personal judgment). 
#	#	#
n = 11 (Pre,manifest HD) and n=64 (Manifest HD) Mean (SD): 
2
 
3. Pre,manifest HD: 55 (1) 
4. Manifest HD: 47 (8) 
 early stage (TFC=11–13) , 51 (4). 
 middle stage (TFC=7–9) , 47 (6). 
 late stage (TFC<=6) , 45 (12). 
"#
+
	
% – 
#
+
	
% – 
"
'!
#%+#	*!

#
#	#$7#	"+


	#
%%	!#%!#<!!
3
 
 
	
 
 
1. Busse ME, Wiles CM, Rosser AE. Mobility and falls in people with Huntington's disease. 			#	2009;80:88,90. 
2. Quinn L, Khalil H, Dawes H, Fritz NE, Kegelmeyer D, Kloos AD$% Reliability and minimal detectable change of physical 
performance measures in individuals with pre,manifest and manifest Huntington disease. #*	2013;93:942,56. 
3. Rao AK, Muratori L, Louis ED, Moskowitz CB, Marder KS. Clinical measurement of mobility and balance impairments in Huntington's 
disease: validity and responsiveness. !#	2009;29:433,6. 
Page 64 of 253Movement Disorders Clinical Practice
For Review Only
 18
4. Busse ME, Khalil H, Quinn L, Rosser AE. Physical therapy intervention for people with Huntington disease. #*	2008;88:820,31. 
5. Busse M, Quinn L, Khalil H, McEwan K. Optimising mobility outcome measures in Huntington's disease. 2014;3:175,
88. 
6. Fekete R, Davidson A, Jankovic J. Clinical assessment of the effect of tetrabenazine on functional scales in huntington disease: a pilot 
open label study. *		&		+
,-.2012;2. 
7. Piira A, van Walsem MR, Mikalsen G, Nilsen KH, Knutsen S, Frich JC. Effects of a One Year Intensive Multidisciplinary Rehabilitation 
Program for Patients with Huntington's Disease: a Prospective Intervention Study. #/		2013;5. 
8. Khalil H, Quinn L, van Deursen R, Dawes H, Playle R, Rosser A$% What effect does a structured home,based exercise programme 
have on people with Huntington's disease? A randomized, controlled pilot study. 	(2013;27:646,58. 
9. Ferrara JM, Mostile G, Hunter C, Adam OR, Jankovic J. Effect of tetrabenazine on motor function in patients with huntington disease. 
	*	2012;1:5. 
 

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	
	
 
 
C0/#	:
<2	C/:2
3
#	# 
	"+
+#!	"
4
The original test consisted of a 12,minute walk that was shortened to 6 minutes.
1, 2
  
A shortened 2,minute walk version has been tested in geriatric and other populations. 
Variations in walking distance impact responsiveness so changing from 6 minutes is 
not recommended (personal judgment). 
!*#567"#"7

4 The 6,minute walk test. 

		8+
		
The test measures how many meters an individual is able to walk in 1, 3, and 6 
minutes.  
It was originally developed as a measure of pulmonary function in athletes, then in 
patients with various diseases in respiratory diseases like COPD and related disorders 
that affect oxygen consumption, but has been applied as a test of walking 
distance/”endurance”; others have applied the test in various populations without 
performing the testing needed for standardization. In the context of neurological 
conditions, it is used as a measure of endurance (i.e., different from shorter walking 
tests that measure velocity of walking speed).
3
 
 
	!!*	8#%4 No. 
	!+#	*!*	8#%4 Severity. 
 
	"#	!	"
##		
#!*#
+#


%
4
Severity is measured in continuous values of meters. 


93	#	
	#	
The standardized approach includes two practice tests, lasting up to 30 minutes.  
The practice test is not always used, which is problematic for consistency of the 
obtained results.
4, 5
  
 
 
	#	6
%#+6###
 Clinician. 
!###
0
	6#	
##%!
#
	# No, but it is necessary to follow and specify a standardized protocol. 
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#4
 
*#%"	#
#4 Public domain. 
$7
	"
	
#
7#	4
For example: http://www.cscc.unc.edu/spir/public/ 
UNLICOMMSMWSixMinuteWalkTestFormQxQ08252011.pdf 
$
	"
#"#	"
%
%4 Not applicable. 
3
	#

3		+
##	*
 
*!#	%
	#
8	# No. 
3-
+
##	*   
	"#	!	"
+#!!		
!	"#!#
#4
No. The items are not intended to do so. 
	"
"
+#*7#%"		7

	!
	"
##	

7"#"	!	"

#
	+4
The distance walked in a specified time. 
#			
	##	
	"

	#	8
%#+
4
Current state. 
:"
	#	"	#!
3%3;#%	"
	
7<=4
Current time. 
3 
 	
+#	*6#
%#!
	"
#4
To measure walking endurance (severity). 
	"
	0!!4!$6!0$
(	!$3
Normative data , needs to be age,matched as distances reduce with age.  
Summary in 011%'(	%	 
3	
##	*   
	"%	"!	"

#
	4
It is time consuming compared to other walking tests, but it measures endurance, while 
other tests measure speed/velocity (personal judgment). 
	"
#%#	###		#	
	#	8
	


#
4
No. 
	"
#%#	##
	#%
"4 Not applicable. 
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	"	#
#
	!#
$

	#4
Not applicable. 
	"

#

$#
	
%4
	"$	
%#7"#"	"
#	

#
4
Used in pre,manifest and across mild to severe manifest HD. 
3, 6
  
It cannot be used with those who need physical assistance to walk (personal judgment). 
(.2 If people cannot walk six minutes they can rest and resume, and the distance 
walked in the total six minutes (including the rest time) is recorded. If they cannot 
resume, the distance walked is recorded. 
3$
	"#
#!#
*+!
#$*84
No. 
3!*		"
+6"
	"
*#
$*%	"	"
	"+4
Not applicable. 
 !
 
	"##0*"	#	##$4 Yes. 

3'#
##	*
 
>	
 Assessed in HD.
3
 
	
#	* Not applicable.  
2	0		#
##	*
n = 11 (Pre,manifest HD) and n=64 (Manifest HD) 

 
1. Pre,manifest HD: ICC=0.98. 
2. Manifest HD: ICC=0.94: 
 early stage (TFC=11–13) , ICC= 0.97. 
 middle stage (TFC=7–9) , ICC= 0.86. 
 late stage (TFC<=6) , ICC= 0.97. 
	0
	#
##	* Not assessed in HD. 
3?
##	*#$   
+3	
 Not assessed in HD. 
#	#+
##	*
*
#7#	"%0
	


  
		+
##	*   
-
	

*# Not assessed in HD. 
+%	+
##	* Manifest HD: 
C
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6MWT 
%UHDRS,TMS (n=62): r= ,0.25 (at 6 minutes) but n.s. at 1 and 3 minutes; 
6MWT 
%UHDRS Functional Assessment (n=61): r= 0.37, 0.38 and 0.41 at 1, 3, 6 
minutes (all significant); 6MWT 
%UHDRS,TFC (n=62):  r = 0.25, 0.29 and 0.29 at 1, 
3, 6 minutes (all significant). 
 
	 Correlation signs are correct given direction of measures. 
#+%	+
##	* Not assessed in HD. 
.+
##%>	%

!!
*6
@%	

	
	
– 
A
#B
##	*   
"7	+
#
	
*	
%!$4 Limited use for non,ambulatory subjects (personal judgment). 
"7	+
##
*
	#7#	"	#

#%#!#
	%#	#+#
#	4
No. 
'#+		"
%+	##	"		 
	
		#	#+	"
%"
%+
	#		
		4
Manifest HD, n=37. Change in response to a 1,year rehabilitation multidisciplinary 
program intervention = 68.71 meters (group).
7
   
 
	 less than MDC95 of Quinn 2013
3
 (individual change needed), so 
we conclude that it was not meaningful. 

Manifest HD, n=31. A 12,week Community,Based Exercise Program vs. usual care 
RCT. Treatment effect estimate: [95 % CI]: 27.2 [,2.8 to 57.2], p=0.08
8
 
		
##	*
$
	"##
##
*#	
	"
%

##
##
*+
	#	
#!!

4
No.  
 
(.2 MDC95 (formula based on SEM): pre,manifest HD, 39.22 meters; Manifest 
HD, overall 86.57 meters; early HD 56.60, mid HD 126.14 and late HD 70.65 meters.  
Only 6,minute results seem to be reported, and only one walk was conducted. 
-
##%!!	 Not assessed in HD. 
#	#	#
It is unclear how values discriminate among pre, and manifest HD severity levels 
according to confidence intervals (CI) on means overlap; it seems that values may 
separate pre, and mild from mid/severe levels based on CIs.
3
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Moderate and severe HD also have similar values. (i.e., two groups). 
"#
+
	
%
It is reasonably short although other walking tests are much shorter. 
High reliability. 
#
+
	
%
It has not been used in HD according to the original protocol, which would make it 
longer. There is a conceptual issue due to the original intent being to assess pulmonary 
function and not a measure of walking distance. 
"
'!
#%7
<#%
+#	*#$7#	"+


	#
 
 
	
 
 
1. Balke B. A Simple Field Test for the Assessment of Physical Fitness. Rep 63,6. '
	'231963:1,8. 
2. Butland RJ, Pang J, Gross ER, Woodcock AA, Geddes DM. Two,, six,, and 12,minute walking tests in respiratory disease. "	
,' .1982;284:1607,8. 
3. Quinn L, Khalil H, Dawes H, Fritz NE, Kegelmeyer D, Kloos AD$% Reliability and minimal detectable change of physical 
performance measures in individuals with pre,manifest and manifest Huntington disease. #*	2013;93:942,56. 
4. Guyatt GH, Thompson PJ, Berman LB, Sullivan MJ, Townsend M, Jones NL$% How should we measure function in patients with 
chronic heart and lung disease? 	1985;38:517,24. 
5. Guyatt GH, Pugsley SO, Sullivan MJ, Thompson PJ, Berman L, Jones NL$% Effect of encouragement on walking test performance. 
*	41984;39:818,22. 
6. Busse M, Quinn L, Khalil H, McEwan K. Optimising mobility outcome measures in Huntington's disease. 2014;3:175,
88. 
7. Piira A, van Walsem MR, Mikalsen G, Nilsen KH, Knutsen S, Frich JC. Effects of a One Year Intensive Multidisciplinary Rehabilitation 
Program for Patients with Huntington's Disease: a Prospective Intervention Study. #/		2013;5. 
8. Busse M, Quinn L, Debono K, Jones K, Collett J, Playle R$% A randomized feasibility study of a 12,week community,based exercise 
program for people with Huntington's disease. 	#*	2013;37:149,58. 

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Downloaded from: http://www.cscc.unc.edu/spir/public/UNLICOMMSMWSixMinuteWalkTestFormQxQ08252011.pdf 
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	
	
 
 
2#D
%E2	2A
3
#	# 
	"+
+#!	"
4
Yes (in terms of scoring method). 
The initial study design by Podsiadlo and Richardson consisted of one practice and one 
test.
1
 
In HD: 1) Rao et al.
2
 used the mean score of three tests. 2) Quinn et al.
3
 and Busse et 
al.
4
 used the mean of two tests. 
!*#567"#"7

4
All were considered: mean of two tests, mean of three tests and one practice and one 
test.
2, 3, 5,9
 

		8+
		
The test covers mobility and balance, and falls’ risk.
9
 
The patient sits in the chair with his/her back against the back of the chair. 
On the command “go”, the patient rises from the chair, walks 3 meters at a comfortable 
and safe pace, turns, walks back to the chair and sits down. 
Timing begins at the instruction “go” and stops when the patient is seated. 
Podsiadlo & Richardson
1
 quantified the test by recommending timing the duration 
(sec) between the command “go” and the moment the buttocks touch the chair. 
The patient should have one practice test that is not included in the score.
1
 
The patient must use the same assistive device each time he/she is tested so that scores 
can be compared.  
The chair also needs to be consistent within and between patients for comparisons to 
be made. 
There is an alternative way of scoring performance from 1 to 5 based on the observer's 
perception of the patient’s risk of falling, 
10
 which has not been used in HD. 
 
	!!*	8#%4 No. 
	!+#	*!*	8#%4 No. 
 
	"#	!	"
##		
#!*#
+#


%
4
Scored in continuous values of seconds. 
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

93	#	
	#	
3 minutes total, including set,up. 
http://www.rehabmeasures.org/Lists/RehabMeasures/DispForm.aspx?ID=903 
 
 
	#	6
%#+6###
 Clinician. 
!###
0
	6#	
##%!
#
	#
#4
No. 
 
*#%"	#
#4 Public. 
$7
	"
	
#
7#	4 http://www.rehabmeasures.org/Lists/RehabMeasures/DispForm.aspx?ID=903 
$
	"
#"#	"
%
%4 No (it is not necessary). 
3
	#

3		+
##	*
 
*!#	%
	#
8	# Not applicable. 
3-
+
##	*   
	"#	!	"
+#!!		
!	"#!#
#4
Yes , sit to stand, walking and turning, and stand to sit (personal judgment). 
	"
"
+#*7#%"		7

	!
	"
##	

7"#"	!	"

#
	+4
Content of activity reflects more mobility than balance (personal judgment).  
#			
	##	
	"

	#	8
%#+
4
Current state. 
:"
	#	"	#!
3%3;#%	"
	
7<=4
Not applicable. 
3 
 	
+#	*6#
%#!
	"
#4
To measure severity, screen for ability to go outside alone safely, and screen for risk of 
falls.
1, 9
 
	"
	0!!4!$6!0$
Yes. For cut,off of TUG>14 / Predicted probability for being a “faller” was virtually 
60%. “Fallers” ≥1 fall in the previous 12 months.
9
 
3	
##	*   
	"%	"!	"

#
	4 Yes (personal judgment). 
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	"
#%#	###		#	
	#	8
	


#
4
Number of tests that should be performed varies (practice, test or average of 2 or 3). 
In some studies, it is not clear how many tests were performed.
1, 3, 8, 9
 
	"
#%#	##
	#%
"4 No (personal judgment). 
	"	#
#
	!#
$

	#4
Not applicable. 
	"

#

$#
	
%4
	"$	
%#7"#"	"
#	

#
4
It is not applicable in later stages, it is potentially not sensitive in early stages.
2, 3, 8
 
3$
	"#
#!#
*+!
#$*84
No. 
3!*		"
+6"
	"
*#
$*%	"	"
	"+4
Not applicable. 
 !
 
	"##0*"	#	##$4 Yes.
3
 

3'#
##	*
 
>	
 Assessed. 
	
#	* Not applicable in HD. 
2	0		#
##	*
n = 11 (Pre,manifest HD) and n=64 (Manifest HD).
3
 
1. Pre,manifest HD: ICC=0.93 
2. Manifest HD: ICC=0.96: 
 early stage (TFC=11–13) , ICC= 0.94. 
 middle stage (TFC=7–9) , ICC= 0.95. 
 late stage (TFC≤6) , ICC= 0.97. 
	0
	#
##	* Not assessed in HD. 
3?
##	*#$   
+3	
 Not assessed in HD. 
#	#+
##	*
*
#7#	"%0
	


, 
		+
##	*   
-
	

*# Not assessed in HD.  
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+%	+
##	*
Manifest HD:
4
  (Mean values of TUG as average of two tests). 
TUG 
%UHDRS,TMS (n=61): r= 0.16 (n.s.); TUG 
%UHDRS Functional 
Assessment (n=60): r= ,0.33 (p<0.01); TUG 
%UHDRS,TFC (n=61):  r = ,0.25 (n.s.).  
#+%	+
##	* Not assessed in HD. 
.+
##%>	%

!!
*6
@%	

	
	
Good (personal judgment). 
Maybe useful in mild stages of the disease when speed/bradykinesia becomes more of 
a factor, but also becomes more variable at that point.
3
 
A
#B
##	*   
"7	+
#
	
*	
%!$4
Early,mid stages of HD; not pre,manifest; it appears sensitive to disease progression.
2, 
3, 8
 
"7	+
##
*
	#7#	"	#

#%#!#
	%#	#+#
#	4
The TUG may demonstrate less reliability among patients suffering from cognitive 
impairment. 
http://www.rehabmeasures.org/Lists/RehabMeasures/DispForm.aspx?ID=903 
'#+		"
%+	##	"		 
	
		#	#+	"
%"
%+
	#		
		4
Yes. 
Manifest HD, n=30. Task,specific mobility training vs. usual care, RCT
7
: Effect size: 
0.17, n.s.
Manifest HD, n=37. Change in response to a 1,year rehabilitation multidisciplinary, no 
control. Program intervention = ,1.3 sec (group). NOTE: within the MDC. 
6
 
Manifest HD, n=30, 6,week program of intervention for posture and gait, no control. 
S.S. improvement in TUG but results given in graphic, no values reported. 
5
 
		
##	*
$
	"##
##
*#	
	"
%

##
##
*+
	#	
#!!

4
No.  
 
(.2 MDC: 1.34 seconds in pre,manifest HD and 2.98 sec in manifest HD.
3
 
-
##%!!	
Yes, both.  
Patients were at the lower (better) range of TUG scores and likely have ceiling effects 
for improvement (data not reported so unable to determine percent).
5
 
#	#	# In HD, ranging from 7,14 sec.
3
 
"#
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+
	
%
Timing measure , continuous variable. General measure of mobility.  Incorporates 
turning and sit to stand which is a problem with patients. 
#
+
	
%
May not be sensitive to change.  
Speed/bradykinesia may not be the biggest problem in patients with HD. 
The test is not useful in pre,manifest and end stage HD.
2, 3
 
"
%%	!
#%


##	*+#	*
%%	!#%!#<!!
 
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	
	
 
 
F0	7
<		F/:2
3
#	# 
	"+
+#!	"
4
Yes, in the sense that other walking tests of varying length e.g., 6 minutes, exist.  
The test can be performed at patient self,selected/comfortable
1,3
 walking pace or at 
maximum pace.  
The 10,meter self,selected or 'comfortable pace' walking pace is the most common. 
!*#567"#"7

4 N/A 

		8+
		
The 10MWT assesses walking speed in meters per second over a short duration.  
 
Self,selected or 'comfortable pace' walking speed and number of steps taken;  
10 meter walk with 2 meters at the beginning and at the end to allow for acceleration 
and de,acceleration; requires 10 meter floor markings and a stopwatch.  
Single performance measure scored in meters/seconds and number of steps taken.  
In HD, the score has been based on the average of two tests.
1, 2
  
 
The 10MWT score can also be calculated using the average of the three trials. 
http://www.rehabmeasures.org/Lists/RehabMeasures/DispForm.aspx?ID=901 
 
(.2 Piira et al.
4
 used fast,paced, while Busse et al.
3
 used both self,selected and fast 
paced. 
 
	!!*	8#%4 No. 
	!+#	*!*	8#%4 Yes.  
 
	"#	!	"
##		
#!*#
+#


%
4
Continuous score (seconds); step count, although time in seconds or gait speed is more 
commonly reported.  
Note: timing measure is problematic, if a person is unable to perform the test. 


93	#	
	#	 < 5 minutes. 
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http://www.rehabmeasures.org/Lists/RehabMeasures/DispForm.aspx?ID=901 
 
 
	#	6
%#+6###
 Clinician. 
!###
0
	6#	
##%!
#
	#
#4
No, but it is necessary to follow standardized instructions from test to test with 
documentation of self,selected or fast pace; walking aid is permissible but needs to be 
documented. Personal assistance with walk is not permitted. 
 
*#%"	#
#4 Public domain. 
$7
	"
	
#
7#	4 http://www.rehabmeasures.org/Lists/RehabMeasures/DispForm.aspx?ID=901 
$
	"
#"#	"
%
%4 Not applicable. 
3
	#

3		+
##	*
 
*!#	%
	#
8	# No. 
3-
+
##	*
 
	"#	!	"
+#!!		
!	"#!#
#4
No. 
	"
"
+#*7#%"		7

	!
	"
##	

7"#"	!	"

#
	+4
Not applicable. 
#			
	##	
	"

	#	8
%#+
4
Current state. 
:"
	#	"	#!
3%3;#%	"
	
7<=4
Current time. 
3 
 	
+#	*6#
%#!
	"
#4
To measure severity. 
	"
	0!!4!$6!0$
No. 
NOTE: there are age, and sex,based normative data in healthy adults aged in their 20s 
to 70s. 
Males comfortable speed ranges are 1.39 m/s to 1.33, and females 1.41 to 1.27 m/s and 
range for fast,paces for males from 2.53 to 2.08 m/s and for females from 2.47 to 1.74 
Page 82 of 253Movement Disorders Clinical Practice
For Review Only
 36
m/s (note, n=230, age 20,70 measure over 6.62 meters with acceleration and 
deceleration period so compatible with 10 meter walk – (25 foot walk).
5
 
3	
##	*   
	"%	"!	"

#
	4 Yes. 
	"
#%#	###		#	
	#	8
	


#
4
No. 
	"
#%#	##
	#%
"4 Not applicable. 
	"	#
#
	!#
$

	#4
Yes, if ambulatory and the patients do not require personal assistance. 
	"

#

$#
	
%4
	"$	
%#7"#"	"
#	

#
4
No, patients need to be able to walk without personal assistance. 
3$
	"#
#!#
*+!
#$*84
No. 
3!*		"
+6"
	"
*#
$*%	"	"
	"+4
Not applicable. 
 !
 
	"##0*"	#	##$4 Yes. 

3'#
##	*
 
>	
 Assessed in HD. 
	
#	* Not applicable 
2	0		#
##	*
F/:2!0
  
n = 11 (Pre,manifest HD) and n=64 (Manifest HD).

 
1. Pre,manifest HD: ICC=0.96. 
2. Manifest HD: ICC=0.95: 
 early stage (TFC=11–13) , ICC= 0.97. 
 middle stage (TFC=7–9) , ICC= 0.92. 
 late stage (TFC<=6) , ICC= 0.96. 
 
(.2MDC ranges 0.20 to 0.46 (stage dependent and non,linear).
 ##
GF
,
: Fast,paced version. MDC ranged from 0.16 in late manifest HD, mid 
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HD, 0.24, 0.20 early manifest HD); 0.20 overall for manifest HD. 
	0
	#
##	* Not assessed. 
3?
##	*#$   
+3	
 Assessed in HD.
2
 
#	#+
##	*
*
#7#	"%0
	


No 
		+
##	*   
-
	

*# N/A 
+%	+
##	*
Manifest HD
2
  (Mean values of TUG as average of two tests). 

F/:2!0
 is not associated with UHDRS Motor Score: correlation ,0.19 
and ,0.15 (n=62, p>0.05) at time 1 and time 2 (one week later); it is significantly 
associated with the UHDRS Functional Assessment Scale 0.35 and 0.34 (times 1 and 
2, respectively, n=62, p<0.05), but not with the UHDRS,TFC (0.24 and 0.22) (time 1 
and 2, respectively, n=62). 
 
	 Higher correlations are not expected with performance measure 
and these measures. 
(.2 not set up as a study of validity.   
#+%	+
##	* No, see above. 
.+
##%>	%

!!
*6
@%	

	
	
Very good test,retest reliability, reasonable construct validity with measures provided 
(as expected). 
A
#B
##	*   
"7	+
#
	
*	
%!$4
Questionable validity in pre,manifest HD.  
For late HD: potentially not applicable as patients must be ambulatory to perform test 
(personal judgment). 
"7	+
##
*
	#7#	"	#

#%#!#
	%#	#+#
#	4
It is unclear if it can be used in the severely cognitively impaired (personal judgment). 
'#+		"
%+	##	"		 
	
		#	#+	"
%"
%+  ##
GF
,
: Fast,paced version. Mild to moderate manifest HD (n=37) with 
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	#		
		4 rehabilitation intervention. Statistically significant improvement of 0.27 m/s which 
exceeds MDC.  
1GF

 Community walking program pilot, RCT (n=18 total) n.s. change in 
self,paced or fast,paced walking test. Note, means and ES also indicate no effect so it 
is not simply an issue of small numbers. 
		
##	*
$
	"##
##
*#	
	"
%

##
##
*+
	#	
#!!

4
No. 
NOTE: MDC as per data mentioned in reliability above. 
-
##%!!	 No. 
#	#	#
n = 11 (Pre,manifest HD) and n=64 (Manifest HD) Mean (SD): 
1
 
1. Pre,manifest HD: 1.31 (0.31). 
2. Manifest HD: 1.20 (0.39). 
 early stage (TFC=11–13) , 1.34 (0.29). 
 middle stage (TFC=7–9) , 1.10 (0.42). 
 late stage (TFC<=6) , 1.15 (0.42). 
NOTE: scores across HD severity are not linear.
1
 
"#
+
	
%
Very easy to administer but critical conditions (e.g., instructions/standardization are 
reported). 
#
+
	
%
 
"
%%	!
	!7
<#%#
#!	$3
(10MWT self,paced has more clinimetric data) 
 
	
 
 
1. Quinn L, Khalil H, Dawes H, Fritz NE, Kegelmeyer D, Kloos AD$% Reliability and minimal detectable change of physical 
performance measures in individuals with pre,manifest and manifest Huntington disease. #*	2013;93:942,56. 
2. Busse M, Quinn L, Khalil H, McEwan K. Optimising mobility outcome measures in Huntington's disease. 2014;3:175,
88. 
3. Busse M, Quinn L, Debono K, Jones K, Collett J, Playle R$% A randomized feasibility study of a 12,week community,based exercise 
program for people with Huntington's disease. 	#*	2013;37:149,58. 
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4. Piira A, van Walsem MR, Mikalsen G, Nilsen KH, Knutsen S, Frich JC. Effects of a One Year Intensive Multidisciplinary Rehabilitation 
Program for Patients with Huntington's Disease: a Prospective Intervention Study. #/		2013;5. 
5. Bohannon RW. Comfortable and maximum walking speed of adults aged 20,79 years: reference values and determinants. 
1997;26:15,9. 
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	
	
 
 
-
			-2
3
#	# 
	"+
+#!	"
4 No. 
!*#567"#"7

4 Not applicable 

		8+
		
Dynamic balance measured in seconds.
6
 
 
Test of dynamic balance that clinically assesses a person’s ability to step over objects forward, 
sideways, and backwards. A test procedure may be demonstrated and one practice test is 
allowed prior to administering the actual test: 
1. Two trials are then performed, and the better time (in seconds) is taken as the score. 
2. Timing starts when the right foot contacts the floor in the square. 
 
Instructions:  
“Try to complete the sequence as fast as possible without touching the sticks. Both feet must 
make contact with the floor in each square. If possible, face forward during the entire 
sequence.”  
 
    Repeat a test if the patient: 
 Fails to complete the sequence successfully. 
 Loses balance. 
 Makes contact with the cane. 
 Patient steps over four canes set,up like a cross on the floor with the tips of the canes 
facing together. 
    At the start of the test, the patient stands on the upper left square (in Square #1, facing 
Square #2). 
 The stepping sequence is (clockwise): 
  1, Square 2, Square 4, Square 3, return to Square 1 with both feet. 
 Then (counterclockwise): 
 Back to Square 3, Square 4, Square 2, and end in Square 1 with both feet.  
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    *Patients who are unable to face forward during the entire sequence and may turn before 
stepping into the next square and are timed accordingly. 
 
	!!*	8#%4 No. 
	!+#	*!*	8#%4 No. 
 
	"#	!	"
##	
	#!*#
+#


%

4
No. 


93	#	
	#	 5,10 minutes (personal judgment). 
 
 
	#	6
%#+6###
 Clinician. 
!###
0
	6#	
##%!
#
	#
#4
No. 
 
*#%"	#
#4 Public domain. 
$7
	"
	
#

7#	4
http://www.rehabmeasures.org/Lists/RehabMeasures/DispForm.aspx?ID=900 
$
	"
#"#	"

%
%4
No. 
3
	#

3		+
##	*
 
*!#	%
	#
8
	#
Not applicable. 
3-
+
##	*   
	"#	!	"
+#!!	
	!	"#!#
#4
Not applicable. 
	"
"
+#*7#%"		7


	!	"
##	

7"#"
Not applicable. 
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	!	"
#
	+4
#			
	##	

	"
	#	8
%#+
4
Current state. 
:"
	#	"	#!
3%3;#%	"
	
7<=4
Current time: performance based. 
3 
 	
+#	*6
#
%#!	"
#4
To measure severity of motor planning/balance. 
	"
	0!!4!$6!0
$
No. 
3	
##	*   
	"%	"!	"

#
	4 Yes (personal judgment). 
	"
#%#	###		#	

	#	8
	

#
4
No (personal judgment). 
	"
#%#	##
	#%
"4 No (personal judgment). 
	"	#
#
	!#

$
	#4
Yes (personal judgment). 
	"

#

$#

	
%4
	"$	
%#7"#"	"
#	

#
4
Applicable in later stages of HD.
1
 
3$
	"#
#!#
*+
!#$*84
No.
6
 
3!*		"
+6"
	"

*#$*%	"	"
	"
+4
Not applicable. 
 !
 
	"##0*"	#	#
#$4
Yes. 

3'#
##	*
 
>	
 Not assessed in HD. 
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	
#	* Not applicable. 
2	0		#
##	*
n = 11 (Pre,manifest HD) and n=64 (Manifest HD).
1
 
1. Pre,manifest HD: ICC=0.91. 
2. Manifest HD: ICC=0.78: 
 early stage (TFC=11–13) , ICC= 0.74. 
 middle stage (TFC=7–9) , ICC= 0.53. 
 late stage (TFC<=6) , ICC= 0.91. 
 
Manifest HD (n = 20): ICC= 0.86 (0.76,1.00).
7
 
	0
	#
##	* Not assessed. 
3?
##	*#$   
+3	
 Not assessed. 
#	#+
##	*
*
#7#	"%0
	


 No. 
		+
##	*   
-
	

*# No. 
+%	+
##	*
Manifest HD (n = 20):  
FSST 
% ABC scale (Pearson correlation = ,0.57, p<0.05); 
% TMT (Pearson correlation = –
0.67, p<0.01); 
% gait velocity (Pearson correlation = , 0.69, p<0.01).
7
 
#+%	+
##	* No. 
.+
##%>	%

!!
*6
@%	

	
	
Limited information. 
A
#B
##	*   
"7	+
#
	
*	
%!$4 No. 
"7	+
##
*
	#7#	"
	#
#%#!#
	%#	#+
#
#	4
No. 
'#+		"
%+	##	"		 
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	
		#	#+	"
%
"
%+	#		
		4
No.   
Adjusted mean difference in one exercise cross,over, controlled, single,blinded, six,week 
study:  , 0.06 (,1.72, 0.60).
8
 
		
##	*
$
	"##
##
*#	
	"
%

##
##
*+
	#	

#!!
4
No. 
 
NOTE: MDC , Pre,manifest HD, , 1.9
1
; Manifest HD, 15.2
1
; and 3.25.
7
 
-
##%!!	
Not reported. 
 
In stroke: Floor effect: 40,62% of participants had unsuccessful test at least once during 
testing.
9
 
#	#	#
n = 11 (Pre,manifest HD) and n=64 (Manifest HD) Mean (SD):
1
 
1. Pre,manifest HD: 11.68 (2.36). 
2. Manifest HD: 14.98 (11.19): 
 early stage (TFC=11–13) , 12.91 (6.82). 
 middle stage (TFC=7–9) , 17.50 (8.71). 
 late stage (TFC<=6) , 14.79 (15.64). 
"#
+
	
%
Unique measure of balance and motor planning.   
Easy to administer.   
May be good sensitive measure in early stages/pre,manifest HD. 
#
+
	
%
Is difficult for patients in later stages. If they are unable to complete the test it is not clear how 
scoring should be performed. 
" %%	!
	!*
#

#$3
 
 
	
 
 
1. Quinn L, Khalil H, Dawes H, Fritz NE, Kegelmeyer D, Kloos AD$% Reliability and minimal detectable change of physical 
performance measures in individuals with pre,manifest and manifest Huntington disease. #*	2013;93:942,56. 
2. Busse M, Quinn L, Khalil H, McEwan K. Optimising mobility outcome measures in Huntington's disease. 2014;3:175,
88. 
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3. Busse M, Quinn L, Debono K, Jones K, Collett J, Playle R$% A randomized feasibility study of a 12,week community,based exercise 
program for people with Huntington's disease. 	#*	2013;37:149,58. 
4. Piira A, van Walsem MR, Mikalsen G, Nilsen KH, Knutsen S, Frich JC. Effects of a One Year Intensive Multidisciplinary Rehabilitation 
Program for Patients with Huntington's Disease: a Prospective Intervention Study. #/		2013;5. 
5. Bohannon RW. Comfortable and maximum walking speed of adults aged 20,79 years: reference values and determinants. 
1997;26:15,9. 
6. Dite W, Temple VA. A clinical test of stepping and change of direction to identify multiple falling older adults. 	#'(
2002;83:1566,71. 
7. Kloos AD, Fritz NE, Kostyk SK, Young GS, Kegelmeyer DA. Clinimetric properties of the Tinetti Mobility Test, Four Square Step Test, 
Activities,specific Balance Confidence Scale, and spatiotemporal gait measures in individuals with Huntington's disease. !#	
2014;40:647,51. 
8. Kloos AD, Fritz NE, Kostyk SK, Young GS, Kegelmeyer DA. Video game play (Dance Dance Revolution) as a potential exercise 
therapy in Huntington's disease: a controlled clinical trial. 	(2013;27:972,82. 
9. Blennerhassett JM, Jayalath VM. The Four Square Step Test is a feasible and valid clinical test of dynamic standing balance for use in 
ambulant people poststroke. 	#'(2008;89:2156,61. 


 
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	
	
 
 
/##012	
3
#	# 
	"+
+#!	"
4
No. 
The Mini,BESTest, the original BESTest 4 level (0 , 3) scoring was revised to 3 levels 
(0 , 2) due to redundancy. 
!*#567"#"7

4 – 

		8+
		
The Mini BESTest is a 14,item test scored on a 3,level ordinal scale as a measure of 
dynamic balance.  
Total score = 28 points per test directions.  
Two items have right and left assessment in which the lower score is used within the 
total score (directions specify which to use).  
For research, many studies specify use of both left and right data, thus calculating data 
based on 32 (vs. 28) points.
1
 
 
	!!*	8#%4 — 
	!+#	*!*	8#%4 — 
 
	"#	!	"
##		
#!*#
+#


%
4
Discrete steps (3,level ordinal scale). 


93	#	
	#	 10,15 minutes (personal judgment). 
 
 
	#	6
%#+6###
 Clinician. 
!###
0
	6#	
##%!
#
	#
#4
No. 
 
*#%"	#
#4 Copyright. 
$7
	"
	
#
7#	4 — 
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$
	"
#"#	"
%
%4 Not applicable. 
3
	#

3		+
##	*
 
*!#	%
	#
8	# Item generation described in original author paper.
1
 
3-
+
##	*   
	"#	!	"
+#!!		
!	"#!#
#4
Dynamic balance scale, evaluates domains of postural control namely anticipatory 
postural adjustments during voluntary postural transitions, postural responses to an 
externally induced loss of balance, standing balance under challenging sensory 
conditions and gait. 
	"
"
+#*7#%"		7

	!
	"
##	

7"#"	!	"

#
	+4
No. 
#			
	##	
	"

	#	8
%#+
4
Current state. 
:"
	#	"	#!
3%3;#%	"
	
7<=4
Not applicable 
3 
 	
+#	*6#
%#!
	"
#4
To measure severity. 
	"
	0!!4!$6!0$
No.  
A cut,off of 27 has been used to differentiate HD vs. non,HD (82% specificity and 
78% sensitivity).
2
 
3	
##	*   
	"%	"!	"

#
	4 Yes (personal judgment). 
	"
#%#	###		#	
	#	8
	


#
4
No (personal judgment). 
	"
#%#	##
	#%
"4 No (personal judgment). 
	"	#
#
	!#
$

	#4
Yes (personal judgment). 
	"

#

$#
	
%4
	"$	
%#7"#"	"
#	
Not applicable for non,ambulatory HD (personal judgment). 
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#
4
3$
	"#
#!#
*+!
#$*84
No. 
3!*		"
+6"
	"
*#
$*%	"	"
	"+4
Not applicable. 
 !
 
	"##0*"	#	##$4
 

3'#
##	*
 
>	
 Not assessed in HD. 
	
#	* – 
2	0		#
##	* – 
	0
	#
##	* – 
3?
##	*#$   
+3	
 Assessed in HD. 
#	#+
##	*
*
#7#	"%0
	


 No gold standard available. 
		+
##	*   
-
	

*#
 
+%	+
##	*
Manifest HD (n=18). 
Association between Mini,BESTest and: ABC,UK (r2=0.45, p=0.0024), UHDRS,TFC 
(r2=0.75, p <0.0001) and UHDRS,TMS (r2=0.68, p =0.00003).
2
 
#+%	+
##	* , 
.+
##%>	%

!!
*6
@%	

	
	
Limited information. 
A
#B
##	*   
"7	+
#
	
*	
%!$4
Unknown; not assessed comprehensively across stages of HD (n=9 stage 1, n=6 stage 
2, n=3 stage 3).
2
 
"7	+
##
*
	#7#	"	#

#%#!#
	%#	#+#
#	4
Unknown. 
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'#+		"
%+	##	"		 
	
		#	#+	"
%"
%+
	#		
		4
Not in HD. 
		
##	*
$
	"##
##
*#	
	"
%

##
##
*+
	#	
#!!

4
Not in HD. 
-
##%!!	 Likely to have floor effects in HD, not applicable for non,ambulatory individuals. 
#	#	# Mean (95% CI) in non,HD =98 (96,99); in HD, 76 (64,87). 
"#
+
	
% Comprehensively assesses multiple domains of balance impairment. 
#
+
	
% Not fully validated in HD. 
" %%	!
#%+#	*!

#
#	#$3
 
 
	
 
 
1. Franchignoni F, Horak F, Godi M, Nardone A, Giordano A. Using psychometric techniques to improve the Balance Evaluation Systems 
Test: the mini,BESTest. '(2010;42:323,31. 
2. Jacobs JV, Boyd JT, Hogarth P, Horak FB. Domains and correlates of clinical balance impairment associated with Huntington's disease. 
!#	2015;41:867,70. 
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	
	

 
 "*#
 !
2	  2
3
#	# 
	"+
+#!	"
4
Yes. 
Two Versions: 9,item scale and 7,item scale. 
http://www.rehabmeasures.org/Lists/RehabMeasures/DispForm.aspx?ID=1104 
!*#567"#"7

4 The 9,item scale.
1
 

		8+
		
The scale is composed of multiple domains of physical function using observed 
performance of tasks that simulate activities of daily living of various degrees of 
difficulty.
1
 
A 5,point scale of (0,4) on each item.  Minimum score of 0 for both scales.   
Maximum of 36 for 9,item scale.  
A higher total score is indicative of better physical performance.  
Subject is given a command “go” to perform a task. Time to comple, in seconds, is 
recorded. A corresponding score is given from 0,4 determined by seconds taken to 
complete the task. Scores from each task are totaled.
1
  
http://www.rehabmeasures.org/Lists/RehabMeasures/DispForm.aspx?ID=1104 
 
	!!*	8#%4 No. 
	!+#	*!*	8#%4 No. 
 
	"#	!	"
##		
#!*#
+#


%
4
5 point scale (0,4).
1
 


93	#	
	#	
5,10 minutes. 
http://www.rehabmeasures.org/Lists/RehabMeasures/DispForm.aspx?ID=1104 
 
 
	#	6
%#+6###
 Clinician. 
!###
0
	6#	
##%!
#
	#
#4
No. 
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 
*#%"	#
#4 Public domain. 
$7
	"
	
#
7#	4 http://www.rehabmeasures.org/Lists/RehabMeasures/DispForm.aspx?ID=1104 
$
	"
#"#	"
%
%4 No. 
3
	#

3		+
##	*
 
*!#	%
	#
8	# Unknown. 
3-
+
##	*   
	"#	!	"
+#!!		
!	"#!#
#4
Yes , writing, eating, dressing, walking, and climbing stairs. 
	"
"
+#*7#%"		7

	!
	"
##	

7"#"	!	"

#
	+4
Balance not specifically covered; items apply to general functional tasks (personal 
judgment). 
#			
	##	
	"

	#	8
%#+
4
Current state. 
http://www.rehabmeasures.org/Lists/RehabMeasures/DispForm.aspx?ID=1104 
:"
	#	"	#!
3%3;#%	"
	
7<=4
Current state. 
http://www.rehabmeasures.org/Lists/RehabMeasures/DispForm.aspx?ID=1104 
3 
 	
+#	*6#
%#!
	"
#4
To measure severity of mobility.  
	"
	0!!4!$6!0$ No (personal judgment). 
3	
##	*   
	"%	"!	"

#
	4 Yes (personal judgment). 
	"
#%#	###		#	
	#	8
	


#
4
No (personal judgment). 
	"
#%#	##
	#%
"4 No (personal judgment). 
	"	#
#
	!#
$

	#4
Yes (personal judgment). 
	"

#

$#
	
%4
	"$	
%#7"#"	"
#	

#
4
Possibly pre,manifest. Applicable in late stages.
G
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3$
	"#
#!#
*+!
#$*84
No. 
3!*		"
+6"
	"
*#
$*%	"	"
	"+4
Not applicable. 
 !
 
	"##0*"	#	##$4 Yes. 

3'#
##	*
 
>	
 Assessed. 
	
#	* Not assessed. 
2	0		#
##	*
n = 11 (Pre,manifest HD) and n=64 (Manifest HD) 
2
 
1. Pre,manifest HD: ICC=0.76. 
2. Manifest HD: ICC=0.95: 
 early stage (TFC=11–13) , ICC= 0.92. 
 middle stage (TFC=7–9) , ICC= 0.93. 
 late stage (TFC<=6) , ICC= 0.94. 
(.2 MDC: 3 in pre,manifest HD ; 5 in manifest HD.
2
  
	0
	#
##	* Not assessed. 
3?
##	*#$   
+3	
 Assessed.  
.+
##%>	% Limited information. 
#	#+
##	*
*
#7#	"%0
	


 Not assessed in HD. 
		+
##	*   
-
	

*# Not assessed in HD. 
+%	+
##	*
1GF,
3
: (although not really set up as study of validity): (n=63) manifest HD, 
PPT was correlated with: UHDRS TMS (r=,0.4; p<0.01); UHDRS Functional 
Assessment Scale (r=0.59, p<0.01; and Total Functional Capacity (r=0.48, p<0.05). 
 
 
<#E#
Concurrent validity in PD:  Good correlation of the 9,item scale 
with basic Katz Activities of daily living (r = 0.65).
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#+%	+
##	* Not assessed in HD. 
.+
##%>	%

!!
*6
@%	

	
	
Good (personal judgment). 
A
#B
##	*   
"7	+
#
	
*	
%!$4 No. Not in pre,manifest HD.
G
 
"7	+
##
*
	#7#	"	#

#%#!#
	%#	#+#
#	4
Yes.
4
 
'#+		"
%+	##	"		 
	
		#	#+	"
%"
%+
	#		
		4
Task,specific training vs. usual care in 30 HD patients. Effect size=0.01.
G

 
Non,randomized study with no control group of an inpatient rehabilitation program. 
manifest HD, n=40. After a three,week period of treatment there was a significant 
average improvement in the PPT (5.21, p<0.001)
G6H

 
RCT of structured home,based exercise 
% usual care: early to moderate HD with 
walking or balance difficulties, n=25: Mean difference: 4.8 (95% CI: 2.0, 7.7, 
p=0.002).
C
 
		
##	*
$
	"##
##
*#	
	"
%

##
##
*+
	#	
#!!

4
No. 
-
##%!!	 There is a ceiling effect in pre,manifest HD.
G
 
#	#	#
n = 11 (Pre,manifest HD) and n=64 (Manifest HD) Mean (SD):
2
 
1. Pre,manifest HD: 31 (2). 
2. Manifest HD: 23 (7): 
 early stage (TFC=11–13) , 27 (5). 
 middle stage (TFC=7–9) , 22 (7). 
 late stage (TFC≤6) , 20 (7). 
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	 whether values discriminate among pre, and manifest severity levels is 
unclear as confidence intervals (CI) on means overlap; may separate pre, and mild 
from mid/severe levels based on CIs. 
"#
+
	
%
Measures range of physical functioning; timed measures are quantitative and not 
subjective. 
#
+
	
%
Cut,offs for categories (converting time to numbers) may not be appropriate for HD.  
Need some equipment , e.g., coffee can; beans, lab coat.   
Don't know if converted scores are appropriate for HD (have been validated in other 
populations). 
"
%%	!+#	*!#
#	!"*#
!	#
	#+#	#!
#*
#+#%3


	
 
 
 
1. Reuben DB, Siu AL. An objective measure of physical function of elderly outpatients. The Physical Performance Test. !		
1990;38:1105,12. 
2. Quinn L, Khalil H, Dawes H, Fritz NE, Kegelmeyer D, Kloos AD$% Reliability and minimal detectable change of physical 
performance measures in individuals with pre,manifest and manifest Huntington disease. #*	2013;93:942,56. 
3. Busse M, Quinn L, Khalil H, McEwan K. Optimising mobility outcome measures in Huntington's disease. 2014;3:175,
88. 
4. Farrell MK, Rutt RA, Lusardi MM, Williams AK. Reliability of the Physical Performance Test in People with Dementia. #)
&*	2!		2010;28:144,53. 
5. Zinzi P, Salmaso D, De Grandis R, Graziani G, Maceroni S, Bentivoglio A$% Effects of an intensive rehabilitation programme on 
patients with Huntington's disease: a pilot study. '(2007;21:603,13. 
6. Khalil H, Quinn L, van Deursen R, Dawes H, Playle R, Rosser A$% What effect does a structured home,based exercise programme 
have on people with Huntington's disease? A randomized, controlled pilot study. 	(2013;27:646,58. 
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 "*#
 !
2	 
 
Testing Protocol:  Administer the test as outlined below. Subjects are given up to two chances to complete each item. Assistive devices are permitted for tasks 
6 – 9. 
 
1. Ask the subject, when given the command to “go” to write the sentence “whales live in the blue ocean.” Time from the word “go” until the pen is lifted 
from the page at the end of the sentence. All words must be included and legible. Period need not be included for task to be considered completed. 
2. Five kidney beans are placed in a bowl, 5 inches from the edge of the desk in front of the patient. An empty coffee can is placed on the table at the 
patient’s non,dominant side. A teaspoon is place in the patient’s dominant hand. Ask the subject on the command “go” to pick up the beans, one at a time 
and place each in the coffee can. Time from the command “go” until the last bean is heard hitting the bottom of the can. 
3. Place a Physician’s Desk Reference or other heavy book on a table in front of the patient. Ask the patient, when given the command “go” to place the 
book on a shelf above shoulder level. Time from the command “go” to the time the book is resting on the shelf. 
4. If the subject has a jacket cardigan sweater, ask them to remove it. If not, give the subject a lab coat. Ask the subject, on the command “go” to put the coat 
on completely such that it is straight on their shoulders and then remove the garment completely. Time from the command “go” until the garment has been 
complexly removed. 
5. Place a penny approximately1 foot from the patient’s foot on the dominant side. Ask the patient, on the command “go” to pick up the penny from the floor 
and stand up. Time from the command “go” until the subject is standing erect with a penny in hand. 
6. With subject in a corridor or in and open room, ask the subject to turn 360 degrees. Evaluate using the scale on PPT scoring sheet. 
7. Bring subject to start on a 50 –foot walk test course (25 feet out and 25 feet back) and ask the subject, on the command “go” to walk to the 25,foot mark 
and back. Time from the command “go” until the starting line is crossed on the way back. 
8. Bring subject to foot of stairs (nine to 12 steps) and ask subject, on the command ”go” to begin climbing stairs until they feel tired and wishes to stop. 
Before beginning this task, alert the subject to the possibility of developing chest pain or shortness of breath and inform the subject to tell you if any of 
these symptoms occur. Escort the subject up the stairs. Time from the command “go” until the subjects’ first foot reaches the top of the first flight of 
stairs. Record the number of flights (maximum is four) completed (up and down is one flight). 
 
 
Page 103 of 253 Movement Disorders Clinical Practice
For Review Only
 57
 "*#
 !
2	  
 
Scoring Sheet 
 
 
 
 
  
Time 
 
Scoring 
 
Score 
1. 
 
Write a sentence. 
(Whales live in the blue ocean.) 
Seconds  ≤ 10 sec            = 4 
10.5,15 sec      = 3 
15.5 – 20 sec    = 2 
>20 sec             = 1 
unable               =  0 
 
2.  Simulated eating Seconds  ≤ 10 sec            = 4 
10.5,15 sec      = 3 
15.5 – 20 sec    = 2 
>20 sec             = 1 
unable               =  0 
 
3. Lift a book and put it on a shelf 
    Book PDR 1988: 5.5 lbs 
    Bed height 59 cm 
    Shelf height 118 cm 
    All sitting with feet on floor 
Seconds  ≤ 2 sec            = 4 
2.5, 4 sec        = 3 
4.5 – 6 sec       = 2 
> 6 sec             = 1 
unable            =  0 
 
4. Put on and remove a jacket 
1. Standing 
2. Use of bathrobe; button down 
shirt; hospital gown. 
Seconds  ≤ 10 sec            = 4 
10.5,15 sec      = 3 
15.5 – 20 sec    = 2 
>20 sec             = 1 
unable               =  0 
 
5. Pick up a penny from floor. Seconds  ≤ 2 sec            = 4 
2.5, 4 sec        = 3 
4.5 – 6 sec       = 2 
> 6 sec             = 1 
unable            =  0 
 
6. Turn 360 degrees  Discontinuous steps            = 0 
Continuous steps                   = 2 
 
Unsteady (grabs, staggers)  = 0 
Steady                                  = 2 
 
7. 50,foot walk test. Seconds  ≤ 15 sec            = 4  
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  Starting sitting for instructions. 15.5, 20 sec      = 3 
20.5 – 25 sec    = 2 
>25 sec             = 1 
unable               =  0 
8. Climb one flight of stairs.+ Seconds  ≤ 5 sec            = 4 
5.5, 10 sec      = 3 
10.5 – 15 sec    = 2 
>15 sec             = 1 
unable               =  0 
 
9. Climb stairs.+  Number of flights of stairs up and down 
(maximum 4) 
 
 TOTAL SCORE (maximum 36 for 
nine,item, 28 for seven,item) 
 
 
 
   
 (*Round time measurements to nearest 
0.5 seconds.) 
(+ omit for 7 item test) 
 
 
 
  
9,item score 
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	
	
 
 
#9#	#'%		#
3
#	# 
	"+
+#!	"
4
The 6 condition Romberg test can be scored as individual conditions.  
Stance with feet together, tandem stance and one limb stance have been assessed in HD. 
!*#567"#"7


4
The 6 condition Romberg test has been assessed.   

		8+
		
Assessed standing balance under various conditions. 
 
Romberg and Sharpened Romberg tests are performed with and without cognitive loading and 
with eyes open and eyes closed. 
 
Starting position is feet close together, with both eyes open and then eyes closed, for a maximum 
of 30 seconds under each condition.  
 
Participants then perform the Sharpened Romberg test by standing with one foot placed directly 
in front of the other, with the front heel touching the toes of the back foot (tandem standing), 
again with eyes open and eyes closed. Both conditions of the Sharpened Romberg test are 
performed as a dual task, with the addition of a secondary cognitive task (counting backward by 
3 from100).  
 
The amount of time the patient maintains the position without loss of balance for all 6 conditions 
is recorded (maximum score 180 seconds, with higher scores indicating better balance). 
 
http://www.rehabmeasures.org/Lists/RehabMeasures/DispForm.aspx?ID=1173; 
http://www.rehabmeasures.org/Lists/RehabMeasures/DispForm.aspx?ID=1160 
 
	!!*	8#%4 No. 
	!+#	*!*	8#%4 No. 
 
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	"#	!	"
##	
	#!*#
+#



%
4
Time is scored. 


93	#	
	#	 5 minutes (personal judgment). 
 
 
	#	6
%#+6###
 Clinician (personal judgment). 
!###
0
	6#	
##%!

#
	##4
No. 
 
*#%"	#
#4 Public domain. 
$7
	"
	
#

7#	4
Not applicable 
$
	"
#"#	"

%
%4
– 
3
	#

3		+
##	*
 
*!#	%
	#
8
	#
No. 
3-
+
##	*   
	"#	!	"
+#!!	
	!	"#!#
#4
Not applicable. Performance based test. 
	"
"
+#*7#%"		7


	!	"
##	


7"#"	!	"
#
	
+4
Not applicable. Performance based test. 
#			
	##	

	"
	#	8
%#+
4
Current state. 
:"
	#	"	#!
3%3;#%	"

	7<=4
Not applicable. Performance based test. 
3 
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 	
+#	*6
#
%#!	"
#4
To measure severity of balance impairment. 
	"
	0!!4!$6!0
$
No. 
3	
##	*   
	"%	"!	"

#
	4 Not applicable. 
	"
#%#	###		#	

	#	8
	

#
4
Not applicable. 
	"
#%#	##
	#%
"4 Not applicable. 
	"	#
#
	!#

$
	#4
Not applicable. 
	"

#

$#

	
%4
	"$	
%#7"#"	"
#	

#
4
No, not applicable in non,ambulatory HD. 
3$
	"#
#!#
*+
!#$*84
No. 
3!*		"
+6"
	"

*#$*%	"	"
	"
+4
Not applicable. 
 !
 
	"##0*"	#	#
#$4  

3'#
##	*
 
>	
 Assessed in HD.
1
 
	
#	* – 
2	0		#
##	*
n = 11 (Pre,manifest HD) and n=64 (Manifest HD).
1
 
1) Pre,manifest HD: ICC=0.73. 
2) Manifest HD: ICC=0.89: 
 early stage (TFC=11–13) , ICC= 0.91. 
 middle stage (TFC=7–9) , ICC= 0.86. 
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 late stage (TFC<=6) , ICC= 0.84. 
 
 
	(relatively consistent across disease stages).  
	0
	#
##	* — 
3?
##	*#$   
+3	
 Not assessed in HD.  
#	#+
##	*
*
#7#	"
%0	


No defined gold standard. 
		+
##	*   
-
	

*# N/A 
+%	+
##	* Not assessed. 
#+%	+
##	* Not assessed. 
.+
##%>	%

!!
*6

@%	
	
	
No information for an impression to be given. 
A
#B
##	*   
"7	+
#
	
*	
%!$4 Yes, if the patient is ambulatory.
1
 
"7	+
##
*
	#7#	"
	#
#%#!#
	%#	#+
#
#	4
No (personal judgment). 
'#+		"
%+	##	"		 
	
		#	#+	"
%
"
%+	#		
		4
No.
2
 
		
##	*
$
	"##
##
*#	
	
"
%
##
##
*+
	
#	
#!!
4
MDC: pre,manifest HD=29.70 seconds, manifest HD=37.43 seconds (fairly consistent across 
stages).
1
 
-
##%!!	 Likely to have floor effects for non,ambulatory individuals. 
#	#	# Pre,manifest HD: mean (SD) 158.77 (22.22), manifest HD: mean (SD) 69.98 (41.06).
1
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"#
+
	
%
Useful to differentiate between pre,manifest and manifest HD.  
May have potential as a tool for identifying early stage clinical improvement 
#
+
	
% Difficult to administer in the presence of cognitive deficits. 
" %%	!
#%+#	*!

#
#	#$3
 
 
	
 
 
1. Quinn L, Khalil H, Dawes H, Fritz NE, Kegelmeyer D, Kloos AD$% Reliability and minimal detectable change of physical 
performance measures in individuals with pre,manifest and manifest Huntington disease. #*	2013;93:942,56. 
2. Kegelmeyer DA, Kloos AD, Fritz NE, Fiumedora MM, White SE, Kostyk SK. Impact of tetrabenazine on gait and functional mobility in 
individuals with Huntington's disease. 	2014;347:219,23. 
 
 

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	
	
 
 
-	#
'
"2	
3
#	# 
	"+
+#!	"
4
Yes, one conducted in a standing position and a modified version conducted in a sitting 
position.  
 
http://www.rehabmeasures.org/Lists/RehabMeasures/PrintView.aspx?ID=950 
!*#567"#"7

4 Standing version.
3
 

		8+
		
The test assesses a patient's stability. 
 
It consists of a single task, the patient is asked to reach outside the base of support, and 
the furthest distance reached is measured in inches/centimeters. 
Instructions:
4, 5
 
 The patient is instructed to stand close to, but not touching, a wall, and position 
the arm that is closest to the wall at 90 degrees of shoulder flexion with a 
closed fist. 
 The assessor records the starting position at the 3rd metacarpal head on the 
yardstick. 
 Instruct the patient to “Reach as far as you can forward without taking a step”. 
 The location of the 3rd metacarpal is recorded. 
 The difference between the start and end position is the distance reached, 
usually measured in inches. 
 The test allows for five total trials: two practice trials, followed by three "test" 
trials. The distances of the last three trials are averaged to obtain the patient's 
score. 
 
http://www.rehabmeasures.org/Lists/RehabMeasures/PrintView.aspx?ID=950 
 
	!!*	8#%4 No. 
	!+#	*!*	8#%4 No. 
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 
	"#	!	"
##		
#!*#
+#


%
4
No, measured as continuous values (inches). 


93	#	
	#	
< 2 minutes.
3, 6
  
< 5 minutes (personal judgment). 
 
 
	#	6
%#+6###
 Clinician. 
!###
0
	6#	
##%!
#
	#
#4
No, but standardized instructions must be followed. 
 
*#%"	#
#4 Public domain. 
$7
	"
	
#
7#	4 http://www.rehabmeasures.org/Lists/RehabMeasures/PrintView.aspx?ID=950 
$
	"
#"#	"
%
%4 Not applicable. 
3
	#

3		+
##	*
 
*!#	%
	#
8	# Not applicable. 
3-
+
##	*   
	"#	!	"
+#!!		
!	"#!#
#4
Not applicable. 
	"
"
+#*7#%"		7

	!
	"
##	

7"#"	!	"

#
	+4
Not applicable. 
#			
	##	
	"

	#	8
%#+
4
Current time. 
:"
	#	"	#!
3%3;#%	"
	
7<=4
Current time. 
3 
 	
+#	*6#
%#!
	"
#4
To screen for risk of falls. 
	"
	0!!4!$6!0$ No. 
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NOTE: non,HD, cut,off values have been looked at in various conditions in relation to 
fall risk. http://www.rehabmeasures.org/Lists/RehabMeasures/PrintView.aspx?ID=950 
3	
##	*   
	"%	"!	"

#
	4 Yes (personal judgment). 
	"
#%#	###		#	
	#	8
	


#
4
No (personal judgment). 
	"
#%#	##
	#%
"4 Not applicable.  
	"	#
#
	!#
$

	#4
Yes (personal judgment). 
	"

#

$#
	
%4
	"$	
%#7"#"	"
#	

#
4
No, did not identify changes in pre,manifest HD.
6
 
3$
	"#
#!#
*+!
#$*84
No. 
3!*		"
+6"
	"
*#
$*%	"	"
	"+4
Not applicable. 
 !
 
	"##0*"	#	##$4 Yes. 

3'#
##	* Not assessed in HD. 
>	
 Not assessed in HD. 
	
#	* Not assessed in HD. 
2	0		#
##	*
Not assessed in HD. 
 
Other conditions: 
Community dwelling elderly. ICC = 0.89,0.92.
4, 5
   
Parkinson’s disease: ICC = 0.84
7
 in one study, while another reported ICC= 0.42 in PD 
with no falls history and a ICC=0.93 if falls were present in history.
8
 
	0
	#
##	*
Not assessed in HD. 
 
Other conditions: 
Multiple studies outside PD: all generally ≥ 0.90, 
4, 5, 7
 In PD ICC was reported to be 
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0.64.
9
 
3?
##	*#$   
+3	
 Assessed in HD. 
#	#+
##	*
*
#7#	"%0
	


 No. 
		+
##	*   
-
	

*# No. 
+%	+
##	*
Pre,manifest HD (n=15):
6
 
1) FRT 
% gait parameters of velocity, stride length, cadence (correlations <0.23 
and not significantly different than 0).  
2) FRT 
% dynamic balance, measures: double support % and support base 
(correlations  n.s).
6
  
 
Manifest HD (n=64, excluded: severe dementia or if a walking aid was used, scored 
average of three tests): 
1) FRT 
% gait parameters of velocity: stride length, cadence (correlations = 0.70, 
0.81, 0.60, all significant).  
2) FRT 
% dynamic balance measures: double support % and support base 
(correlations =0.581 and ,0.440, all significant).
3
 
3) FRT 
 UHDRS,TFC (correlation = 0.66, p<0.001).3  
4) FRT 
 HD,ADL (correlation = , 0.451, p<0.05).3 
#+%	+
##	*
.+
##%>	%

!!
*6
@%	

	
	
Good; no concerns based on existing data. 
A
#B
##	*   
"7	+
#
	
*	
%!$4
Not for pre,manifest HD.
6
 
NOTE: Predicted symptom onset was not correlated with FRT (Correlations = 0.23, P 
= 0.44).
6
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Manifest HD: increasing HD severity correlated with decreased scores in the FRT: 
stage I , 14.39 cm, stage II , 12.39 cm, stage III , 8.44 cm, overall and pair,wise 
comparisons were significant (p values <0.01).
3
  
"7	+
##
*
	#7#	"	#

#%#!#
	%#	#+#
#	4
Not tested in severe dementia. 
'#+		"
%+	##	"		 
	
		#	#+	"
%"
%+
	#		
		4
Not assessed in HD. 
		
##	*
$
	"##
##
*#	
	"
%

##
##
*+
	#	
#!!

4
Not assessed in HD. 
-
##%!!	 Not assessed in HD. 
#	#	#
Manifest HD: increasing HD severity correlated with decreased scores in the FRT: 
stage I , 14.39 cm, stage II , 12.39 cm, stage III , 8.44 cm, overall and pair,wise 
comparisons were significant (p values <0.01).
3
  
"#
+
	
% It is a short, easy to use scale that is discriminative. 
#
+
	
%
One used by one group, and because there are some data available – albeit minimal – 
the criteria for “suggested” are met. 
"
%%	$# 

	
(
.  
 
 
	
 
 
1. Quinn L, Khalil H, Dawes H, Fritz NE, Kegelmeyer D, Kloos AD$% Reliability and minimal detectable change of physical 
performance measures in individuals with pre,manifest and manifest Huntington disease. #*	2013;93:942,56. 
2. Kegelmeyer DA, Kloos AD, Fritz NE, Fiumedora MM, White SE, Kostyk SK. Impact of tetrabenazine on gait and functional mobility in 
individuals with Huntington's disease. 	2014;347:219,23. 
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3. Rao AK, Muratori L, Louis ED, Moskowitz CB, Marder KS. Clinical measurement of mobility and balance impairments in Huntington's 
disease: validity and responsiveness. !#	2009;29:433,6. 
4. Weiner DK, Duncan PW, Chandler J, Studenski SA. Functional reach: a marker of physical frailty. !		1992;40:203,7. 
5. Duncan PW, Weiner DK, Chandler J, Studenski S. Functional reach: a new clinical measure of balance. !	1990;45:M192,7. 
6. Rao AK, Louis ED, Marder KS. Clinical assessment of mobility and balance impairments in pre,symptomatic Huntington's disease. !
#	2009;30:391,3. 
7. Schenkman M, Cutson TM, Kuchibhatla M, Chandler J, Pieper C. Reliability of impairment and physical performance measures for 
persons with Parkinson's disease. #*	1997;77:19,27. 
8. Smithson F, Morris ME, Iansek R. Performance on clinical tests of balance in Parkinson's disease. #*	1998;78:577,92. 
9. Lim LI, van Wegen EE, de Goede CJ, Jones D, Rochester L, Hetherington V$% Measuring gait and gait,related activities in 
Parkinson's patients own home environment: a reliability, responsiveness and feasibility study. #	+'	2005;11:19,24. 
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	
	
 
 
H2##			
2	-22
3
#	# 
	"+
+#!	"
4 No. 
!*#567"#"7

4 Not applicable. 

		8+
		
A measure of functional lower limb muscle strength.  May be useful in quantifying 
functional change of transitional movements. 
 
Measures time to complete 5 repetitions of chair stands from a standard chair with 
arms, with arms crossed at shoulders. Inability to complete five repetitions without 
assistance or use of upper extremity support indicates failure of test. (any modifications 
should be documented). 
 
http://www.rehabmeasures.org/Lists/RehabMeasures/PrintView.aspx?ID=1015 
 
	!!*	8#%4 No. 
	!+#	*!*	8#%4 No. 
 
	"#	!	"
##		
#!*#
+#


%
4
Continuous value as it is a measure based on timing. 


93	#	
	#	
1 minute. 
http://www.rehabmeasures.org/Lists/RehabMeasures/PrintView.aspx?ID=1015 
 
 
	#	6
%#+6###

Clinician. 
http://www.rehabmeasures.org/Lists/RehabMeasures/PrintView.aspx?ID=1015 
!###
0
	6#	
##%!
#
	#
#4
No. 
 
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*#%"	#
#4 Public domain. 
$7
	"
	
#
7#	4 http://www.rehabmeasures.org/Lists/RehabMeasures/PrintView.aspx?ID=1015 
$
	"
#"#	"
%
%4 No. 
3
	#

3		+
##	*
 
*!#	%
	#
8	# Not applicable. 
3-
+
##	*   
	"#	!	"
+#!!		
!	"#!#
#4
Not applicable. 
	"
"
+#*7#%"		7

	!
	"
##	

7"#"	!	"

#
	+4
Not applicable. 
#			
	##	
	"

	#	8
%#+
4
Current time. 
:"
	#	"	#!
3%3;#%	"
	
7<=4
Current time – performance based. 
3 
 	
+#	*6#
%#!
	"
#4
Measures severity, i.e., the ability to move from sitting to standing. 
	"
	0!!4!$6!0$ No. 
3	
##	*   
	"%	"!	"

#
	4 Yes (personal judgment). 
	"
#%#	###		#	
	#	8
	


#
4
No (personal judgment). 
	"
#%#	##
	#%
"4 No (personal judgment). 
	"	#
#
	!#
$

	#4
Yes (personal judgment). 
	"

#

$#
	
%4
	"$	
%#7"#"	"
#	

#
4
Unknown; possibly applicable across later stages (personal judgment). 
3$
	"#
#!#
*+! No. 
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#$*84
3!*		"
+6"
	"
*#
$*%	"	"
	"+4
Not applicable. 
 !
 
	"##0*"	#	##$4 No 

3'#
##	*
 
>	
 Not assessed in HD. 
	
#	* Not assessed in HD. 
2	0		#
##	* Not assessed in HD. 
	0
	#
##	* Not assessed in HD. 
3?
##	*#$   
+3	
 Not assessed in HD. 
#	#+
##	*
*
#7#	"%0
	


 No. 
		+
##	*   
-
	

*# Not assessed in HD. 
+%	+
##	* Not assessed in HD. 
#+%	+
##	* Not assessed in HD. 
.+
##%>	%

!!
*6
@%	

	
	
Fair.  
A
#B
##	*   
"7	+
#
	
*	
%!$4
Not assessed. 
"7	+
##
*
	#7#	"	#

#%#!#
	%#	#+#
#	4
No. 
'#+		"
%+	##	"		 
	
		#	#+	"
%"
%+
	#		
		4
Yes.   
Manifest HD (n=15): Open label assessment OFF (at least 18 h before testing) and ON 
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tetrabenazine (TBZ): OFF,TBZ , 15.52 (3.91) seconds; ON,TBZ:  12.61(3.00) 
seconds.
1
 
		
##	*
$
	"##
##
*#	
	"
%

##
##
*+
	#	
#!!

4
No. 
-
##%!!	 Yes. 
#	#	#
Unknown. Only one report. Values described above in %&#
''#( 
"#
+
	
%
Easy to administer. 
Quick; continuous variable. 
#
+
	
%
Does not consider how someone performs the task. Speed may not be the primary 
problem.   
 
*			
(% 
"
%%	$#

	
(
. 
 
 
	
 
 
1. Kegelmeyer DA, Kloos AD, Fritz NE, Fiumedora MM, White SE, Kostyk SK. Impact of tetrabenazine on gait and functional mobility in 
individuals with Huntington's disease. 	2014;347:219,23. 
 
 
 

 
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				
	 

!	" 
#
	
$"	
%"
&	"

		"
	'"$"()%
	
				""
&	"

	""	(

*		 
+	

	&
,%-
	.%$-

-"	('

!
	 
		$&"	"
	
		
	"	"	(
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	
	
 
 
F"
#	
F2
3
#	# 
	"+
+#!	"
4
No.  
http://www.rehabmeasures.org/Lists/RehabMeasures/DispForm.aspx?ID=1122 
!*#567"#"7


4
Not applicable. 

		8+
		
The test measures the strength of the lower extremities. 
Consists of measuring the number of chair stands a patient can perform in 30 seconds.  
 
http://www.rehabmeasures.org/Lists/RehabMeasures/DispForm.aspx?ID=1122 
 
	!!*	8#%4 No. 
	!+#	*!*	8#%4 Yes. 
 
	"#	!	"
##	
	#!*#
+#



%
4
No, a count. 


93	#	
	#	 30 seconds (personal judgment). 
 
 
	#	6
%#+6###
 Clinician. 
!###
0
	6#	
##%!
#
	#
#4
No, but standardized instructions should be followed. 
 
*#%"	#
#4 Public domain. 
$7
	"
	
#

7#	4
http://www.rehabmeasures.org/Lists/RehabMeasures/DispForm.aspx?ID=1122 
$
	"
#"#	" Not applicable. 
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
%
%4
3
	#

3		+
##	*
 
*!#	%
	#
8
	#
No. 
3-
+
##	*   
	"#	!	"
+#!!	
	!	"#!#
#4
Not applicable. 
	"
"
+#*7#%"		7


	!	"
##	

7"#"
	!	"
#
	+4
Not applicable. 
#			
	##	

	"
	#	8
%#+
4
Current state. 
:"
	#	"	#!
3%3;#%	"

	7<=4
Current time. 
3 
 	
+#	*6
#
%#!	"
#4
To measure severity. 
	"
	0!!4!$6!0
$
No, but there are age,based normative data for community dwelling elderly. 
 
http://www.rehabmeasures.org/Lists/RehabMeasures/DispForm.aspx?ID=1122 
3	
##	*   
	"%	"!	"

#
	4 Yes. 
	"
#%#	###		#	

	#	8
	

#
4
No. 
	"
#%#	##
	#%
"4 No. 
	"	#
#
	!#

$
	#4
Not applicable. 
	"

#

$#

	
%4	"
$	
%#7"#"	"
#	
It has only been used in early to mid,stage HD.
1, 2
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#
4
3$
	"#
#!#
*+
!#$*84
No. 
3!*		"
+6"
	"

*#$*%	"	"
	"
+4
Not applicable. 
 !
 
	"##0*"	#	#
#$4
No. 

3'#
##	*
 
>	
 Not assessed in HD. 
	
#	* Not assessed in HD. 
2	0		#
##	* Not assessed in HD. 
	0
	#
##	* Not assessed in HD. 
3?
##	*#$   
+3	
 Not assessed in HD. 
#	#+
##	*
*
#7#	"
%0	


 – 
		+
##	*   
-
	

*# Not applicable. 
+%	+
##	* Not assessed in HD. 
#+%	+
##	* Not assessed in HD. 
.+
##%>	%

!!
*6

@%	
	
	
– 
A
#B
##	*   
"7	+
#
	
*	
%!$4 Not assessed in HD. 
"7	+
##
*
	#7#	"
	#
#%#!#
	%#	#+
#
#	4
Not applicable. 
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'#+		"
%+	##	"		 
	
		#	#+	"
%
"
%+	#		
		4
Task,specific training 
% usual care in a randomized feasibility 8,week trial; Manifest HD, 
n=30: Treatment effect: 1.3 (95% CI: ,0.7, 3.3, n.s.).
2
 
Trial of structured home,based exercise 
% usual care: early to moderate HD with walking or 
balance difficulties, n=25: Mean difference: 3.4 (95% CI: 1.0–5.7, p=0.008).
1
  
		
##	*
$
	"##
##
*#	
	
"
%
##
##
*+
	
#	
#!!
4
No. 
-
##%!!	 Not tested. 
#	#	# Unknown. 
"#
+
	
% Short test requiring minimal equipment, and easy to carry out. 
#
+
	
% Virtually no clinimetric data 
" %%	$#
 
 
	
 
 
1. Khalil H, Quinn L, van Deursen R, Dawes H, Playle R, Rosser A$% What effect does a structured home,based exercise programme 
have on people with Huntington's disease? A randomized, controlled pilot study. 	(2013;27:646,58. 
2. Quinn L, Debono K, Dawes H, Rosser AE, Nemeth AH, Rickards H$% Task,specific training in Huntington disease: a randomized 
controlled feasibility trial. #*	2014;94:1555,68. 
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	
	

 
*
#A
#	9A
3
#	# 
	"+
+#!	"
4
Yes. There are 8 and 4,item tests available. 
http://www.rehabmeasures.org/Lists/RehabMeasures/DispForm.aspx?ID=898 
!*#567"#"7

4 The 8,item version. 

		8+
		
Assesses an individual’s ability to modify balance while walking in the presence of 
external demands. Performed with a marked distance of 20 feet. Can be performed 
with or without an assistive device. 
 
Tasks include 1) steady state walking, 2) walking with changing speeds, 3) walking 
with head turns both horizontally and vertically, 4) walking while stepping over and 
around obstacles, 5) pivoting while walking, and 6) stair climbing. 
 
Highest possible score is 24 points. 
 
http://www.rehabmeasures.org/Lists/RehabMeasures/DispForm.aspx?ID=898 
 
	!!*	8#%4 Not applicable. 
	!+#	*!*	8#%4 Not applicable. 
 
	"#	!	"
##		
#!*#
+#


%
4
Scores are based on a 4,point scale: 
3 = No gait dysfunction 
2 = Minimal impairment 
1 = Moderate impairment 
0 = Severe impairment 
http://www.rehabmeasures.org/Lists/RehabMeasures/DispForm.aspx?ID=898 


93	#	
	#	
<10 minutes 
http://www.rehabmeasures.org/Lists/RehabMeasures/DispForm.aspx?ID=898 
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 
 
	#	6
%#+6###
 Clinician. 
!###
0
	6#	
##%!
#
	#
#4
None. 
 
*#%"	#
#4 Public. 
$7
	"
	
#
7#	4 http://www.rehabmeasures.org/Lists/RehabMeasures/DispForm.aspx?ID=898 
$
	"
#"#	"
%
%4
Yes. Spanish and Arabic. 
http://www.rehabmeasures.org/Lists/RehabMeasures/DispForm.aspx?ID=898 
3
	#

3		+
##	*
See: http://www.rehabmeasures.org/Lists/RehabMeasures/DispForm.aspx?ID=898 
for detailed review of clinimetric properties assessed in non,HD. 
 
*!#	%
	#
8	# Not applicable.  
3-
+
##	*   
	"#	!	"
+#!!		
!	"#!#
#4
– 
	"
"
+#*7#%"		7

	!
	"
##	

7"#"	!	"

#
	+4
– 
#			
	##	
	"

	#	8
%#+
4
Current. 
:"
	#	"	#!
3%3;#%	"
	
7<=4
Current. 
3 
 	
+#	*6#
%#!
	"
#4
To measure severity and screen for risk of falls. 
	"
	0!!4!$6!0$
Not in HD. 
Only in non,HD (e.g., PD, community dwelling elderly): 
http://www.rehabmeasures.org/Lists/RehabMeasures/DispForm.aspx?ID=898 
3	
##	*   
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	"%	"!	"

#
	4 Yes (personal judgment). 
	"
#%#	###		#	
	#	8
	


#
4
No (personal judgment). 
	"
#%#	##
	#%
"4 No (personal judgment). 
	"	#
#
	!#
$

	#4
Yes (personal judgment). 
	"

#

$#
	
%4
	"$	
%#7"#"	"
#	

#
4
Not applicable in non,ambulatory. 
3$
	"#
#!#
*+!
#$*84
No. 
3!*		"
+6"
	"
*#
$*%	"	"
	"+4
Not applicable. 
 !
 
	"##0*"	#	##$4 No. 

3'#
##	*
 
>	
 Not assessed in HD. 
	
#	* Not assessed in HD. 
2	0		#
##	* Not assessed in HD. 
	0
	#
##	* Not assessed in HD. 
3?
##	*#$   
+3	
 Not assessed in HD. 
.+
##%>	%  – 
#	#+
##	*
*
#7#	"%0
	


 – 
		+
##	*
 
-
	

*# Not assessed in HD. 
+%	+
##	* Not assessed in HD. 
#+%	+
##	* Not assessed in HD. 
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.+
##%>	%

!!
*6
@%	

	
	
No data. 
A
#B
##	*   
"7	+
#
	
*	
%!$4 Unknown. Not applicable to non,ambulatory HD (personal judgment). 
"7	+
##
*
	#7#	"	#

#%#!#
	%#	#+#
#	4
Unknown. 
'#+		"
%+	##	"		 
	
		#	#+	"
%"
%+
	#		
		4
Withdrawal of tetrabenazine resulted in significant reduction of DGI scores in an HD 
cohort (n=10): OFF,TBZ: 14.4 (7.01), ON,TBZ: 17.5 (6.94). 
 
NOTE: no change in cognitive or behavioral measures.
1
 
		
##	*
$
	"##
##
*#	
	"
%

##
##
*+
	#	
#!!

4
No. 
-
##%!!	 Unknown. 
#	#	# Unknown. 
"#
+
	
% , 
#
+
	
% Very limited use in HD. 
" %%	$#3
 

	
 
 
1. Fekete R, Davidson A, Jankovic J. Clinical assessment of the effect of tetrabenazine on functional scales in huntington disease: a pilot 
open label study. *		&		+
,-.2012;2. 
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	
	
 

:
<#%7"#	
<#%		::22
3
#	# 
	"+
+#!	"
4 Yes, simple and complex versions.
1
 
!*#567"#"7

4 Both.
1, 2
 

		8+
		
The WWTT is a dual task measure of divided attention to examine cognitive,motor 
interactions, especially in the context of identifying fallers.
 
Subjects are asked to recite the letters of the alphabet while sitting,
2
 then to walk 40 
feet, then asked to walk 40 feet while reciting the letters of the alphabet aloud (WWT,
simple).
1
 
 
Subjects recite alternate letters of the alphabet (a, c, e etc.) while walking (WWT,
complex task).
1, 2
 
 
The time to complete the task is recorded and serves as the test score. 
 
NOTE: indices have been calculated based on differential performance in different 
tasks.  
Dual,task cost (DTC) , the change in performance under dual,task conditions 
relative to the single task condition, as well as a Gait DTC for Simple and Complex 
versions and a Cognitive DTC.
2, 3
 
 
#	#
!: 
http://www.rehabmeasures.org/Lists/RehabMeasures/PrintView.aspx?ID=1059 
 
	!!*	8#%4 No.
1
 
	!+#	*!*	8#%4 No.
1
 
 
	"#	!	"
##		 Performance,based test (time in seconds and number of errors recorded).
1
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#!*#
+#


%
4


93	#	
	#	
Less than 1 minute, but 3,10 minutes including instructions to participant and warm,up 
test. 
http://www.rehabmeasures.org/Lists/RehabMeasures/PrintView.aspx?ID=1059 
 
 
	#	6
%#+6###
 Clinician. 
!###
0
	6#	
##%!
#
	#
#4
No. 
 
*#%"	#
#4 Public.  
$7
	"
	
#
7#	4 Unknown. 
$
	"
#"#	"
%
%4 – 
3
	#

3		+
##	*
 
*!#	%
	#
8	# Not applicable. 
3-
+
##	*   
	"#	!	"
+#!!		
!	"#!#
#4
Not applicable. 
	"
"
+#*7#%"		7

	!
	"
##	

7"#"	!	"

#
	+4
Not applicable. 
#			
	##	
	"

	#	8
%#+
4
Current state. 
http://www.rehabmeasures.org/Lists/RehabMeasures/PrintView.aspx?ID=1059 
:"
	#	"	#!
3%3;#%	"
	
7<=4
Not applicable. 
http://www.rehabmeasures.org/Lists/RehabMeasures/PrintView.aspx?ID=1059 
3 
 	
+#	*6#
%#!
	"
#4
Screen for risk of falls. 
 
	"
	0!!4!$6!0$
Not for HD. 
In non,HD:  ≥33 seconds for WWT complex versions and risk of falls in a non,
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demented community,living elderly: sensitivity of 38.5, specificity of 95.6, positive 
predictive value of 71.4.
1
 
http://www.rehabmeasures.org/Lists/RehabMeasures/PrintView.aspx?ID=1059 
3	
##	*   
	"%	"!	"

#
	4 Yes (personal judgment). 
	"
#%#	###		#	
	#	8
	


#
4
No (personal judgment). 
	"
#%#	##
	#%
"4
 
	"	#
#
	!#
$

	#4
Yes, in ambulatory HD patients.
2
 
	"

#

$#
	
%4
	"$	
%#7"#"	"
#	

#
4
No. Applicable in ambulatory HD only.
2
 
3$
	"#
#!#
*+!
#$*84
No. 
3!*		"
+6"
	"
*#
$*%	"	"
	"+4
Not applicable. 
 !
 
	"##0*"	#	##$4 Yes.
2
 

3'#
##	*
 
>	
 Not assessed. 
	
#	* Not assessed. 
2	0		#
##	* Not assessed. 
	0
	#
##	*
Not assessed. 
3?
##	*#$   
+3	
 Not assessed. 
#	#+
##	*
*
#7#	"%0
	


 – 
		+
##	*   
-
	

*#
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+%	+
##	*
Manifest HD, n=32
2
  
 
a. Time to complete: 
 WWTT,simple: correlated with UHDRS,TMS (Spearman’s Rho of 0.37 
[95%CI ,0.01 to 0.66] although CI goes over 0, p<0.05), but not age, 
gender, or UHDRS,TFC (Spearman’s ,0.29, n.s.). Slower time to 
complete the WWTT,simple is reported to be correlated with poorer 
performance on the Trail Making Tests A and B (Spearman’s Rho 0.52, 
and 0.42), Stroop word and interference, and Symbol Digit Modalities 
Test (SDMT) (Spearman’s ,0.42, ,0.51, and ,0.43) all p<0.05).  
 WWTT,complex: not correlated with UHDRS,TMS (Spearman’s Rho 
of 0.310, n.s.). Correlated with UHDRS,TFC (Spearman’s Rho of ,
0.618 [95%CI ,0.832 to 0.321] p<0.01). Slower time to complete the 
WWTT,complex is reported to be correlated with poorer performance 
on both Trails A and Trails B (Spearman’s Rho 0.53, and 0.51), as well 
as poorer performance on the Stroop color (,0.37), word (,0.35), and 
interference (,0.38) and the SDMT (,0.50), all p<0.05).  
b. The number of prospective falls was reported to be related to WWTT,simple (r = 
0.86; p < 0.001; 95% CI (0.62– 0.96)), and moderately WWTT,complex (r = 0.44; 
p = 0.058; 95% CI (0.01–0.73).  
 
#+%	+
##	*
Manifest HD, n=35 
2
 
 
No correlation between WWTT and disease,specific measures in individuals with 
UHDRS,TMS ≥ 35.
2
 
.+
##%>	%

!!
*6
@%	

	
	
– 
A
#B
##	*   
"7	+
#
	
*	
%!$4 No.
2
 
"7	+
##
*
	#7#	"	#

#%#!#
	%#	#+#
#	4
Unknown. 
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'#+		"
%+	##	"		 
	
		#	#+	"
%
"
%+	#		
		4
Not assessed. 
		
##	*
$
	"##
##
*#	
	"
%

##
##
*+
	#	
#!!

4
No. 
-
##%!!	 Unknown. 
#	#	#
Manifest HD, n=32
2
 
 
$'02/IH3
Simple (s) , 11.9 (3.3). 
Complex (s) , 17.1 (8.5). 
 
$'02/JH3
Simple (s) ,  14.9 (7.0). 
Complex (s) , 21.9 (17.9). 
"#
+
	
% This test may be useful in predicting future falls in individuals with HD. 
#
+
	
% Sparse data in HD limited to a single study. 
" %%	$#3
 
	
 
 
1. Verghese J, Buschke H, Viola L, et al. Validity of divided attention tasks in predicting falls in older individuals: a preliminary study. J 
Am Geriatr Soc 2002;50:1572,1576. 
2. Fritz NE, Hamana K, Kelson M, Rosser A, Busse M, Quinn L. Motor,cognitive dual,task deficits in individuals with early,mid stage 
Huntington disease. Gait Posture 2016;49:283,289. 

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	
	
 
 
2#GH-	:
<2	2GH-:
3
#	# 
	"+
+#!	"
4 No. 
!*#567"#"7

4
 
Not applicable. 

		8+
		
The T25FW is a clinical tool to evaluate patients for quantitative mobility and leg 
function performance in a timed, 25,foot walk. 
 
The patient is directed to walk 25 feet as quickly and as safely as possible from one 
marked end to the other (a straight distance without turns).  
 
The time is calculated from the moment the patient is instructed to begin, until the 
patient has reached the 25,foot mark. The second test is immediately administered 
again by having the patient walk the same distance. Patients may use assistive devices 
while doing this task. 
 
This is a single measure of time based on average of two tests 
 
http://www.rehabmeasures.org/Lists/RehabMeasures/DispForm.aspx?ID=1204 
 
	!!*	8#%4 No. 
	!+#	*!*	8#%4 No. 
 
	"#	!	"
##		
#!*#
+#


%
4
Time in seconds; note timing score is problematic if person cannot walk 25 feet. 


93	#	
	#	
< 5 minutes, requires stop watch and markings for 25 feet distance on floor. 
http://www.rehabmeasures.org/Lists/RehabMeasures/DispForm.aspx?ID=1204 
 
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	#	6
%#+6###

Clinician. 
http://www.rehabmeasures.org/Lists/RehabMeasures/DispForm.aspx?ID=1204 
!###
0
	6#	
##%!
#
	#
#4
No. 
 
*#%"	#
#4 Public domain. 
$7
	"
	
#
7#	4 Not applicable. 
$
	"
#"#	"
%
%4 Not applicable. 
3
	#

3		+
##	*
 
*!#	%
	#
8	# N/A 
3-
+
##	*   
	"#	!	"
+#!!		
!	"#!#
#4
No. 
	"
"
+#*7#%"		7

	!
	"
##	

7"#"	!	"

#
	+4
No, only a single domain is covered. 
#			
	##	
	"

	#	8
%#+
4
Current state. 
:"
	#	"	#!
3%3;#%	"
	
7<=4
Not applicable. 
3 
 	
+#	*6#
%#!
	"
#4
To measure severity. 
http://www.rehabmeasures.org/Lists/RehabMeasures/DispForm.aspx?ID=1204 
	"
	0!!4!$6!0$
Not in HD. 
 
There are age, and sex,based normative data in healthy adults (age range 20s to 70s): 
Men comfortable speed ranges 1.39 m/s to 1.33, and women 1.41 to 1.27 m/s and 
range fast,paces men 2.53 to 2.08 m/s and women 2.47 to 1.74 m/s (.n=230 age 20,70 
measure over 6.62 m with acceleration and deceleration period so completely 
compatible with 10 meter walk , really 25 foot walk).
4
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3	
##	*   
	"%	"!	"

#
	4 Not applicable. 
	"
#%#	###		#	
	#	8
	


#
4
No. 
	"
#%#	##
	#%
"4 N/A 
	"	#
#
	!#
$

	#4
The task is appropriate. 
	"

#

$#
	
%4
	"$	
%#7"#"	"
#	

#
4
Yes, unless the patient is non,ambulatory. 
3$
	"#
#!#
*+!
#$*84
No. 
3!*		"
+6"
	"
*#
$*%	"	"
	"+4
The scale has been deployed in HD. 
 !
 
	"##0*"	#	##$4
Not in HD. 
 
In non,HD: The American Physiotherapy Task Force Neurology Section, studied the 
T25WT largely for multiple sclerosis but also made recommendations from 
Parkinson’s, Spinal Cord Injury, Stroke, Traumatic Brain Injury and Vestibular task 
forces. 
 
Website provides the summary of measurement properties related to those reported 
here 
http://www.rehabmeasures.org/Lists/RehabMeasures/DispForm.aspx?ID=1204 
  

3'#
##	*
 
>	
 Not assessed in HD. 
	
#	* Not assessed in HD. 
2	0		#
##	* Not assessed in HD. 
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Non,HD: healthy controls; ICC=0.88.
5
 
	0
	#
##	*
Not assessed in HD. 
 
Non,HD: ICC=0.94 in MS patients; ICC=0.88 in healthy controls.
5
 
 
3?
##	*#$   
+3	
 Not assessed. 
#	#+
##	*
*
#7#	"%0
	


– 
		+
##	*   
-
	

*# Not assessed in HD. 
+%	+
##	*
Not assessed in HD. 
 
Non,HD: Excellent correlation with Expanded Disability Status Scale for classifying 
multiple sclerosis (EDSS) (r = 0.6686; p<0.0001, the T100MW (r = 0.9227; 
p<0.0001).  
For patients with limited ambulation, there was an excellent correlation with walking 
distance (r = , 0.7121; n = 53 MS patients).  
For patients with restricted ambulation, there was an excellent correlation with walking 
distance (r = , 0.6861; n = 44 MS patients).
5
 
#+%	+
##	* Not assessed in HD. 
.+
##%>	%

!!
*6
@%	

	
	
No data in HD. 
A
#B
##	*   
"7	+
#
	
*	
%!$4 Unknown. 
"7	+
##
*
	#7#	"	#

#%#!#
	%#	#+#
#	4
No, but there are no concerns about existing measurement properties (personal 
judgment). 
'#+		"
%+	##	"		 
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	
		#	#+	"
%"
%+
	#		
		4
Withdrawal of tetrabenazine resulted in significant reduction of T25WT scores in a 
manifest HD cohort (n=10): Mean(SD) off: 8.5 (3.6) and on drug 8.1 (2.1), n.s.. Same 
trial s.s. change for BBS and DGI. 
Manifest HD with chorea, n=11:
6
 No significant change in response to tetrabenazine 
(TBZ): ON,TBZ ,5.4 ± 1.9 OFF,TBZ , 5.3 ± 1.7. Same trial n.s. change for BBS. 
		
##	*
$
	"##
##
*#	
	"
%

##
##
*+
	#	
#!!

4
No. 
-
##%!!	 Unknown 
#	#	#
See data listed in %&#''#
( 
6
 
"#
+
	
% Quick and requires little equipment. 
#
+
	
%
Only for ambulatory patients.  
Not enough data in HD.  
" #	
 
 
	
 
 
1. Verghese J, Buschke H, Viola L, Katz M, Hall C, Kuslansky G$% Validity of divided attention tasks in predicting falls in older 
individuals: a preliminary study. !		2002;50:1572,6. 
2. Fritz NE, Hamana K, Kelson M, Rosser A, Busse M, Quinn L. Motor,cognitive dual,task deficits in individuals with early,mid stage 
Huntington disease. !#	2016;49:283,9. 
3. Hall CD, Echt KV, Wolf SL, Rogers WA. Cognitive and motor mechanisms underlying older adults' ability to divide attention while 
walking. #*	2011;91:1039,50. 
4. Bohannon RW. Comfortable and maximum walking speed of adults aged 20,79 years: reference values and determinants. 
1997;26:15,9. 
5. Phan,Ba R, Pace A, Calay P, Grodent P, Douchamps F, Hyde R$% Comparison of the timed 25,foot and the 100,meter walk as 
performance measures in multiple sclerosis. 		(	'	2011;25:672,9. 
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6. Ferrara JM, Mostile G, Hunter C, Adam OR, Jankovic J. Effect of tetrabenazine on motor function in patients with huntington disease. 
	*	2012;1:5. 
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	
	

 
G0	7
<#%6"
	
#%#F6
	#	#<GF
3
#	# 
	"+
+#!	"
4 No. 
!*#567"#"7

4 Not applicable. 

		8+
		
The test assesses bradykinesia through timed measures of walking, hand tapping and 
drinking water. 
 
The test consists of assessing walking 12 meters, hand tapping in 30 seconds and the 
time to drink 120 ml of water.   
 
No details of test administration given.
1, 2
 
 
	!!*	8#%4 No. 
	!+#	*!*	8#%4 No. 
 
	"#	!	"
##		
#!*#
+#


%
4
Not applicable. Timed performance measure. 


93	#	
	#	 5,10 min (personal judgment). 
 
 
	#	6
%#+6###
 Clinician. 
!###
0
	6#	
##%!
#
	#
#4
No. 
 
*#%"	#
#4 Not applicable. 
$7
	"
	
#
7#	4 Not applicable. 
$
	"
#"#	"
%
%4 Not applicable. 
3
	#
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3		+
##	*
 
*!#	%
	#
8	# Not applicable. 
3-
+
##	*   
	"#	!	"
+#!!		
!	"#!#
#4
Yes. 
	"
"
+#*7#%"		7

	!
	"
##	

7"#"	!	"

#
	+4
The test covers three separate functional times, but all appear to measure bradykinesia. 
#			
	##	
	"

	#	8
%#+
4
Current state/performance. 
:"
	#	"	#!
3%3;#%	"
	
7<=4
Not applicable. 
3 
 	
+#	*6#
%#!
	"
#4
To measure severity of bradykinesia/time to complete task. 
	"
	0!!4!$6!0$ No. 
3	
##	*   
	"%	"!	"

#
	4 Yes. 
	"
#%#	###		#	
	#	8
	


#
4
Not applicable. 
	"
#%#	##
	#%
"4 Not applicable. 
	"	#
#
	!#
$

	#4
Not applicable. 
	"

#

$#
	
%4
	"$	
%#7"#"	"
#	

#
4
Likely not applicable in more advanced stages, namely in non,ambulatory HD 
(personal judgment). 
3$
	"#
#!#
*+!
#$*84
Yes. 
3!*		"
+6"
	"
*#
$*%	"	"
	"+4
Unknown. 
 !
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	"##0*"	#	##$4 No. 

3'#
##	*
 
>	
 Not assessed in HD. 
	
#	* Not assessed in HD. 
2	0		#
##	* Not assessed in HD. 
	0
	#
##	* Not assessed in HD. 
3?
##	*#$   
+3	
 Not assessed in HD. 
#	#+
##	*
*
#7#	"%0
	


No. 
		+
##	*   
-
	

*# Not assessed in HD. 
+%	+
##	* Not assessed in HD. 
#+%	+
##	* Not assessed in HD. 
.+
##%>	%

!!
*6
@%	

	
	
Unable to assess due to lack of data. 
A
#B
##	*   
"7	+
#
	
*	
%!$4 Yes, except in pre,manifest HD and non,ambulatory HD (personal judgment). 
"7	+
##
*
	#7#	"	#

#%#!#
	%#	#+#
#	4
No. 
'#+		"
%+	##	"		 
	
		#	#+	"
%"
%+
	#		
		4
It has been shown to be sensitive to change in time in a longitudinal study.
1
 
		
##	*
$
	"##
##
*#	
	"
%

##
##
*+
	#	
#!!

4
No. 
-
##%!!	 No. 
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#	#	# No. 
"#
+
	
%
The different timing measures appear to be sensitive to change in time.   
It measures bradykinesia across three unique tasks, including drinking, which is 
unique. 
#
+
	
%
Unknown if it is sensitive to change secondary to treatment.  
Lack summary measure for the whole test. 
" #	3
 
 
	
 
 
1. Barker RA, Mason SL, Harrower TP, Swain RA, Ho AK, Sahakian BJ$% The long,term safety and efficacy of bilateral 
transplantation of human fetal striatal tissue in patients with mild to moderate Huntington's disease. 		$			)
#	2013;84:657,65. 
2. Michell AW, Goodman AO, Silva AH, Lazic SE, Morton AJ, Barker RA. Hand tapping: a simple, reproducible, objective marker of 
motor dysfunction in Huntington's disease. 	2008;255:1145,52. 
 

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	
	
 

K02
*$
-	#2	
3
#	# 
	"+
+#!	"
4 No. 
!*#567"#"7

4 Not applicable. 

		8+
		
Seven,item test designed to provide an objective measure of various aspects of hand 
function. Measures unilateral hand function. Assesses speed, not quality of 
performance.
1
 
 
Participants are timed performing common functional activities: writing, card turning 
(simulated page turning), picking up small common objects, simulated feeding, 
stacking checkers, lifting light cans, and lifting weighted cans (scored as total time to 
complete tasks, high score=impaired).
2
 
 
Time spent to perform each task has also been reported.
3
 Maximum time allotted per 
subtest is 120 seconds. Each item performed with each hand separately – non,dominant 
hand first.
1
 
 


	!!*	8#%4 No. 
	!+#	*!*	8#%4 No. 
 
	"#	!	"
##		
#!*#
+#


%
4
Not applicable. Timed performance measure. 


93	#	
	#	 15 minutes.
1
 


 
	#	6
%#+6###
 Clinician. 
!###
0
	6#	
##%!
#
	# No. 
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#4
 
*#%"	#
#4 Copyright. 
$7
	"
	
#
7#	4 A test kit is sold commercially through multiple vendors.
1
 
$
	"
#"#	"
%
%4 Not applicable. 
3
	#

3		+
##	*
 
*!#	%
	#
8	# Not applicable. 
3-
+
##	*   
	"#	!	"
+#!!		
!	"#!#
#4
Yes. 
	"
"
+#*7#%"		7

	!
	"
##	

7"#"	!	"

#
	+4
The test covers various functional tasks that cover different aspects of upper extremity 
function (personal judgment). 
#			
	##	
	"

	#	8
%#+
4
Current state/performance. 
:"
	#	"	#!
3%3;#%	"
	
7<=4
Not applicable. 
3 
 	
+#	*6#
%#!
	"
#4
Measure impairment of speed of hand function tasks (severity).
1
 
	"
	0!!4!$6!0$ Not applicable. 
3	
##	*
 
	"%	"!	"

#
	4 Yes (personal judgment). 
	"
#%#	###		#	
	#	8
	


#
4
Not applicable. 
	"
#%#	##
	#%
"4 Not applicable. 
	"	#
#
	!#
$

	#4
Not applicable. 
	"

#

$#
	
%4
	"$	
%#7"#"	"
#	
Not applicable. 
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#
4
3$
	"#
#!#
*+!
#$*84
No. 
3!*		"
+6"
	"
*#
$*%	"	"
	"+4
Not applicable. 
 !
 
	"##0*"	#	##$4 No. 

3'#
##	*
 
>	
 Not assessed in HD. 
	
#	* Not assessed in HD. 
2	0		#
##	* Not assessed in HD. 
	0
	#
##	* Not assessed in HD. 
3?
##	*#$   
+3	
 Not assessed in HD. 
#	#+
##	*
*
#7#	"%0
	


No. 
		+
##	*   
-
	

*# Not assessed in HD. 
+%	+
##	* Not assessed in HD. 
#+%	+
##	*
ON, and OFF,tetrabenazine open label study (n=11)
3
: negative correlation between 
multiple items of the JTHFT and the MoCA score, stronger for dominant hand. 
.+
##%>	%

!!
*6
@%	

	
	
Unable to assess due to lack of data. 
A
#B
##	*   
"7	+
#
	
*	
%!$4 No. Used only in symptomatic HD with chorea. 
2, 3
 
"7	+
##
*
	#7#	"	#

#%#!#
	%#	#+#
#	4
No (personal judgment). 
'#+		"
%+	##	"		 
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	
		#	#+	"
%"
%+
	#		
		4
ON, and OFF,tetrabenazine open label study (n=11)
3
: no s.s. difference. 
 
ON, and OFF,tetrabenazine open label study (n=10)
2
 : #
	"
 – OFF, 131.2 
(73.3); ON, 125.0 (57.1), p=0.647; non,#
	"
 – OFF, 193.1 (111.6); ON, 
217.3 (111.3), p=0.285 
		
##	*
$
	"##
##
*#	
	"
%

##
##
*+
	#	
#!!

4
No. 
-
##%!!	 Unknown in HD. 
#	#	#  Scores on the JTHFT were globally slower.
3
 
"#
+
	
% Attempts to measure upper limb function in HD. 
#
+
	
% Little use in HD. 
" #	3
 

	
 
 
1. Rehab Measures: Jebsen Hand Function Test. In; 2012. 
2. Fekete R, Davidson A, Jankovic J. Clinical assessment of the effect of tetrabenazine on functional scales in huntington disease: a pilot 
open label study. *		&		+
,-.2012;2. 
3. Ferrara JM, Mostile G, Hunter C, Adam OR, Jankovic J. Effect of tetrabenazine on motor function in patients with huntington disease. 
	*	2012;1:5. 

Page 148 of 253Movement Disorders Clinical Practice
For Review Only
 102

'2(A

 
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	
	
 

 
2"#!#$	#%	&#
'
	#%
$'2	
-	#


#	*2-
3
#	# 
	"+
+#!	"
4 No.
1
 
!*#567"#"7

4 Not applicable.
1
 

		8+
		
The UHDRS,Total Functional Capacity (TFC) is part of a multi,component scale 
designed originally to prospectively evaluate all patients with HD and individuals at 
risk for HD. The UHDRS,TFC focuses on assessment of capacity rather than actual 
performance. 
 
UHDRS,TFC is a brief interview involving the patient and a close family member or 
friend familiar with the patient’s functioning. There are 5 items covering basic 
activities of living: 1) occupation, 2) handling finances, 3) domestic responsibilities, 4) 
ADLs (eating, dressing, bathing), and 5) level of care (home or facility).  
 
The UHDRS,TFC places emphasis on the clinician’s judgment and does not require 
rigorous documentation of performance.  
 
Higher scores on the function scales indicate better functioning than lower scores.  
 
The Shoulson and Fahn HD Staging system categorizes the total UHDRS,TFC scores 
in the stages I (11,13), II (7,10), III (3,6), IV (1,2), and V (0).
2
 
 
	!!*	8#%4 No.
2
 
	!+#	*!*	8#%4 Yes.
2
 
 
	"#	!	"
##		
#!*#
+#


%
4
Discrete steps. Variable range (3 to 4 steps).
2
 


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93	#	
	#	
2,5 min (personal judgment). 
The full UHDRS will take approx. 30 min.
1
 
 
 
	#	6
%#+6###
 Clinician (with information from patient and caregiver) (personal judgment). 
!###
0
	6#	
##%!
#
	#
#4
No (personal judgment). 
 
*#%"	#
#4 Copyright.
2
 
$7
	"
	
#
7#	4 HSG, prior written permission is required. E,mail: info@hsglimited.org 
$
	"
#"#	"
%
%4
Yes (Portuguese, French, German, Dutch, Danish, Italian, Polish, Russian, Czech, 
Norwegian, Swedish).
3
 
3
	#

3		+
##	*
 
*!#	%
	#
8	#
Yes. 
1
 
1) Creation of a single scale based on pre,existing scales: Quantitated neurological 
exam (QNE), HD functional capacity scale (HDFCS), the HD motor rating 
scale (HDMRS), the Physical Disability and Independence scales, Marsden and 
Quinn’s chorea severity scale, the HD Activities of Daily Living scale, and 
other relevant measures.  
2) Followed by "several months of pilot experience". 
3) Neurologists, psychiatrists, neuropsychologists, and other professionals 
participated in the drafting of the scale.  
3-
+
##	*   
	"#	!	"
+#!!		
!	"#!#
#4
Yes (occupation, financial, domestic chores, activities of the daily living, care level).
2
 
	"
"
+#*7#%"		7

	!
	"
##	

7"#"	!	"

#
	+4
– 
#			
	##	
	"

	#	8
%#+
4
Current state based on clinical best judgment and patient/caregiver report. 
:"
	#	"	#!
3%3;#%	"
	 Current state. 
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7<=4
3 
 	
+#	*6#
%#!
	"
#4
Measure severity of functional capacity (personal judgment). 
	"
	0!!4!$6!0$ No (personal judgment). 
3	
##	*   
	"%	"!	"

#
	4 Yes (5 items) (personal judgment). 
	"
#%#	###		#	
	#	8
	


#
4
No (personal judgment). 
	"
#%#	##
	#%
"4 No (personal judgment). 
	"	#
#
	!#
$

	#4
Yes (personal judgment). 
	"

#

$#
	
%4
	"$	
%#7"#"	"
#	

#
4
Yes. No. (personal judgment). 
3$
	"#
#!#
*+!
#$*84
Yes.
2
 
3!*		"
+6"
	"
*#
$*%	"	"
	"+4
Yes.
2, 4,6
 
 !
 
	"##0*"	#	##$4 Yes. 

3'#
##	*
 
>	
 Assessed in HD. 
	
#	* Not assessed. 
2	0		#
##	* Not assessed. 
	0
	#
##	*
Agreement among 7 raters , fully concordant in 27% ratings, within one unit 65% 
concordance. Spearman’s correlation for identical item score. Range: 0.44 , 0.82(mean 
0.62). 
)
 
 
n=29, UHDRS,TFC modified for assessment of ability and not capacity: HD patient 
and caregiver , ICC 0.96 (0.92, 0.98).
8
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3?
##	*#$   
+3	
 Assessed in HD. 
#	#+
##	*
*
#7#	"%0
	


There is no gold,standard (personal judgment). 
		+
##	* 
-
	

*# No. 
+%	+
##	*
Manifest HD, n=25: UHDRS,TFC X HD,ADL r=,0.89 p<0.001, vs disease duration 
r=,0.38 p<0.05, vs MMSE r=0.71 p<0.001.
9
 
 
Manifest HD, n=489: UHDRS,TFC X UHDRS,FAS r=0.94 p<0.005, UHDRS,TFC X 
UHDRS,IS  r=0.94 p<0.005. 
1
 
 
Manifest HD, n=22: UHDRS,TFC X Unspecified 5,point response QoL scale, r=0.54 
p<0.05.
10
 
 
Manifest HD, n= 70: UHDRS,TFC x SF,36 mental summary score, r=0.42, p=0.000, 
vs SF,36 physical summary score, r=0.68, p=0.000.
11
 
 
Manifest HD, n=30, UHDRS,TFC x Functional reach test r=0.66, p<0.001, UHDRS,
TFC x Timed up and go r=,0.68, p<0.001, UHDRS,TFC x Berg Balance Test r=0.60, 
p<0.01, UHDRS,TFC x UHDRS,TMS r=,0.546 p<0.01.
G
 
 
Manifest HD, n=132, 3'*5,
	
			.) x HD,PRO,TRIAD r=0.72 p<0.05.
8
 
 
Manifest HD, n=18, Association between UHDRS,TFC and MiniBESTest Score: 
r2=0.45, p=0.0024.
14

 
Manifest HD, n=69/46 (2 cohorts), UHDRS,TFC x UHDRS,TMS r= ,0.87/ ,0.83 both 
p<0.001.
15
 
 
Manifest HD, n=82, UHDRS,TFC x UHDRS,TMS, r=,0.08 p<0.005, x several 
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cognitive assessments including object recall, word fluency, Stroop, all p<0.0005.  
UHDRS,TFC x PBA,HD Subscales: apathy r = ,0.85, p<0.0001, irritability and 
depression subscales, p=ns.
16
  
 
Manifest HD with UHDRS,TFC≤5, n=53, UHDRS,TFC x UHDRS,FAS r= ,0.90 
p<0.001, UHDRS,TFC x UHDRS,TMS r=,0.69 p<0.001, UHDRS,TFC x UHDRS ,
behavioral p=n.s., x UHDRS,TFC x UHDRS cognitive assessment r=0.76, p<0.001.
17
 
#+%	+
##	* , 
.+
##%>	%

!!
*6
@%	

	
	
Lacks reliability data, despite widespread use (personal judgment). 
A
#B
##	*   
"7	+
#
	
*	
%!$4 Yes (personal judgment). 
"7	+
##
*
	#7#	"	#

#%#!#
	%#	#+#
#	4
Potentially with caregiver information (personal judgment). 
'#+		"
%+	##	"		 
	
		#	#+	"
%"
%+
	#		
		4
Manifest HD, n=22, mean f/u of 27 months. Decline from a mean±SEM of 7.9 ± 0.72 
to 4.0 ± 0.67 (p < 0.001), at a rate of 1.8 units per yr. The rate of decline was similar 
for minimally disabled patients (stages I and II) and for those with more advanced 
disability (stages III through V).
G
 
 
Manifest HD, n=47, mean 2.2 years. The average UHDRS,TFC score changed from 
8.2 ± 0.50 units (mean ± SEM) at the initial examination to 5.9 ± 0.51 units at the last 
examination. Average TFC decline of 1.05 UHDRS,TFC units/yr. Average rate of 
decline per initial HD stage: 1.6 units/yr (stage I), 0.9 units/yr (stage II), 0.5 units/yr 
(stage III), 0.3 units/yr  (stage IV).
5
 
 
Manifest HD, n=26, RCT of baclofen vs. placebo, follow,up 30 months.  Change 
in  UHDRS,TFC Units/year (mean±SD): ,0.53 ± 0.45 / year (placebo), ,0.85 ± 0.64 / 
year (baclofen).
4
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Manifest HD, n=50, mean ± SD f/u=4.4 ± 2.9 years,  mean ± SD UHDRS,TFC rate of 
decline per year = 0.5  ± 0.6.
L
 
 
Manifest HD, n=129 mean ± SD f/u = 3.6 ± 2.3 years, mean ± SD UHDRS,TFC rate 
decline per year= ,0.63 ± 0.75.
M
 
 
Manifest HD, n=202, mean ± SD f/u = 8.0 ± 2.4 months, mean ± SD UHDRS,TFC 
decline in 6 months= ,0.3 ± 1.6.

 
 
Manifest HD, RCT Fluoxetine vs. placebo, n=12/11, f/u=4 months, Mean change ± SD 
scores of UHDRS,TFC: 0.25 ± 2.7 (Fluoxetine) 
% 0.09 ± 2.0 (placebo) p=n.s.
20
 
 
Manifest HD, RCT OPC,14117 vs. placebo, n=40/16, f/u=20 weeks, no statistically 
significant differences.
G
 
 
Manifest HD, n=72, UHDRS,TFC decline after one year: 0.56 95% CI:  0.02,1.09, 
p=0.042. 
22
 
 
Manifest HD, RCT Lamotrigine vs. placebo, n= 28/27, f/u=30 months. Mean change 
(± SD) scores of UHDRS,TFC: 1.89 ± 2.46/ 2.11 ± 1.00, n.s..
23
 
 
Manifest HD, n=960, mean follow,up= 18.3 months.
24
 
Mean (SE) UHDRS,TFC decline ,0.72(0.04)/yr. 
Rate of UHDRS,TFC decline in function of symptom’s duration: 
24
 
1. 1.11 (0.16) units/yr for those with 0 to 2 yrs duration. 
2. 0.85 (0.09) units/yr for those with 2,5 yrs duration. 
3. 0.60 (0.07) units/yr for those with 5,10 yrs duration. 
4. 0.66 (0.08) units/yr for those with 10,20 yrs duration.  
Rate of functional decline for stage I HD: 1.15 (0.09) units/yr; 0.84 (0.08) units/yr for 
stage II; 0.38 (0.08) units/yr for stage III; 0.06 (0.10) units/yr for stages IV and V.
24
 
 
Manifest HD,  RCT CoQ10 vs. remacemide vs. combination vs. placebo, 
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n=87/86/87/87 f/u=31months. Mean change ± SD scores of UHDRS,TFC:  
placebo =,2.7 ± 2.3; CoQ10 treated = ,2.4 ± 2.2; Non,CoQ10 treated =  ,2.7 ± 2.3; 
combination = ,2.4 ± 2.1, comparison between arms all n.s..
GH
 
 
Manifest HD,  n=815, mean f/u =2.7 years, UHDRS,TFC decline = ,0.73/ yr;  95% CI: 
0.67–0.78, p<0.0001.
GC
 
 
Manifest HD, RCT placebo vs. riluzole 100 mg vs. riluzole 200 mg, n=22/18/23 f/u=8 
weeks. Mean change ± SD scores of UHDRS,TFC: , 0.3 ±1.1/ 0.1 ± 0.9/ ,0.1 ± 1.4 
p=n.s.
G)
 
 
Manifest HD, RCT placebo vs. minocycline 100 mg vs.  minocycline 200 mg, 
n=23/18/19, f/u= 8 weeks, Mean change ± SD scores of UHDRS,TFC at =+0.04 
±1.26/ ,0.22 ± 0.73/ +0.11 ± 0.94, p=n.s.
GL
 

Manifest HD, RCT ethyl,EPA/placebo, n=39/44, f/u=12 months, UHDRS,TFC 
decline: n.s. between arms.
29
 
 
Manifest HD, RCT ethyl,EPA vs. placebo, n=316, f/u = 6 + 6 (open label) months, 
UHDRS,TFC at 6 months:  ,0.2 vs. ,0.3, p=n.s; UHDRS,TFC at 12 months: ,0.6/ ,0.4 
p=n.s. arm comparison.
30
  
 
Manifest HD, RCT placebo/donepezil, n=12/12 1:1 f/u=12w, Median change UHDRS,
TFC 0 / 0.5, p=0.07 for difference between arms.
31
 
 
Manifest HD, RCT placebo/riluzole,: n=180/357, f/u=3yrs, Mean change ± SD scores 
of UHDRS,TFC : ,4.4 ± 4.1/,4.6 ± 4.2, n.s. (ITT population), n.s. arm comparison.
32
 
 
Manifest HD, n=335, f/u=30 months, Mean change ± SD scores of UHDRS,TFC: ,2.7 
± 2.3.
33
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Manifest HD, RCT latrepirdine/placebo, n=46/44, f/u= 90 days, Mean change ± SD 
scores of UHDRS,TFC: ,0.04 ± 0.15/  0.01 ± 0.15, treatment comparison n.s.
34
 
 
2'N0$
Pre,manifest (pre,HD A and B) and Early manifest (HD1/earlier and HD2/later: 
a) n=330 f/u=12 months,  Mean change scores of UHDRS,TFC compared with 
controls: HD: ,0.73 (HD1: ,0.91, HD2: ,0.44), preHD: ,0.06 ( preHDa: ,0.07, 
preHDb: ,0.05).
35
 
b) n=334 f/u=36 months, Mean change scores of UHDRS,TFC compared with 
controls: HD1: ,1.67, HD2:  , 1.48, preHDa:  , 0.21, preHDb: , 0.07.
36
 
 
Manifest HD, RCT citalopram vs. placebo, n=16/15, f/u=17 weeks, Mean ± SEM 
change scores of UHDRS,TFC at 17 weeks: ,0.54 ± 0.46/ ,0.06 ±  0.5, n.s. arm 
comparison.
37
 
 
Manifest HD, RCT placebo/ Selisistat 10mg or 100mg, n=19/17/19, f/u 14 days, Mean 
change scores of UHDRS,TFC n.s. between arms.
38
 
		
##	*
$
	"##
##
*#	
	"
%

##
##
*+
	#	
#!!

4
No. 
-
##%!!	 Ceiling effect for early stage, floor effect for late stage (personal judgment).
24
 
#	#	# – 
"#
+
	
% Widely used scale. Easy and quick to administer. 
#
+
	
% More extensive clinimetric data is required, considering purpose proposed for UHDRS. 
" %%	!
#%+#	*!##	
	##!	#


#	*#$3 
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	
	

 
2"#!#$	#%	&#
'
	#%
$'-	#
	

3
#	# 
	"+
+#!	"
4 No
1
 
!*#567"#"7

4 N/A 

		8+
		
The UHDRS,FAS is part of a multi,component scale originally designed to 
prospectively evaluate all patients with HD as well as those at risk for HD.  
It consists of 25 questions which screen capacity to complete the tasks mentioned in 
the assessment. It is considered an extension of the Total Functional Capacity and is 
more detailed in certain tasks.
1
  
The checklist is summed by giving a score of 1 to all “yes” replies. A higher score 
indicates better functioning than a lower score.
1
 
 
	!!*	8#%4 Yes.
1
 
	!+#	*!*	8#%4 No.
1
 
 
	"#	!	"
##		
#!*#
+#


%
4
Yes (2, Y/N).
1
 


93	#	
	#	 5 ,10 min (personal judgment). 
 
 
	#	6
%#+6###

Clinician (in the presence of a family or friend to get the clinician’s best judgment 
based on both responses).
1
 
!###
0
	6#	
##%!
#
	#
#4
Written instructions (personal judgment). 
 
*#%"	#
#4 Copyright. 
$7
	"
	
#
7#	4
Huntington Study Group (HSG), prior written permission is required. E,mail: 
info@hsglimited.org 
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$
	"
#"#	"
%
%4
Yes (Portuguese, French, German, Dutch, Danish, Italian, Polish, Russian, Czech, 
Norwegian, Swedish).
2
 
3
	#

3		+
##	*
 
*!#	%
	#
8	#
Yes. 
1) Creation of a single scale based on pre,existing scales: Quantitated neurological 
exam (QNE), HD functional capacity scale (HDFCS), the HD motor rating 
scale (HDMRS), the Physical Disability and Independence scales, Marsden and 
Quinn’s chorea severity scale, the HD Activities of Daily Living scale, and 
other relevant measures.  
2) Followed by "several months of pilot experience".  
3) Neurologists, psychiatrists, neuropsychologists, and other professionals 
participated in the drafting of the scale.
1
 
3-
+
##	*   
	"#	!	"
+#!!		
!	"#!#
#4
No (personal judgment). 
	"
"
+#*7#%"		7

	!
	"
##	

7"#"	!	"

#
	+4
N/A. 
#			
	##	
	"

	#	8
%#+
4
Based on clinician’s impression with input from patient/caregiver (personal judgment). 
:"
	#	"	#!
3%3;#%	"
	
7<=4
N/A. 
3 
 	
+#	*6#
%#!
	"
#4
Severity, longitudinal measurement (personal judgment). 
	"
	0!!4!$6!0$ No (personal judgment). 
3	
##	*   
	"%	"!	"

#
	4 Yes (personal judgment). 
	"
#%#	###		#	
	#	8
	


#
4
No (personal judgment). 
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	"
#%#	##
	#%
"4 No (personal judgment). 
	"	#
#
	!#
$

	#4
Yes (personal judgment). 
	"

#

$#
	
%4
	"$	
%#7"#"	"
#	

#
4
Yes (personal judgment). 
3$
	"#
#!#
*+!
#$*84
Yes.
1
 
3!*		"
+6"
	"
*#
$*%	"	"
	"+4
Yes.
1, 3,17
 
 !
 
	"##0*"	#	##$4 Yes.
1
 

3'#
##	*
 
>	
 Assessed in HD.
1
 
	
#	* Manifest HD, n=489: Cronbach's alpha 0.95.
1
 
2	0		#
##	* — 
	0
	#
##	* — 
3?
##	*   
+3	
 Assessed in HD. 
#	#+
##	*
*
#7#	"%0
	


There is no gold,standard (personal judgment). 
		+
##	* 
-
	

*# — 
+%	+
##	*
Manifest HD, n=489: 
1
 UHDRS,FA X UHDRS,TFC r=0.94 p<0.005, X UHDRS,TMS 
r=,0.75 p<0.005, X Verbal fluency r=0.59 p<0.005, X Symbol Digit r=0.65 p<0.005, X 
Stroop word r=0.60 p<0.005, X Stroop color word r=0.61 p<0.005, X UHDRS,
behavior total r=,0.07 p=n.s., X subscale mood r=0.06 r=n.s., X subscale behavior r=,
0.13 p=n.s., X subscale psychosis r=,0.14 p<0.005.  
 
Manifest HD, n=69/46 (2 cohorts, Dutch/US)
18
: UHDRS,FA X UHDRS,TMS r=0.88 
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p<0.001/r=0.83 p<0.001. 
 
Manifest HD, n=21, UHDRS,FA X UHDRS,TMS r=,0.686 p<0.001.
M
 
 
Manifest HD, n=80, UHDRS,FA X SF,36 r=0.46 p<0.05, X CBI r=,0.56 p<0.05, X 
UHDRS,TMS r=,0.82 p<0.05, X UHDRS cognitive r=0.76 p<0.05, X HAM,D r=,0.43 
p<0.05, X UHDRS behavioral r=,0.35 p<0.05, X UHDRS apathy r=,0.47 p<0.05, X 
UHDRS psychotic symptoms r=,0.25 p=n.s., X UHDRS anxiety r=,0.20 p=n.s., X 
UHDRS irritability r=0.2 p=n.s., X UHDRS aggression ,0.19 p=n.s.
20
 
 
Manifest HD, n=48
21
, UHDRS,FA X UHDRS,TFC r=,0.9 p<0.001, X UHDRS,IS r=,
0.91 p<0.001, X UHDRS,TMS r=0.77 p<0.001, X UHDRS behavior r=,0.10 p=0.47, 
X UHDRS cognitive r=,0.85 p<0.001, X UHDRS,FAP motor r=0.90 p<0.001, X 
UHDRS,FAP behavioral r=0.00 p=0.97, X UHDRS,FAP somatic r=0.71 p<0.001, X 
UHDRS,FAP cognitive r=,0.71 p<0.001.      
#+%	+
##	*   
.+
##%>	%

!!
*6
@%	

	
	
More extensive clinimetric analyses are required (personal judgment). 
A
#B
##	*   
"7	+
#
	
*	
%!$4 Yes (personal judgment). 
"7	+
##
*
	#7#	"	#

#%#!#
	%#	#+#
#	4
Yes (personal judgment). 
'#+		"
%+	##	"		 
	
		#	#+	"
%"
%+
	#		
		4
Manifest HD, n=171, f/u=6 m, Mean change ± SD scores UHDRS,FA at 6m= , 0.9 ± 
3.0.
1
 
 
Manifest HD, n=71, f/u=1.07 year (SD 0.38), UHDRS,FA at last follow,up= ,1.5, 95% 
CI: 0.76, 2.33, p<0.0001.
3
 
 
Manifest HD, RCT CoQ10 vs. remacemide vs. combination vs. placebo, 
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n=87/86/87/87, f/u=31months, Mean change ± SD scores of UHDRS,FA: placebo ,4.0 
± 4.5; Q10 ,3.1 ± 3.6; Remacemide ,4.3 ± 4.5; Combination ,3.4 ± 4.0.
,
 
 
Manifest HD, RCT placebo vs. riluzole 100 mg vs. riluzole 200 mg, n=22/18/23, f/u=8 
weeks, mean change ± SD scores of UHDRS,FA =,0.8 ±1.3 / ,0.2 ± 1.2/ ,0.2 ±1.8 
p=0.50.
6
 
 
Manifest HD, n=815, mean f/u =2.7 yrs, estimated rate of progression (points/year)for 
UHDRS,FA: ,1.4, 95% CI: 1.3 , 1.6. 
17
 
 
Manifest HD, RCT placebo vs. minocycline 100 mg vs.  minocycline 200 mg, 
n=23/18/19, f/u= 8 weeks, Mean change ± SD scores of UHDRS,FA: ,0.30 ± 1.69/ ,
0.39 ± 1.14/ 0.58 ± 1.95. 
7
 
 
Manifest HD, RCT ethyl,EPA/placebo, n=39/44, f/u=12 months, UHDRS, FA 
decline= n.s. between arms.
8


Manifest HD, RCT placebo/donepezil, n=12/12 1:1 f/u=12w, Median change UHDRS,
FA 0 / +0.5, p=0.07 for difference between arms.
9
 
 
Manifest HD, RCT placebo/TBZ, n=30/54  f/u=9w, Mean change ± SD scores of 
UHDRS,FA: +0.4 ± 0.4 / ,0.8 ± 0.3, p=0.02.
10
 
 
Manifest HD, RCT placebo/riluzole, n=128/251 (PPT population), f/u=3yrs, UHDRS,
FA at 3yrs=,3.6 ± 4.2/,3.3 ± 3.7.
22
 
 
Manifest HD, n=335, f/u=30 months, Mean change ± SD scores of UHDRS,FA: ,4.0 ± 
4.5.
12
 
 
Manifest HD, RCT minocycline/placebo, n=87/27, f/u=18m, Mean change ± SD scores 
of UHDRS,FA at 18m = ,2.4 ± 4.04.
13
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Manifest HD, RCT latrepirdine/placebo, n=46/44, f/u= 90 days, Mean change ± SD 
scores of UHDRS,FA at 90 d: 0.01 ± 0.25/ 0.11 ± 0.26, p=0.79.
14
  
 
Manifest HD, RCT placebo/ Selisistat 10mg or 100mg, n=19/17/19, f/u 14 days, 
16
 
UHDRS,FA at 14 d vs baseline: ,0.05/,0.12/,0.21. Treatment comparison n.s. 
		
##	*
$
	"##
##
*#	
	"
%

##
##
*+
	#	
#!!

4
No. 
-
##%!!	 — 
#	#	# — 
"#
+
	
% Used extensively. 
#
+
	
% More extensive clinimetric analyses are necessary. 
" %%	!
#%+#	*!##	
	##!	#


#	*#$3 
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	
	

 
2"#!#$	#%	&#
'
	#%
$'0

3
#	# 
	"+
+#!	"
4 No.
1
 
!*#567"#"7

4 N/A. 

		8+
		
The UHDRS, IS is part of a multi,component scale originally designed to 
prospectively evaluate all patients with HD and at risk for HD. The UHDRS,IS 
assesses functional disability.
1
 
 
The UHDRS,IS is a useful clinical tool to follow progression of functional disability. It 
covers a wide range of functioning. The scale is rated from 100 (no special care 
needed) to 0 (tube,fed, total bed care); descriptors are provided to gauge function 
levels at every 10 points (personal judgment). 
 
	!!*	8#%4 Yes (personal judgment). 
	!+#	*!*	8#%4 Yes (personal judgment). 
 
	"#	!	"
##		
#!*#
+#


%
4
Yes, from 100 to 10.
1
 


93	#	
	#	 5 min (personal judgment). 
 
 
	#	6
%#+6###
 Clinician.
1
 
!###
0
	6#	
##%!
#
	#
#4
Written instructions (personal judgment). 
 
*#%"	#
#4 Copyright. 
$7
	"
	
#
7#	4 Myers 1985.
1
 
$
	"
#"#	"
%
%4 Yes (Portuguese, French, German, Dutch, Danish, Italian, Polish, Russian, Czech, 
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Norwegian, Swedish).
2
 
3
	#

3		+
##	*
 
*!#	%
	#
8	#
Yes. 
1) Creation of a single scale based on pre,existing scales: Quantitated neurological 
exam (QNE), HD functional capacity scale (HDFCS), the HD motor rating 
scale (HDMRS), the Physical Disability and Independence scales, Marsden  
and Quinn’s chorea severity scale, the HD Activities of Daily Living scale, and 
other relevant measures. 
2) Followed by "several months of pilot experience". 
3) Neurologists, psychiatrists, neuropsychologists, and other professionals 
participated in the drafting of the scale. 
3-
+
##	*   
	"#	!	"
+#!!		
!	"#!#
#4
Yes (personal judgment). 
	"
"
+#*7#%"		7

	!
	"
##	

7"#"	!	"

#
	+4
No (personal judgment). 
#			
	##	
	"

	#	8
%#+
4
Based on clinician’s impression with input from patient/caregiver (personal judgment). 
:"
	#	"	#!
3%3;#%	"
	
7<=4
N/A. 
3 
 	
+#	*6#
%#!
	"
#4
Severity (personal judgment). 
	"
	0!!4!$6!0$ No (personal judgment). 
3	
##	*   
	"%	"!	"

#
	4 Yes (personal judgment). 
	"
#%#	###		#	
	#	8
	


#
4
No (personal judgment). 
	"
#%#	##
	#%
"4 No (personal judgment). 
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	"	#
#
	!#
$

	#4
Yes (personal judgment). 
	"

#

$#
	
%4
	"$	
%#7"#"	"
#	

#
4
Yes (personal judgment). 
3$
	"#
#!#
*+!
#$*84
Yes. 
3!*		"
+6"
	"
*#
$*%	"	"
	"+4
Yes.
3,7
 
 !
 
	"##0*"	#	##$4 Yes.
1, 3, 4, 8,13
  

3'#
##	*
 
>	
 Assessed in HD.
8
 
	
#	* — 
2	0		#
##	* — 
	0
	#
##	*
Patient (n=132) vs. carers (n=40): ICC , 0.71 (0.48, 0.85).
8
 
(.2#!#+#
3?
##	*#$   
+3	
 Assessed in HD.
1, 3, 4, 8,13
 
#	#+
##	*
*
#7#	"%0
	


 There is no gold standard (personal judgment). 
		+
##	*  – 
-
	

*# – 
+%	+
##	*
Manifest HD, n=489, UHDRS,IS X UHDRS,TFC r=0.92 p<0.005, X UHDRS,FA 
r=0.90 p<0.005, X UHDRS,TMS r=,0.75 p<0.005, X visual fluency r=0.58 p<0.005, 
X Sym Digit  r=0.63 p=<0.005, X Stroop word r=0.62 p<0.005, X Stroop color r=0.63 
p<0.005, X Stroop color word r=0.54 p<0.005, X UHDRS behavior r=,0.05 p=ns, X  
UHDRS sub mood r=0.09 p=ns, X UHDRS sub behavior r,0.14 p<0.005, X UHDRS 
sub psychosis r=,0.14 p<0.005.
3
  
 
Manifest HD, n=69/46, UHDRS,IS X UHDRS,TMS r=,0.88 p<0.001/,0.91 p<0.001.
,
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Manifest HD, n=21, UHDRS,IS X UHDRS,TMS r=,0.745 p<0.001.
10
  
 
65 HD patients and 56 carers, UHDRS,IS correlated significantly with the majority 
SF,36 and SIP sub,items.
11
 
 
Manifest HD, n=53, UHDRS,IS X UHDRS,TFC r=0.86 p<0.001, X UHDRS,FA r=,
0.91 p<0.001, X UHDRS,TMS r=0.77 p<0.001, X UHDRS behavior r=,0.10 p=0.47, 
X UHDRS cognitive r=,0.85 p<0.001, X UHDRS,FAP behavior r=0.02 p=0.86, 
UHDRS,FAP r=,0.88 p<0.001, X UHDRS,FAP somatic r=,0.70 p<0.001, X UHDRS,
FAP cognitive r=0.75 p<0.001.

 
#+%	+
##	* — 
.+
##%>	%

!!
*6
@%	

	
	
Good, but needs further clinimetric evaluation. 
A
#B
##	*   
"7	+
#
	
*	
%!$4
Yes.  
n=960, mean f/u=18.3 months, rate of IS decline per disease duration:  
0 to 2 years, 5.70 units/year (SE 0.76).  
2 to 5 years, 4.87 units/year (SE 0.44).  
5 to 10 years, 4.08 units/year (SE 0.37).  
10 to 20 years, 4.50 units/year (SE 0.48).
5
 
"7	+
##
*
	#7#	"	#

#%#!#
	%#	#+#
#	4
Yes (personal judgment). 
'#+		"
%+	##	"		 
	
		#	#+	"
%"
%+
	#		
		4
Manifest HD, n=78, mean±SD f/u =1.07 y ± 0.38, Mean change score UHDRS,IS at 
1yr = ,3.60.
7
 
 
Manifest HD, n=960 f/u mean=18.3m ± 9.7, UHDRS,IS at 1yr = ,4.52 SE 0.23.
5
 
 
Manifest HD, RCT CoQ10 vs. remacemide vs. combination vs. placebo, 
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n=73/76/66/63, f/u=30m, Mean change ± SD UHDRS,IS: placebo ,12.2 ± 11.0; Q10 ,
10.0 ± 10.6; Remacemide ,11.4 ± 10.7; combination ,9.4 ± 10.2.
15
 
 
Manifest HD, RCT placebo vs. riluzole 100 mg vs. riluzole 200 mg, n=22/18/23, 
placebo/riluzole 100mg/200mg f/u=8w, mean change ± SD scores of UHDRS,IS at 8w 
= ,3.0 ± 5.9/,4.2 ± 5.5/,1.5 ± 4.6.
6
 
 
Manifest HD, n=815, mean f/u =2.7 yrs, estimated rate of progression (points/year)for 
UHDRS,IS: ,4.3, 95% CI: 4.0 , 4.6.
16
 
 
Manifest HD, RCT placebo vs. minocycline 100 mg vs.  minocycline 200 mg, 
n=23/18/19, f/u= 8 weeks, Mean change ± SD scores of UHDRS,IS at 8w=,0.30 ± 
1.69/,0.38 ± 1.14/+0.58 ± 1.95.
17
 
 
Manifest HD, RCT ethyl,EPA/placebo, n=39/44, f/u=12 months, UHDRS,IS at 12m=,
1.78 /,2.58, n.s. difference between arms.
18
 
 
Manifest HD, RCT placebo/donepezil, n=12/12 1:1 f/u=12w, Median change UHDRS,
IS at 12w=0/+0.5.
19
  
 
Manifest HD, RCT placebo/riluzole, n=128/251 (PPT population), f/u=3yrs, UHDRS,
IS at 3yrs=,11.7 ± 11.7 / ,9.9 ± 10.2.
20
 
 
Manifest HD, n=335, f/u=30 months, Mean change ± SD scores of UHDRS,IS = ,11.3 
± 10.8.
21
 
 
Manifest HD, n=158/158 ethyl,EPA/placebo f/u=12m, UHDRS,IS at 6m=,1.2/,1.8 
p=0.50; UHDRS,IS at 12m=,3.5/,2.8 p=0.50.
22
 
 
Manifest HD, RCT minocycline/placebo, n=87/27, f/u=18m, Mean change ± SD scores 
of UHDRS,IS at 18m=,8.81 ± 10.77. Data not available for the placebo arm.
23
 
 
Page 172 of 253Movement Disorders Clinical Practice
For Review Only
 126
Manifest HD, RCT latrepirdine/placebo, n=46/44, f/u= 90 days, Mean change ± SD 
scores of UHDRS,IS at 90=,0.48 ± 0.77/,0.58 ± 0.78, p=0.93.
24
 
 
Manifest HD, RCT placebo/ Selisistat 10mg or 100mg, n=19/17/19, f/u 14 days, 
UHDRS,IS at 14d=0.27/,0.59/0.79. 
25
 
		
##	*
$
	"##
##
*#	
	"
%

##
##
*+
	#	
#!!

4
No (personal judgment). 
-
##%!!	 There is a ceiling effect for presymptomatic HD (personal judgment). 
#	#	# — 
"#
+
	
% Quick and easy to apply (personal judgment). 
#
+
	
% Lack of clinimetric validation (personal judgment). 
" %%	!
#%+#	*!##	
	##!	#

##	*#$33
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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 
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	
	
 

'#+
/##	*9
3
#	# 
	"+
+#!	"
4 No. 
!*#567"#"7

4 — 

		8+
		
The Rivermead Mobility Index (RMI) consists of 14,self,reported items about a patient’s 
ability to perform a wide range of activities, from turning over in bed to running, and 1 direct 
observation item (standing for 10 seconds without any aid).
1
 
http://www.rehabmeasures.org/lists/rehabmeasures/dispform.aspx?id=926 
 
	!!*	8#%4 – 
	!+#	*!*	8#%4 – 
 
	"#	!	"
##	
	#!*#
+#


%

4
Discrete steps (0 or 1). Scores are reported as either unable or able (0–1) and added to 
produce a total score (0–15). A higher score reflects better mobility. 


93	#	
	#	
5 minutes. 
http://www.rehabmeasures.org/lists/rehabmeasures/dispform.aspx?id=926 
 
 
 
	#	6
%#+6###
 Clinician and patient. 
!###
0
	6#	
##%!
#
	#
#4
No. 
 
*#%"	#
#4
Provided courtesy of Dr. Derick Wade and the Oxford Centre for Enablement. 
http://www.rehabmeasures.org/lists/rehabmeasures/dispform.aspx?id=926 
$7
	"
	
#

7#	4
http://www.rehabmeasures.org/lists/rehabmeasures/dispform.aspx?id=926 
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$
	"
#"#	"

%
%4
No. 
3
	#

3		+
##	*
 
*!#	%
	#
8
	#
— 
3-
+
##	*   
	"#	!	"
+#!!	
	!	"#!#
#4
— 
	"
"
+#*7#%"		7


	!	"
##	

7"#"
	!	"
#
	+4
— 
#			
	##	
	"

	#	8
%#+
4
Both (personal judgment). 
:"
	#	"	#!
3%3;#%	"
	
7<=4
Present time (undefined) 
3 
 	
+#	*6
#
%#!	"
#4
To measure severity. 
	"
	0!!4!$6!0$ No. 
3	
##	*   
	"%	"!	"

#
	4 Yes (personal judgment). 
	"
#%#	###		#	

	#	8
	

#
4
No (personal judgment). 
	"
#%#	##
	#%
"4 No (personal judgment). 
	"	#
#
	!#
$

	#4
Yes (personal judgment). 
	"

#

$#

	
%4
	"$	
%#7"#"	"
#	

#
4
Yes (personal judgment). 
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3$
	"#
#!#
*+!
#$*84
No. 
3!*		"
+6"
	"

*#$*%	"	"
	"
+4
 
 !
 
	"##0*"	#	##
$4
Yes. 

3'#
##	*
 
>	
 Assessed in HD. 
	
#	* Not assessed. 
2	0		#
##	*
ICC (pre,manifest HD, n=11): 0.81; ICC (manifest HD, n=62) : 0.94. 
NOTE: consistent across stages.
2
 
	0
	#
##	* Not assessed in HD. 
3?
##	*#$   
+3	
 Not assessed in HD. 
#	#+
##	*
*
#7#	"%0
	


  
		+
##	*   
-
	

*# Not assessed. 
+%	+
##	* – 
#+%	+
##	* – 
.+
##%>	%

!!
*6
@%	

	
	
– 
A
#B
##	*   
"7	+
#
	
*	
%!$4 No. Little differentiation across stages.
2
 
"7	+
##
*
	#7#	"
	#
#%#!#
	%#	#+#
#	4
No. 
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'#+		"
%+	##	"		 
	
		#	#+	"
%"
%
+	#		
		4
No. 
		
##	*
$
	"##
##
*#	
	"
%

##
##
*+
	#	

#!!
4
No. The Minimum Detectable Change (MDC) has been determined:  
MDC=1 in premanifest (n=11), MDC=2 in manifest HD.
2
 
-
##%!!	 Ceiling effect in pre,manifest HD. 
#	#	#
Premanifest HD: 15 (0.5), range: [14–15], n=11.
2
 
Manifest HD:13 (2), range: [13–14], n=64.
2
 
"#
+
	
% Quick and easy to administer. 
#
+
	
%
Very limited development in HD 
Ceiling effect in early stages of HD 
" %%	!
#%+#	*!##	*	#	#

%#

 
 
	
 
 
1. Collen FM, Wade DT, Robb GF, Bradshaw CM. The Rivermead Mobility Index: a further development of the Rivermead Motor 
Assessment. 2(1991;13:50,4. 
2. Quinn L, Khalil H, Dawes H, Fritz NE, Kegelmeyer D, Kloos AD$% Reliability and minimal detectable change of physical 
performance measures in individuals with pre,manifest and manifest Huntington disease. #*	2013;93:942,56. 
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	
	

 
	#+#	*0#!#


1
3
#	# 
	"+
+#!	"
4 Yes.
1
 ABC, modified version for UK (ABC,UK). 
!*#567"#"7

4 Primarily, ABC.
1
 

		8+
		
The ABC Scale measures confidence and fear of falling and has proven reliability and valid 
in the elderly and with some neurological populations.  
Individuals rate their balance confidence from 0 to 100 in each of 16 tasks; higher scores 
indicate greater confidence and lower fall risk. 
 
	!!*	8#%4 – 
	!+#	*!*	8#%4 – 
 
	"#	!	"
##	
	#!*#
+#


%

4
Visual analogue scale from 0 to 100. 


93	#	
	#	
6,30 minutes. 
http://www.rehabmeasures.org/Lists/RehabMeasures/DispForm.aspx?ID=949 
 
 
	#	6
%#+6###
 Can be self,administered, face,to,face interview is recommended.
1
 
!###
0
	6#	
##%!
#
	#
#4
No. 
 
*#%"	#
#4 Public domain. 
$7
	"
	
#

7#	4
http://www.exercisepd.com/uploads/3/5/3/1/3531021/activities_specific_balance_scale_nov
_5_2012.pdf 
$
	"
#"#	"

%
%4
Yes. 
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3
	#

3		+
##	*
 
*!#	%
	#
8
	#
Items for the newly developed 16,item ABC Scale were generated by 15 clinicians and 12 
elderly outpatients. Psychometric testing involved 60 community seniors (aged 65,95) self,
classified as either high or low in mobility confidence according to their perceived need for a 
walking aid and personal assistance to ambulate outdoors.
1
 
3-
+
##	*   
	"#	!	"
+#!!	
	!	"#!#
#4
Yes. 
	"
"
+#*7#%"		7


	!	"
##	

7"#"
	!	"
#
	+4
No. 
#			
	##	
	"

	#	8
%#+
4
Patient self,assessment. 
:"
	#	"	#!
3%3;#%	"
	
7<=4  
3 
 	
+#	*6
#
%#!	"
#4
To measure severity of falls risk. 
	"
	0!!4!$6!0$
Not in HD. 
 
Cut,off scores have been established in Parkinson’s disease (69%, with 93% sensitivity and 
69% specificity)
2
 and stroke (81.1%)
3
 patients. 
3	
##	*   
	"%	"!	"

#
	4 Yes (personal judgment). 
	"
#%#	###		#	

	#	8
	

#
4
No (personal judgment). 
	"
#%#	##
	#%
"4 No (personal judgment). 
	"	#
#
	!#
$

	#4
Mostly (personal judgment). 
	"

#

$#
 N/A for non,ambulatory. (personal judgment). 
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	
%4	"
$	
%#7"#"	"
#	
#
4
3$
	"#
#!#
*+!
#$*84
No. 
3!*		"
+6"
	"

*#$*%	"	"
	"
+4
– 
 !
 
	"##0*"	#	##
$4  

3'#
##	*
 
>	
 Assessed. 
	
#	*
Not assessed in HD. 
NOTE: found to have good internal consistency in older people.
1
 
2	0		#
##	* Manifest HD, n = 20, ICC = 0.74, 95% CI: 0.58, 1.0.
4
 
	0
	#
##	* Not assessed. 
3?
##	*#$   
+3	
 Assessed. 
.+
##%>	% Not good (when compared to TMT and four square step test) (personal judgment). 
#	#+
##	*
*
#7#	"%0
	


  
		+
##	*   
-
	

*#
 
Convergent validity 
Manifest HD, n = 20
,

 
A
#	

	 	#+#	#0#!#1

!#

-7
7
<#%  
Velocity   0.42 
Stride length   0.41 
Swing percent –0.18 
Page 181 of 253 Movement Disorders Clinical Practice
For Review Only
 135
Double support percent –0.15 
Base of support –0.58 
CV step time –0.72 
CV stride length –0.53 
CV swing time –0.74 
Backward walking  
Velocity   0.34 
Stride length   0.39 
Swing percent   0.28 
Double support percent –0.29 
Base of support –0.24 
CV step time –0.33 
CV stride length –0.44 
CV swing time –0.01 
 
#+%	+
##	* – 
.+
##%>	%

!!
*6
@%	

	
	
Limited information. 
A
#B
##	*   
"7	+
#
	
*	
%!$4 No. 
"7	+
##
*
	#7#	"
	#
#%#!#
	%#	#+#
#	4
No. 
'#+		"
%+	##	"		 
	
		#	#+	"
%"
%
+	#		
		4
Yes.  
Manifest HD, n = 20, the ABC,UK ‘walking,up,and,down,stairs’ and ‘Walking around,the,
house component’ improved following a 9,month multidisciplinary rehabilitation program.
5
 
		
##	*
$
	"##
##
*#	
	"
%

##
##
*+
	#	

#!!
4
No. The Minimum Detectable Change (MDC) has been determined: Manifest HD, n = 206
MDC: 27.33.
4

-
##%!!	 Unlikely, this is a self,assessment of confidence (personal judgment). 
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#	#	#
 
"#
+
	
% Easy to rate. 
#
+
	
%
Known to be subject to discrepancies between the self,assessment of the person with HD and 
the corresponding carer assessment. 
Questionable use, since lack of insight is a feature in HD. 
"
%%	!
	!!0	

!##$3
 
 
	
 
 
1. Powell LE, Myers AM. The Activities,specific Balance Confidence (ABC) Scale. !	"1995;50A:M28,34. 
2. Mak MK, Pang MY. Fear of falling is independently associated with recurrent falls in patients with Parkinson's disease: a 1,year 
prospective study. 	2009;256:1689,95. 
3. Beninato M, Portney LG, Sullivan PE. Using the International Classification of Functioning, Disability and Health as a framework to 
examine the association between falls and clinical assessment tools in people with stroke. #*	2009;89:816,25. 
4. Kloos AD, Fritz NE, Kostyk SK, Young GS, Kegelmeyer DA. Clinimetric properties of the Tinetti Mobility Test, Four Square Step Test, 
Activities,specific Balance Confidence Scale, and spatiotemporal gait measures in individuals with Huntington's disease. !#	
2014;40:647,51. 
5. Thompson JA, Cruickshank TM, Penailillo LE, Lee JW, Newton RU, Barker RA$% The effects of multidisciplinary rehabilitation in 
patients with early,to,middle,stage Huntington's disease: a pilot study.  		2013;20:1325,9. 
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	
	

 
$	#+#	#!
#*#+#%$0
3
#	# 
	"+
+#!	"
4 No, but there are 20,item
1
 and 17,item
2
 versions available. 
!*#567"#"7

4 17,item. 

		8+
		
Instrumental activities of daily living. 
 
The HD,ADL Scale was modeled after the Scale for Instrumental Activities of Daily 
Living,
3
 and has been reported both as a 20, 

 or 17,item
2
 informant,completed 
instrument on which the informant rates the HD patient’s ability to perform specific 
activities, covering the domains of personal care, household care (domestic activities, 
household upkeep), work and money, social relationships, and communication. For 
each item the patient is rated on a 4,point scale, from normal to severely impaired. The 
score ranges from 0 (normal) to 51 (maximal impairment). When items cannot be 
rated, a pro,rated value is calculated or the item is coded as not impaired (score = 0).
2
 
 
	!!*	8#%4 Yes (depending on the item).
2
 
	!+#	*!*	8#%4 Yes (depending on the item).
2
 
 
	"#	!	"
##		
#!*#
+#


%
4
Yes, discrete steps from 0 (no impairment) to 3 (maximal impairment).
2
 


93	#	
	#	 Unknown. 
 
 
	#	6
%#+6###

Caretaker: spouse, caretaker, or whoever knows the patient or person at risk the best. 
(.2 In Brandt 1984
1
, a structured interview was mentioned. In Bylsma 1993,
2
 HD,
ADL was mailed to informant. 
!###
0
	6#	
##%!
#
	#
#4
N/A 
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 
*#%"	#
#4 Copyright, The Johns Hopkins University Press, 1989.
2
 
$7
	"
	
#
7#	4 Bylsma 1993..
2
 
$
	"
#"#	"
%
%4 No. 
3
	#

3		+
##	*
 
*!#	%
	#
8	#
Scarce information. The HD,ADL Scale was modeled after the Scale for Instrumental 
Activities of Daily Living.
3
 
3-
+
##	*   
	"#	!	"
+#!!		
!	"#!#
#4
Yes (personal judgment). 
	"
"
+#*7#%"		7

	!
	"
##	

7"#"	!	"

#
	+4
No (personal judgment). 
#			
	##	
	"

	#	8
%#+
4
Caregiver recall for "current" state and for some items there is comparison with the 
premorbid functional level.
1, 2
 
:"
	#	"	#!
3%3;#%	"
	
7<=4
Not specified. 
3 
 	
+#	*6#
%#!
	"
#4
Severity (personal judgment). 
	"
	0!!4!$6!0$ No (personal judgment). 
3	
##	*   
	"%	"!	"

#
	4 Moderate (personal judgment). 
	"
#%#	###		#	
	#	8
	


#
4
Yes, time frame that applies to item score (personal judgment). 
	"
#%#	##
	#%
"4 No, although strategies for rating change from item to item (personal judgment). 
	"	#
#
	!#
$

	#4
Yes (personal judgment). 
	"

#

$#
	
%4
	"$	
%#7"#"	"
#	
No.  The HD,ADL scale is not adequate for assessing adaptive functioning in patients 
in the later stages of disease.
2
 A ceiling effect for early HD patients would be expected 
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#
4 (personal judgment). 
3$
	"#
#!#
*+!
#$*84
Yes.
1
 
3!*		"
+6"
	"
*#
$*%	"	"
	"+4
Yes.
2, 4, 5
 
 !
 
	"##0*"	#	##$4 Yes.
2
 

3'#
##	*
 
>	
 Assessed in HD.
2
 
	
#	*
Clinical diagnosis of HD, pre,genetic testing era, n=163:  
Test sample, n=93: coefficient alpha=0.91. 
Replication sample, n=70: coefficient alpha = 0.96.
2
 
2	0		#
##	* Not assessed.  
	0
	#
##	* Not assessed.  
3?
##	*   
+3	
 Assessed.
2
 
#	#+
##	*
*
#7#	"%0
	


There is no gold standard. 
		+
##	*
 
-
	

*#
Clinical diagnosis of HD, pre,genetic testing era, n=163.
2
 
Test sample, n=93; Replication sample, n=70.   
Principal Component Analysis with VARIMAX rotation revealed 4 factors:  
1) General Functioning (personal care and functioning in the community. 
2) Domestic Activities, (meals and housework). 
3) Home Upkeep (house maintenance and repairs, as well as job performance), 
and  
4) Family Relationships (intrafamilial interactions).  
Four factors account for 72,74% of the total variance. Authors documented a stable 
structure from test to replication samples. 
+%	+
##	* Clinical diagnosis of HD, n=163, n=25
2
TFC x total HD,ADL : r= ,0.89, p < 0.001, 
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General Functioning: r = , 0.85, p < 0.001, Domestic Activities: r = , 0.79, p < 0.001, 
Home Upkeep: r = , 0.57, p < 0.002), Family Relationships: n.s.
1, 6
 
#+%	+
##	* '	"#MM: n=80: multiple cognitive measures vs. HD,ADL total (p<0.001).
6
 
.+
##%>	%

!!
*6
@%	

	
	
Requires further testing (personal judgment). 
A
#B
##	*   
"7	+
#
	
*	
%!$4
Multiple correlations with measures of progression in HD were found in different 
studies: 
1) Greater motor disability, 
Clinical diagnosis of HD, n=57. QNE: r=0.68, p<0.01.

 
Clinical diagnosis of HD 
2
: Test sample, n=93 / Replication sample, n=70: 
QNE total (MIS and chorea scores are also available) vs. general function 
(r=0.70 p<0.01/ r=0.76 p<0.001), vs. domestic activities (r=0.44 
p<0.001/r=0.53 p<0.001), vs. home upkeep (p=ns/r=0.42 p<0.001), vs. family 
relationships (both ns), vs. HD,ADL total score (r=0.64 p<0.001/r=0.75 
p<0.001). Correlations were not fully reproduced in smaller sample size testing 
TFC and HD,ADL.  
2) Clinical diagnosis of HD. Test sample, n=93; Replication sample, n=70: 
Duration of chorea vs. general function (r=0.50 p<0.01/r=0.61 p<0.001), vs. 
domestic activities (ns/r=0.57 p<0.001), vs. home upkeep (both ns), vs. family 
relationships (both n.s.), HD,ADL (r=0.49 p<0.001/r=0.59 p<0.001). 
Correlations were not fully reproduced in smaller sample size testing TFC and 
HD,ADL.
2
  
Clinical diagnosis of HD, n=57: duration of chorea r=0.55, p<0.01; duration of 
behavior change r=0.49 p<0.01; duration of symptoms r=0.58 p<0.01; age of 
onset p=n.s.

 
 
"7	+
##
*
	#7#	"	#

#%#!#
	%#	#+#
#	4
Yes.  
Clinical diagnosis of HD only, n=163. Test sample, n=93.  Replication sample, n=70: 
MMSE vs. general function (r=,0.70 p<0.01/r=,0.82 p<0.001), vs. domestic activities 
(r=,0.45 p<0.001/r=,0.48 p<0.001), vs. home upkeep (r=,0.09 p=ns/r=,0.37 p<0.001), 
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vs. family relationships (r=,0.33 p<0.001/r=,0.29 p=n.s.), vs. HD,ADL total score (r=,
0.65 p<0.001/r=,0.77 p<0.001).
2
  
'#+		"
%+	##	"		 
	
		#	#+	"
%"
%+
	#		
		4
Manifest HD, n=73, double blinded placebo,controlled RCT of d,alpha,tocopherol, 
f/u=12 months: total HD,ADL: ,1.7 (d,alpha,tocopherol), ,2.2, (placebo), p=n.s.
H
 
 
Manifest HD, n=91, double blinded placebo ,controlled RCT of idebenone, f/u =12 
months:
)
 
a) based on historical longitudinal data on 49 HD subjects gathered prior to this 
study ,  HD,ADL (mean annual change = 3.1 ± 5.3 (no reference given). 
b) study results. Total HD,ADL: ,2.9 ±3.3 (idebenone); 3.1 ± 4.9 (placebo), 
p=ns, ,3.0 ± 4.1 (all participants). 
Manifest HD, n=46, f/u=2yrs,
L
 total HD,ADL: short repeat length (1year =+2.14, 2 
years=+3.81), long repeat length (1 year=+2.53, at 3 year=+5.18). 
		
##	*
$
	"##
##
*#	
	"
%

##
##
*+
	#	
#!!

4
Not available. 
-
##%!!	 Yes. Floor effect for early HD (personal judgment). 
#	#	#
Clinical diagnosis of HD only, n=163: Test sample, n=93;  Replication sample, n=70: 
Mean(SD) , 24.2 (13.2)/22.9 (15.7). 
2
 
 
Manifest HD, n=91, double blinded placebo ,controlled RCT of idebenone, mean 
(SD): idebenone 11.3 (8.6), placebo 12.5 (8.6).
)
 
"#
+
	
% Comprehensive (more than TFC, includes family related activities). 
#
+
	
%
Needs an informant, it is not possible to score some items in certain individuals, there 
are two ways to impute missing value with completely opposite effects on the overall 
score, needs further clinimetric assessment. 
" %%	!
#%+#	*!##	
	###$ 
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	
 
 
1. Brandt J, Strauss ME, Larus J, Jensen B, Folstein SE, Folstein MF. Clinical correlates of dementia and disability in Huntington's disease. 
	1984;6:401,12. 
2. Bylsma. Assessment of Adaptive Functioning in Huntington’s Disease. 
	1993;8:183,90. 
3. Lawton MP. The functional assessment of elderly people. !		1971;19:465,81. 
4. Starkstein SE, Brandt J, Folstein S, Strauss M, Berthier ML, Pearlson GD$% Neuropsychological and neuroradiological correlates in 
Huntington's disease. 			#	1988;51:1259,63. 
5. Peyser CE, Folstein M, Chase GA, Starkstein S, Brandt J, Cockrell JR$% Trial of d,alpha,tocopherol in Huntington's disease. 
	6		1995;152:1771,75. 
6. Rothlind JC, Brandt J. A brief assessment of frontal and subcortical functions in dementia. 			1993;5:73,7. 
7. Ranen NG, Peyser CE, Coyle JT, Bylsma FW, Sherr M, Day L$% A controlled trial of idebenone in Huntington's disease. 
	
1996;11:549,54. 
8. Brandt J, Bylsma FW, Gross R, Stine OC, Ranen N, Ross CA. Trinucleotide repeat length and clinical progression in Huntington's 
disease. 	1996;46:527,31. 
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	
	
 
 
/#!#!0	 #
##	*
 
3
#	# 
	"+
+#!	"
4 A modified version of the original reported scales was used.
1, 2
 
!*#567"#"7

4 Not applicable 

		8+
		
The SPDDS is a unidimensional questionnaire that assesses disability in nine daily 
activities and was developed for PD patients living at home.  
 
The original SPDDS consisted of 25 items, however, an item has been added and two 
items have been dropped due to high nonresponse. The SPDDS contains 24 items. 
 http://www.rehabmeasures.org/Lists/RehabMeasures/DispForm.aspx?ID=1148 
 
In HD it was used in a 21,item version.
2
 
 
 
	!!*	8#%4 No. 
	!+#	*!*	8#%4 Yes. 
 
	"#	!	"
##		
#!*#
+#


%
4
Discrete. A five,point scale ranging from ‘able to do alone without difficulty’ to 
‘unable to do at all’. 
http://www.rehabmeasures.org/Lists/RehabMeasures/DispForm.aspx?ID=1148 


93	#	
	#	
5 minutes. 
http://www.rehabmeasures.org/Lists/RehabMeasures/DispForm.aspx?ID=1148 
 
 
	#	6
%#+6###
 Patient. 
!###
0
	6#	
##%!
#
	#
#4
Not applicable. 
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 
*#%"	#
#4 Public domain. 
$7
	"
	
#
7#	4 Unknown. 
$
	"
#"#	"
%
%4 Unknown. 
3
	#

3		+
##	*
 
*!#	%
	#
8	# – 
3-
+
##	*   
	"#	!	"
+#!!		
!	"#!#
#4
– 
	"
"
+#*7#%"		7

	!
	"
##	

7"#"	!	"

#
	+4
– 
#			
	##	
	"

	#	8
%#+
4
Patient. 
:"
	#	"	#!
3%3;#%	"
	
7<=4
Unknown. 
3 
 	
+#	*6#
%#!
	"
#4
Severity. 
	"
	0!!4!$6!0$ – 
3	
##	*   
	"%	"!	"

#
	4 Unknown. 
	"
#%#	###		#	
	#	8
	


#
4
Unknown. 
	"
#%#	##
	#%
"4 Unknown. 
	"	#
#
	!#
$

	#4
Unknown. 
	"

#

$#
	
%4
	"$	
%#7"#"	"
#	

#
4
Unknown. 
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3$
	"#
#!#
*+!
#$*84
No. 
3!*		"
+6"
	"
*#
$*%	"	"
	"+4
 
 !
 
	"##0*"	#	##$4
 

3'#
##	*
 
>	
 Not assessed in HD. 
	
#	* – 
2	0		#
##	* – 
	0
	#
##	* – 
3?
##	*#$   
+3	
 Not assessed in HD. 
#	#+
##	*
*
#7#	"%0
	


 – 
		+
##	*   
-
	

*# – 
+%	+
##	* – 
#+%	+
##	* – 
.+
##%>	%

!!
*6
@%	

	
	
Unknown. No information available. 
A
#B
##	*   
"7	+
#
	
*	
%!$4 No. 
"7	+
##
*
	#7#	"	#

#%#!#
	%#	#+#
#	4
No. 
'#+		"
%+	##	"		 
	
		#	#+	"
%
"
%+	#		
		4
In neuroleptic naive patients, Clozapine (n=7) vs. Placebo (n=11), mean differences 
(SD) after 30,day treatment: 5.7 (9.2) (better) 
% ,3.8 (7.7) (worse) p=0.02. 
2
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		
##	*
$
	"##
##
*#	
	"
%

##
##
*+
	#	
#!!

4
No. 
-
##%!!	 Unknown. 
#	#	# – 
"#
+
	
%
 
#
+
	
%
Not validated in HD. 
Lack of insight of patient may be a limitation. 
" %%	$#
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	
 
 
 
1. Brown RG, MacCarthy B, Jahanshahi M, Marsden CD. Accuracy of self,reported disability in patients with parkinsonism. 		
1989;46:955,9. 
2. Vugt JP, Siesling S, Vergeer M, Velde EA, Roos RA. Clozapine versus placebo in Huntington's disease: a double blind randomised 
comparative study. In; 1997. p. 35,9. 
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	
	
 
 
 
1
	"9
3
#	# 
	"+
+#!	"
4
Yes: 20 point earlier version, still in use (not HD).
1
 
10,point scale more commonly used.
2
 
!*#567"#"7

4 The 10,point version,
2
 as it is the one used in HD studies.
3,5
 

		8+
		
An ordinal scale that evaluates the level of assistance needed by patients to perform 10 
basic activities of daily living:  
Feeding, moving from wheelchair to bed and return, personal toilet, getting on and off 
toilet, bathing self, walking on level surface, ascend and descend stairs, dressing, 
controlling bowels, controlling bladder. 
 
	!!*	8#%4 Yes. 
	!+#	*!*	8#%4 Yes. 
 
	"#	!	"
##		
#!*#
+#


%
4
Yes. 


93	#	
	#	 5 minutes (personal judgment). 
 
 
	#	6
%#+6###
 Self,report and clinician. 
!###
0
	6#	
##%!
#
	#
#4
No. 
 
*#%"	#
#4 Copyright, but free for non,funded academic users. 
$7
	"
	
#
7#	4 https://eprovide.mapi,trust.org/instruments/barthel,index 
$
	"
#"#	"
%
%4 Yes. 
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Danish, Dutch, English, French, German, Italian for Italy, Norwegian, Portuguese, 
Russia, Spanish, Thai, Chinese, Japanese, Korean. 
3
	#

3		+
##	*
 
*!#	%
	#
8	# Yes, from a 20 to a 10 version. 
3-
+
##	*   
	"#	!	"
+#!!		
!	"#!#
#4
Yes. 
	"
"
+#*7#%"		7

	!
	"
##	

7"#"	!	"

#
	+4
N/A 
#			
	##	
	"

	#	8
%#+
4
Patient recall and clinician observation. 
:"
	#	"	#!
3%3;#%	"
	
7<=4
Last two days. 
3 
 	
+#	*6#
%#!
	"
#4
To measure severity. 
	"
	0!!4!$6!0$ For acute stroke, but not HD. 
3	
##	*   
	"%	"!	"

#
	4 Yes. 
	"
#%#	###		#	
	#	8
	


#
4
No. 
	"
#%#	##
	#%
"4 N/A 
	"	#
#
	!#
$

	#4
Yes, partially. 
	"

#

$#
	
%4
	"$	
%#7"#"	"
#	

#
4
No, only appropriate in later stages. 
3$
	"#
#!#
*+!
#$*84
No. 
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3!*		"
+6"
	"
*#
$*%	"	"
	"+4
 
 !
 
	"##0*"	#	##$4
 

3'#
##	*
 
>	

Assessed in HD 
 
(.2Well assessed in stroke, elderly patients and neurological rehabilitation. 
	
#	* Not assessed. 
2	0		#
##	* Not assessed. 
	0
	#
##	* Manifest HD, n=64, ICC=0.97. 
4
 
3?
##	*#$   
+3	
 Not assessed in HD. 
#	#+
##	*
*
#7#	"%0
	


Not assessed in HD 
		+
##	*   
-
	

*# N/A 
+%	+
##	* N/A 
#+%	+
##	* N/A 
.+
##%>	%

!!
*6
@%	

	
	
Good as a generic test, interesting in order to compare HD with other neurological 
disease populations. 
A
#B
##	*   
"7	+
#
	
*	
%!$4 No. 
"7	+
##
*
	#7#	"	#

#%#!#
	%#	#+#
#	4
No. 
'#+		"
%+	##	"		 
	
		#	#+	"
%"
%+
	#		
		4
, 
 
Page 197 of 253 Movement Disorders Clinical Practice
For Review Only
 151
		
##	*
$
	"##
##
*#	
	"
%

##
##
*+
	#	
#!!

4
No. 
 
-
##%!!	 Poor. 
#	#	#
Manifest HD, HD stage I – III, n=40, 86.3 (19.0). 
3
 
Pre,manifest HD (n=11), 100 (0), Manifest HD (n=64), 93 (12).
4
 

"#
+
	
% Generic scale, used in many studies. 
#
+
	
% No validation in HD. Rarely used in HD 
" %%	$#
 
 
	
 
 
1. Mahoney FI, Barthel DW. Functional Evaluation: The Barthel Index. 1965;14:61,5. 
2. Granger CV, Dewis LS, Peters NC, Sherwood CC, Barrett JE. Stroke rehabilitation: analysis of repeated Barthel index measures. 	
#'(1979;60:14,7. 
3. Zinzi P, Salmaso D, De Grandis R, Graziani G, Maceroni S, Bentivoglio A$% Effects of an intensive rehabilitation programme on 
patients with Huntington's disease: a pilot study. '(2007;21:603,13. 
4. Quinn L, Khalil H, Dawes H, Fritz NE, Kegelmeyer D, Kloos AD$% Reliability and minimal detectable change of physical 
performance measures in individuals with pre,manifest and manifest Huntington disease. #*	2013;93:942,56. 
5. Piira A, van Walsem MR, Mikalsen G, Nilsen KH, Knutsen S, Frich JC. Effects of a One Year Intensive Multidisciplinary Rehabilitation 
Program for Patients with Huntington's Disease: a Prospective Intervention Study. #/		2013;5. 
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	
	

 
!0	$:<!	#$:-
3
#	# 
	"+
+#!	"
4 No. 
!*#567"#"7

4
 

		8+
		
Perceptions of work function. 
HDWF is a brief self,assessment that may be used to monitor work function.  
 
It captures perceptions of work function as reported by individuals with pre,manifest 
HD and their companions. It asks questions related to work role limitations and effort, 
two components of work function that may be affected by cognitive, behavioral, and 
motor changes in people with pre,manifest HD. The HDWF contains 20 items.  
 
The response categories are on a seven,point Likert scale with verbal anchors only at 
the lowest end (1), “not at all like me”, and at the highest end (7) “very much like me”. 
The instrument includes a checklist for the employment level that best matches the 
worker’s current situation, and what workplace adjustments, if any, have been made. 
Higher scores on the HDWF indicate better function. 
 
	!!*	8#%4 N/A 
	!+#	*!*	8#%4 N/A 
 
	"#	!	"
##		
#!*#
+#


%
4
20 items scored on 7,point Likert scale.
1
 


93	#	
	#	 — 
 
 
	#	6
%#+6###
 Patient. 
!###
0
	6#	
##%!
#
	# Not applicable. 
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#4
 
*#%"	#
#4 — 
$7
	"
	
#
7#	4 — 
$
	"
#"#	"
%
%4 No. 
3
	#

3		+
##	*
 
*!#	%
	#
8	#
Literature review, review of existing measures, focus groups and interviews (expert 
evaluation and cognitive interviews with patients with pre,manifest HD and their 
companions.
1
 
3-
+
##	*   
	"#	!	"
+#!!		
!	"#!#
#4
Motor, behavioral, cognitive and compensatory strategies.
1
 
	"
"
+#*7#%"		7

	!
	"
##	

7"#"	!	"

#
	+4
Weighted toward work function impairment in pre,manifest HD.
1
 
#			
	##	
	"

	#	8
%#+
4
Unknown (unable to procure a copy of the scale). 
:"
	#	"	#!
3%3;#%	"
	
7<=4
Unknown (unable to procure a copy of the scale). 
3 
 	
+#	*6#
%#!
	"
#4
To detect work function ability.
1
 
	"
	0!!4!$6!0$ No. 
3	
##	*   
	"%	"!	"

#
	4 Unknown (unable to procure a copy of the scale). 
	"
#%#	###		#	
	#	8
	


#
4
Unknown (unable to procure a copy of the scale). 
	"
#%#	##
	#%
"4 No, cognitive interviews with HD participants were conducted to refine the questions. 
	"	#
#
	!#
$

	#4
Yes. 
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	"

#

$#
	
%4
	"$	
%#7"#"	"
#	

#
4
No, only for those in employment. 
3$
	"#
#!#
*+!
#$*84
Yes. 
3!*		"
+6"
	"
*#
$*%	"	"
	"+4
No. 
 !
 
	"##0*"	#	##$4 Yes. 

3'#
##	*
 
>	
 Not assessed in HD. 
	
#	* – 
2	0		#
##	* – 
	0
	#
##	* – 
3?
##	*#$   
+3	
 Assessed in HD. 
#	#+
##	*
*
#7#	"%0
	


No gold standard available. 
		+
##	*   
-
	

*# — 
+%	+
##	*
Pre,manifest (n=238) + Companion (n=70): HDWF X Endicott work productivity 
scale (r=,0.56); X Social Adjustment Scale self,report (r=,0.29); X Everyday cognition 
(r=,0.70).
1
 
#+%	+
##	* — 
.+
##%>	%

!!
*6
@%	

	
	
— 
A
#B
##	*   
"7	+
#
	
*	
%!$4 No. 
"7	+
##
*
	#7#	"	#
 No. 
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#%#!#
	%#	#+#
#	4
'#+		"
%+	##	"		 
	
		#	#+	"
%"
%+
	#		
		4
No. 
		
##	*
$
	"##
##
*#	
	"
%

##
##
*+
	#	
#!!

4
No. 
-
##%!!	 — 
#	#	# Total score (mean (sd)) for pre,manifest HD: 98.27 (18.59). 
1
 
"#
+
	
% Clearly described development process. 
#
+
	
%
Not used in studies outside the PREDICT group, difficulty in obtaining a copy for 
review. 
" #	
 
 
	
 
 
1. Brossman B, Williams JK, Downing N, Mills JA, Paulsen JS. Development of the Huntington disease work function scale. &
 
	2012;54:1300,8. 
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#	
 
	
	
 
 
 
1"
+#.+
	#
$	#%	1.$0

3
#	# 
	"+
+#!	"
4 No.
1
 
!*#567"#"7

4 N/A. 

		8+
		
Repeated monitoring for longitudinal assessment, of an inventory of the behavior in the 
later stages of the disease.
1
 
 
The BOSH contains 32 items in 3 subscales:  
1) Activities of daily living (ADL). 
2) Social–cognitive functioning, and  
3) Mental rigidity and aggression. Only the ADL component was considered.1 
 
	!!*	8#%4 Yes.
1
 
	!+#	*!*	8#%4
Yes. Severity by a graded statement expressed in terms of degree of autonomy or 
frequency of a behavior.
1
 
 
	"#	!	"
##		
#!*#
+#


%
4
Discrete (4 steps): no standardized response key for items.
1
 


93	#	
	#	
10 to 15 minutes with a mean of 14 minutes (for the full scale, including the 3 
components); possibly 3,4 minutes (divide total by number of valid items),
1
 (personal 
judgment). 
 
 
	#	6
%#+6###
 Clinician as observation,based (observations of the staff of the nursing home).
1
 
!###
0
	6#	
##%!
#
	# No training required. Instructions are printed on the questionnaire.
1
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#4
 
*#%"	#
#4 Public domain.
1
 
$7
	"
	
#
7#	4
Reinier Timman @ Erasmus Medical Center Rotterdam, Medical Psychology and 
Psychotherapy, P.O. Box 1738, NL,3000 DR Rotterdam, The Netherlands (e,mail: 
r.timman@erasmusmc.nl).
1
 
$
	"
#"#	"
%
%4 No, published in English but only tested in Dutch.
1
 
3
	#

3		+
##	*
 
*!#	%
	#
8	#
Yes. Two pilot questionnaires , both in Dutch ,  preceded the final version of the 
BOSH.  
1) Experts, psychologists of the specialized HD wards, reached consensus based 
on HD patient characteristics for the items of thefirst pilot. Consensus was 
reached on 11 characteristics of the HD patient according to the observations of 
nursing home staff: 1) inflexible behavior, 2) need for social care, 3) need for 
mental care, 4) need for physical care, 5) communication problems, 6) choking 
problems, 7) uncontrolled eating and drinking behaviors, 8) self,oriented 
behavior, 9) repetitive behavior, 10) aggressive behavior, and 11) inability to 
perform complex actions. Principal component analysis (PCA) revealed 6 
components: speech capability, mental rigidity– aggression, social–cognitive 
capacities, obsessive,compulsive behavior, voraciousness, and deterioration of 
ADLs.  
2) For the construction of a second version, the items were restructured in line 
with the 6 components that emerged from the first pilot. Twenty,four items 
with the highest loadings on each component selected on the premise that a 
large conceptual overlap was not present. Four items with lower component 
loadings, which were considered clinically essential aspects of HD, were added. 
These items involved the ability to stop current activities, information 
processing and memory, behavior when a fellow patient needs immediate help, 
and behavior when a fellow patient is helped first. Four items from the 
functional assessment subscale of the UHDRS were included. Experts reached 
consensus on these items that they considered essential to the manifestation of 
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HD. Ambiguous items, double questions and items with an overlap in the 
response possibilities, as well as items with gaps between answer possibilities 
were reformulated. The second version was administered to 84 patients in one 
Belgian and 3 Dutch nursing homes.  
3) For the third and final version administered in Dutch to 91 patients in the 4 
nursing homes, 32 items were reformulated to avoid overlap and gaps, as well 
as ambiguity, and presented in a more logical order. Ratings for outpatients and 
for tube,fed patients were introduced.
1
 
3-
+
##	*   
	"#	!	"
+#!!		
!	"#!#
#4
Yes, the ADL component has 9 items , going to the toilet, going to bed, mobility, 
comprehensibility through nonverbal communication, voice control and articulation, 
eating and drinking, washing and getting dressed, intelligibility, and choking while 
eating or drinking.
1
 
	"
"
+#*7#%"		7

	!
	"
##	

7"#"	!	"

#
	+4
No, it is adapted to late HD. 
#			
	##	
	"

	#	8
%#+
4
Clinician recall.
1
 
:"
	#	"	#!
3%3;#%	"
	
7<=4
Observation over previous two weeks.
1
 
3 
 	
+#	*6#
%#!
	"
#4
Monitor severity longitudinally (personal judgment). 
	"
	0!!4!$6!0$ No (personal judgment). 
3	
##	*   
	"%	"!	"

#
	4 Yes, the ADL subscale has 9 items (personal judgment). 
	"
#%#	###		#	
	#	8
	


#
4
No, but it requires consistency of the clinician over the past two weeks (note completed 
by nurses in testing) (personal judgment). 
	"
#%#	##
	#%
"4
These items have some overlapping responses that are not clearly differentiated: item 
2, regarding going to bed: needs "some assistance" vs just " needs assistance"; item 4, 
regarding going to the toilet: "some assistance vs "almost full assistance"; item 7, 
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regarding voice control: "affected" vs "bad" (personal judgment). 
	"	#
#
	!#
$

	#4
Yes (personal judgment). 
	"

#

$#
	
%4
	"$	
%#7"#"	"
#	

#
4
No, developed and tested in stage 3 and 4 Shoulson and Fahn's staging system (late 
stage).
1
 
3$
	"#
#!#
*+!
#$*84
Yes.
1
 
3!*		"
+6"
	"
*#
$*%	"	"
	"+4
No 
 !
 
	"##0*"	#	##$4 Yes.
1
 

3'#
##	*
 
>	
 Assessed in HD.
1
 
	
#	* Cronbach’s alpha (ADL Component) = 0.94 (Sample 1 and 2).
1
 
2	0		#
##	* N/A 
	0
	#
##	* Intraclass correlation coefficient (nurses) = 0.95.
1
 
3?
##	*#$   
+3	
 Assessed in HD.
1
 
#	#+
##	*
*
#7#	"%0
	


There is no gold standard, but no association with longer disease duration has been 
reported. There is an association with duration of care (beta:0.5, p=0.004) (personal 
judgment). 
		+
##	*   
-
	

*#
PCA and subscale supported by factor structure; VARIMAX rotation. The scree test 
resulted in the selection of a 3,component solution in both samples. (ADL, social–
cognitive capabilities, and rigidity–aggression).
1
 
+%	+
##	* Not assessed.
1
 
#+%	+
##	* Not assessed.
1
 
.+
##%>	%

!!
*6
@%	

Not good at the time of writing, further testing is required.
1
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	
	
A
#B
##	*   
"7	+
#
	
*	
%!$4 No, only at stages 4 and 5 (personal judgment). 
"7	+
##
*
	#7#	"	#

#%#!#
	%#	#+#
#	4
Yes (personal judgment). 
'#+		"
%+	##	"		 
	
		#	#+	"
%"
%+
	#		
		4
Not tested over time. 
		
##	*
$
	"##
##
*#	
	"
%

##
##
*+
	#	
#!!

4
No data. 
-
##%!!	 No data. 
#	#	# No data. 
"#
+
	
%
Easy and quick to apply, attempts to fill a gap in late HD stages where specific scales 
are not available (personal judgment). 
#
+
	
%
Limited testing of measurement properties. Lacks external validation and translation 
into other languages (personal judgment). 
" #	
 
	
 
 
1. Timman R, Claus H, Slingerland H, van der Schalk M, Demeulenaere S, Roos RA$% Nature and development of Huntington disease 
in a nursing home population: The Behavior Observation Scale Huntington (BOSH). "
	2005;18:215,22. 
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	
	
 
 
B"#&#

	#+	*	#+#	#!
#*#+#%
0
3
#	# 
	"+
+#!	"
4 Yes
1
 
!*#567"#"7

4 Unknown.  

		8+
		
An inventory of informant based items to assess activities of daily living and 
instrumental activities of daily living, i.e. functional performance, of Alzheimer’s 
disease (AD). 
 
The ADCS,ADL was the first ADL scale to be developed for use specifically in 
clinical trials with people with AD across the range of severity. 
 
Scores on the 24,item ADCS,ADL range from 0 to 78, higher scores reflect greater 
competence. 
 
	!!*	8#%4 Yes. 
	!+#	*!*	8#%4 Yes. 
 
	"#	!	"
##		
#!*#
+#


%
4
Discrete. 


93	#	
	#	 – 
 
 
	#	6
%#+6###
 Caregiver or clinician. 
!###
0
	6#	
##%!
#
	#
#4  
 
*#%"	#
#4 Copyright. 
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$7
	"
	
#
7#	4
Alzheimer’s Disease Cooperative Study 
 
$
	"
#"#	"
%
%4 — 
3
	#

3		+
##	*
 
*!#	%
	#
8	#
Galasko et al. (1997)
2
 selected the items for the ADCS,ADL from a pool of 45 items 
thought to be relevant to the target population on the basis of existing scales and 
clinical experience. 
An item was included in the final measure fit the criteria. 
It was performed either premorbidly or at baseline by >90% of participants (showing it 
was applicable to the target group), had a kappa agreement statistic at 1–2 months of 
>0.4 (indicating good test,retest reliability), had a significant correlation with MMSE 
score (indicating appropriate scaling and validity), and showed decline over 12 months 
in at least 20% of participants (indicating validity and sensitivity to change). 
 
3-
+
##	*   
	"#	!	"
+#!!		
!	"#!#
#4
– 
	"
"
+#*7#%"		7

	!
	"
##	

7"#"	!	"

#
	+4
– 
#			
	##	
	"

	#	8
%#+
4
It can be completed by a caregiver in questionnaire format, or administered by 
a clinician/researcher as a structured interview with a caregiver. 
:"
	#	"	#!
3%3;#%	"
	
7<=4
‘In the past 4 weeks’.
2
 
3 
 	
+#	*6#
%#!
	"
#4
Severity. 
	"
	0!!4!$6!0$ Not for HD. 
3	
##	*   
	"%	"!	"

#
	4 Yes. 
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	"
#%#	###		#	
	#	8
	


#
4
– 
	"
#%#	##
	#%
"4 – 
	"	#
#
	!#
$

	#4
– 
	"

#

$#
	
%4
	"$	
%#7"#"	"
#	

#
4
– 
3$
	"#
#!#
*+!
#$*84
No. 
3!*		"
+6"
	"
*#
$*%	"	"
	"+4
 
 !
 
	"##0*"	#	##$4 No. 

3'#
##	*
 
>	
 Not assessed in HD. 
	
#	* – 
2	0		#
##	* – 
	0
	#
##	* – 
3?
##	*#$   
+3	
 Not assessed in HD. 
.+
##%>	% – 
#	#+
##	*
*
#7#	"%0
	


  
		+
##	*   
-
	

*# – 
+%	+
##	* – 
#+%	+
##	* – 
.+
##%>	%

!!
*6
@%	

No information available in HD. 
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	
	
A
#B
##	*   
"7	+
#
	
*	
%!$4 No. 
"7	+
##
*
	#7#	"	#

#%#!#
	%#	#+#
#	4
No. 
'#+		"
%+	##	"		 
	
		#	#+	"
%"
%+
	#		
		4
No. 
Treatment Effects on Efficacy Outcomes at Week 26 in RCT of latrepirdine vs 
Placebo: −1.8 vs. −0.8.
3
 
		
##	*
$
	"##
##
*#	
	"
%

##
##
*+
	#	
#!!

4
No. 
-
##%!!	 Unknown. 
#	#	#
Mean Scores (SD) in RCT of latrepirdine Group (n = 200) 59.6 (14.1) vs Placebo 
Group (n = 203) 59.3 (14.4). 
3
 
"#
+
	
% Unknown. 
#
+
	
% Not validated in HD. Used in a single clinical trial. 
" #	3
 
	
 

1. Fish J. Alzheimer’s Disease Cooperative Study ADL Scale. In: Kreutzer JS, DeLuca J, Caplan B, eds. Encyclopedia of Clinical 
Neuropsychology. New York, NY: Springer New York, 2011:111,12. 
2. Galasko D, Bennett D, Sano M, Ernesto C, Thomas R, Grundman M$% An inventory to assess activities of daily living for clinical 
trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. 8		1997;11 Suppl 2:S33,9. 
3. Dorsey ER. A randomized, double,blind, placebo,controlled study of latrepirdine in patients with mild to moderate huntington disease: 
HORIZON investigators of the huntington study group and european huntington's disease network. In; 2013. p. 25,33. 


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	
	
 


O#<#
##	#!6"P$
O#<$
3
#	# 
	"+
+#!	"
4 There is the full version also (DASH). 
!*#567"#"7

4 Quick DASH. 

		8+
		
The purpose of the QuickDASH is to use 11 items to measure physical function and 
symptoms in people with any or multiple musculoskeletal disorders of the upper limb. 
The QuickDASH is a widely used reference of self,reported disability.  
http://www.rehabmeasures.org/Lists/RehabMeasures/DispForm.aspx?ID=1267 


	!!*	8#%4 No. 
	!+#	*!*	8#%4 Yes. 


	"#	!	"
##		
#!*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+#


%
4
Discrete (5 steps). 


93	#	
	#	
10 minutes. 
http://www.rehabmeasures.org/Lists/RehabMeasures/DispForm.aspx?ID=1267 


 
	#	6
%#+6###
 Patient 
!###
0
	6#	
##%!
#
	#
#4
No training required. 
http://www.rehabmeasures.org/Lists/RehabMeasures/DispForm.aspx?ID=1267 
 


*#%"	#
#4
Free of charge. Sole property of the Institute for Work & Health.  
NOTE: some uses require the issue of a license (Commercial or profit publications) 
http://dash.iwh.on.ca/conditions,use?n=quickdash 
Page 212 of 253Movement Disorders Clinical Practice
For Review Only
 166
$7
	"
	
#
7#	4 http://dash.iwh.on.ca/conditions,use?n=quickdash 
$
	"
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3		+
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*!#	%
	#
8	# Yes. 
3-
+
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	!
	"
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
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
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Patient. 
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	
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%#!
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Severity. 
	"
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3	
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
#
	4 Yes (personal judgment). 
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	
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No (personal judgment). 
	"
#%#	##
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"4 Yes: subjective judgment without concrete anchors (personal judgment). 
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#
	!#
$
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Abstract 50 
Limitation of functional ability is a major feature of Huntington’s disease (HD). The 51 
International Parkinson and Movement Disorder Society (MDS) commissioned the 52 
assessment of the clinimetric properties of clinical measures of functional ability in HD to 53 
make recommendations regarding their use based on standardized criteria appraisal of the 54 
use and clinimetric properties of clinical measures of functional ability that have been 55 
applied in HD studies and trials to date, to make recommendations regarding their use 56 
based on standardized criteria. After a systematic literature search, we included a total of 57 
29 clinical measures grouped into two categories: 1) performance*based measures (e.g., 58 
balance, walking, reaching/grasping), and 2) rating scales. Three performance*based measures 59 
are rated as “recommended”: the Tinetti Mobility Test for screening of fall risk and for 60 
severity assessment of mobility in patients with manifest HD (up to stage III); the Berg 61 
Balance Scale for severity of balance impairment; and the Six*Minute Walk Test for 62 
assessment of walking endurance (severity) in HD subjects with preserved ambulation. No 63 
rating scale targeting functional ability reached a “recommended” status, either for screening 64 
or severity measurement.  65 
 66 
The main challenges identified in this review include applying widely accepted conceptual 67 
frameworks to the identified measures, the lack of validation of clinical measures to detect 68 
change over time, and absence of validated measures for upper limb function. Furthermore, 69 
measures of capacity or ability to perform activities of daily living had ceiling effects in 70 
people with early and pre*manifest HD. We recommend that the MDS prioritize the 71 
development of new scales that capture small but meaningful changes in function over time 72 
for outcome assessment in clinical trials, particularly in earlier stages of HD. 73 
  74 
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Introduction 75 
The ability to perform daily life activities depends on the integration of motor, cognitive and 76 
behavioral functioning. These domains are progressively impaired in Huntington’s disease 77 
(HD). A measure of functional ability based on key life activities is thus an attractive outcome 78 
in clinical studies, namely for treatment trials.  A single measure pertinent to patient overall 79 
function would be useful to capture changes occurring simultaneously in the different 80 
symptom domains in HD. Further, functional ability measures are valued as an outcome for 81 
drug development by regulatory agencies.
1
 82 
 83 
There is a need to identify and critically appraise the measurement properties of clinical 84 
measures currently used to capture functional ability in people with HD to inform optimal 85 
application in clinical research. The scope of this review is directed towards physical function 86 
and includes a wide spectrum of clinical measures from those capturing motor tasks such as 87 
walking and balance ability, to those assessing the ability to perform activities of daily living 88 
(ADL). 89 
 90 
The current review aims to provide recommendations and identify gaps in the use of these 91 
clinical measures for HD populations. The current review aims to provide 92 
recommendations and identify gaps in the use and validation of these functional 93 
measures that have been used in HD studies and trials to date. Such information will 94 
inform the field, identifying where additional testing of measurement properties or 95 
development of new measures may be required. 96 
 97 
METHODS 98 
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We followed the methodology proposed by the MDS Committee on Rating Scales 99 
Development described elsewhere,
2
  and includes i) Organization and Critique Process, ii) 100 
Selection of Scales, iii) Inclusion/Exclusion for Review, iv) Criteria for Rating Scales 101 
Recommendation (Table 1). For selection of measures, the keywords selected for this review 102 
were “Huntington*” OR ”Westphal variant” OR “juvenile Huntington*”, and the terms 103 
“scale” OR “questionnaire” OR “index” OR “measure” as well as keywords: “function”, 104 
“activit* daily li*”, “capacity”, “*ability”, “impairment”. Manuscripts published before 105 
October 17, 2016 were retrieved using the above search strategy and thoroughly screened by 106 
the chair of the sub*committee (T.A.M.) to ascertain which clinical measure had been used in 107 
each study. To aid our categorization of clinical measures in this review, we applied a widely 108 
accepted classification of the health components of functioning and disability: The 109 
International Classification of Functioning, Disability and Health (ICF).
3
 The ICF defines: 1) 110 
impairments or problems in body function or structure such as a significant deviation or loss, 111 
2) activity or the execution of a task, 3) and participation or involvement in a life situation.
3
 112 
By consensus, we included clinical measures in this review that captured a) activity or the 113 
execution of a task or tasks, and b) participation or involvement in a life situation. 114 
 115 
Identified Clinical Measures and Their Utilization in Clinical Research 116 
A total of 47 potentially relevant clinical measures were identified. After screening for 117 
exclusion criteria with abstract screening and in*depth review, a total of 29 measures were 118 
included and divided in performance*based measures defined as functional assessments based 119 
on the live performance of a task (e.g., balance, walking, reaching/grasping) (n=17) and rating 120 
scales (n=12) capturing the assessment of various aspects of functional ability based on recall. 121 
(See 	
	
	 for more details) 122 
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 123 
Critique of Measures of Functional Ability  124 
We provide a summary description of the performance*based measures and rating scales 125 
classified as “recommended” or “suggested”. See 	
	
	 for a full 126 
description of all clinical measures included for full review, including those that were 127 
included in the “suggested 		” or “listed” categories. 128 
1) Performancebased measures 129 
“RECOMMENDED” 130 
Tinetti Mobility Test (TMT) 131 
The TMT is a 16*item clinician*administered performance measure, which consists of balance 132 
and gait subscales that measure static and dynamic balance. It was originally developed to 133 
measure balance and screen for risk of falls in the elderly,
4
 but has been used in other patient 134 
populations.
4
 During the 10*15 minute test, patients perform a series of balance and walking 135 
tasks and are rated on a 0*2 scale based on qualitative assessment of performance.
4
 The TMT 136 
has been used in several studies in HD and demonstrates good test*retest reliability in early*, 137 
mid*, and late stage HD (ICC = 0.8*0.9).
5, 6
 Higher scores in the TMT correlated positively 138 
with spatio*temporal measures of gait (e.g., velocity r=0.68; stride length r=0.74), with higher 139 
scores of the UHDRS*FAS (r=0.44) and UHDRS*TFC (r=0.42) and lower scores of the 140 
UHDRS*Total Motor Score (TMS) (r=*0.59).
5, 7, 8
 The TMT has demonstrated responsiveness 141 
in the context of interventional studies, including an intensive rehabilitation intervention 142 
program in patients with HD stages I–III (pre= 15.97, post=20.79, p<0.001), 
9
 and off* (17.09 143 
± 4.04) and on*tetrabenazine (19.91 ± 3.53, p<0.02) study of manifest HD patients. 
10
 144 
However, there was no significant change in the TMT following a video*based balance 145 
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training program.
11
 A cut*off score of 21 has 74% sensitivity and 60% specificity in 146 
identifying fallers in HD.
5
 147 
Recommendation: The TMT is “recommended” for assessment of mobility in patients with 148 
manifest HD (up to stage III) and “recommended” for screening for risk of  falls . 149 
 150 
The Berg Balance Scale (BBS) 151 
The BBS is a performance measure consisting of 14 subtests of various activities related to 152 
balance that takes 10 to 15 minutes to complete. These activities include static postures (e.g., 153 
sitting, standing), transitions (e.g., sitting to standing, transferring between chairs), and 154 
challenging positions (e.g., standing with eyes closed). Quality of performance for each item 155 
is scored using a 4*point scale, with higher scores indicating better balance, and a possible 156 
maximum score of 56. Although originally developed to measure balance in older people, the 157 
BBS has been widely used in HD, although it has limited applicability in non*ambulatory HD 158 
due to the nature of the activities.
6, 12*19
 The available clinimetric data show that it has good 159 
test*retest reliability in both pre*manifest (ICC=0.86) and manifest HD (ICC=0.96).
6
 A 160 
minimal detectable change (MDC) of 5 in people with manifest HD has been reported.
6
 161 
Convergent validity has been reported between the BBS and the HD*ADL (r= *0.47), UHDRS 162 
TFC (r=0.60
19
 and r=0.43
7
),  UHDRS*FAS (r=0.48)
7
, and UHDRS*TMS (r= *0.55).
7
 163 
Sensitivity to change following treatment withdrawal (tetrabenazine) was reported in a small 164 
open*label cohort.
14
 A cut*off score of 40 was used as a cut*off to predict being a “faller” for 165 
a plotted probability of  60%.
86
 166 
Recommendation: The BBS is “recommended” for assessing severity of balance impairment 167 
in ambulatory HD. The BBS is “suggested” for screening for fall risk, as no sensitivity or 168 
specificity data for falls have been reported. 169 
Page 223 of 253 Movement Disorders Clinical Practice
For Review
 O
nly
9 
 
 170 
The SixMinute Walk Test 171 
The Six*Minute Walk test measures how many meters an individual can walk in 6 minutes. 
20, 
172 
21
 Two practice tests are recommended, but not always carried out.
22, 23
 It has been applied as 173 
a measure of endurance in neurological conditions, in contrast to shorter walk tests that 174 
generally measure velocity of walking speed.
6
 It has been used in patients with pre*manifest 175 
and manifest HD, although it cannot be used for those who are non*ambulatory. Excellent 176 
test*retest reliability data have been reported in pre*manifest (ICC = 0.98) and manifest HD 177 
(IC=0.94; early and late HD = 0.97, and mid*stage HD=0.86).
6, 24
 It is unclear how values 178 
discriminate among pre* and manifest HD severity levels as there is an overlap of the 95% 179 
confidence interval (CI) around mean values in both groups. On the other hand, values may 180 
separate pre* and early manifest HD from mid* to late stage HD.
6
 Low correlations have been 181 
reported between the Six*Minute Walk Test and the UHDRS*FAS,
7
 but higher correlations 182 
are not expected due to the limited overlap of the measure constructs. The MDC has been 183 
reported to be 39.2 meters for pre*manifest HD and 86.6 meters for manifest HD (range: 56.6 184 
to 126.1 meters).
6
 185 
Recommendation: The Six*Minute Walk test is “recommended” for the assessment of 186 
walking endurance (severity) across HD severity. 187 
 188 
“SUGGESTED”  189 
Timed ‘up and go’ Test (TUG)190 
The TUG is a simple and quick (<3 minutes) to use test that assesses mobility, balance and 191 
risk of falls. Although not specifically developed for use in HD, it has been used in pre*192 
manifest and manifest HD to measure severity and screen for risk of falls.
13, 25
 The TUG 193 
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measures the time it takes for a patient to rise from a chair, walk three meters, turn around, 194 
walk back to the chair, and sit down. One practice test is recommended before scoring the 195 
test.
25
 Mean scores for patients with manifest HD range from 9*17 seconds 
6, 19
 and a cut*off 196 
score of  14 seconds has been reported to predict being a “faller” for a plotted probability of  197 
60%.
13
 Test*retest reliability in HD has been shown to be excellent (ICC = 0.93 [pre*manifest 198 
HD], 0.96 [manifest HD]) and the MDC has been reported to be 1.34 seconds in pre*manifest 199 
HD and 2.98 seconds in manifest HD.
6
 The TUG was not statistically significantly correlated 200 
with the UHDRS*TMS or the UHDRS*TFC and correlated weakly with the UHDRS*FAS (r= 201 
*0.33, p<0.01).
7
 Pre*post scores improved by an average of 1.3 seconds following training in a 202 
non*controlled study, that follow within the MDC.
26
 The TUG can be used in early to mid*203 
stages of HD, but not in pre*manifest or late stage HD, and it appears to be sensitive to 204 
disease progression, but does not discriminate between disease subtypes.
6, 19, 27
 205 
Recommendation: The TUG is “suggested” for assessing severity of balance and mobility, 206 
and “suggested” for screening for fall risk. There is no sensitivity or specificity data for the 207 
reported cut*off point. Construct validity needs further assessment. 208 
 209 
The TenMeter Walk Test 210 
The Ten*Meter Walk test is a quick and easy performance*based measure that assesses 211 
walking speed. The score is based on the mean of two tests. The test has been used in pre*212 
manifest and manifest HD with varying walking speeds: self*paced
6, 7, 24
 and fast*paced.
6, 17, 24
 213 
Test*retest reliability has been shown to be good in both pre*manifest and manifest HD for the 214 
self*paced version.
6
 For the self*paced version there was no correlation with the UHDRS*215 
TMS, a weak correlation was reported with the UHDRS*FAS (r=0.35, p<0.01) and none with 216 
the UHDRS*TFC.
7
 The fast*paced version of the test has been shown to be sensitive to 217 
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change following a rehabilitation program intervention in mild to moderate manifest HD 218 
(improvement of 0.27 m/s).
17
 Following a 12*week community*based exercise program there 219 
was no significant change for either the self* or fast*paced versions.
24
 220 
Recommendation: The Ten*Meter walk test is “suggested” for assessing walking speed in 221 
manifest HD. The vast majority of the clinimetric data sustaining this recommendation was 222 
obtained using the self*paced version. 223 
 224 
Four Square Step Test (FSST) 225 
The FSST is a 5*10 minute test of dynamic balance. The FSST clinically assesses a patient’s 226 
ability to step over canes positioned in a cross shape in three directions in a set sequence: 227 
forward, sideways, and backwards. The test was not specifically developed for use in HD, but 228 
has been used in three studies in HD, and some clinimetric data are available in pre* and 229 
manifest HD.
6, 8, 11
 Test*retest reliability has been reported to be excellent in pre*manifest HD 230 
(ICC=0.91), and good in manifest HD (ICC=0.78).
6
 The MDC is higher in manifest HD 231 
(15.2) than in pre*manifest HD (1.9).
6
 Moderate to high correlation has been shown between 232 
the FSST and the ABC (Pearson correlations: –0.57; p<0.05); the Tinetti Mobility Test 233 
(Pearson correlations: –0.67, p<0.01), and gait velocity (Pearson correlations: –0.69, 234 
p<0.01).
8
 The FSST has not been shown to be sensitive to change in one exercise study.
11
 235 
Recommendation: The FSST is “suggested” for assessing dynamic balance in HD  236 
 237 
Mini Balance Evaluation Systems Test (MiniBESTest) 238 
The Mini*BESTest is a 14*item measure of dynamic balance. Derived from the Balance 239 
Evaluation Systems Test (BESTest), factor analysis was used for item reduction to include 240 
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dynamic balance only, and to improve clinical utilization.
28
 Administered in 10*15 minutes, 241 
the Mini*BESTest evaluates domains of postural control. Each question is rated from normal 242 
to severe and scored between 0 and 2, for a maximum total score of 28 points. The test was 243 
not specifically developed for HD, and has not been assessed comprehensively across stages 244 
of HD. The test is not applicable to non*ambulatory patients.
29
 Convergent validity has been 245 
shown between the Mini*BESTest and the ABC (r
2
=0.45), UHDRS*TFC (r
2
=0.75) and 246 
UHDRS*TMS (r
2
=0.68).
29
  247 
Recommendation: The Mini*BESTest is “suggested” for assessing severity of balance 248 
impairment in HD, as it has been used in only one study with a very small sample size across 249 
HD severity with a partial clinimetric assessment. 250 
 251 
Physical Performance Test (PPT) 252 
The PPT is a ten*minute test, which assesses multiple domains of physical function using 253 
observed performance of tasks that simulate activities of daily living (ADL) of various 254 
degrees of difficulty (writing, eating, dressing, walking, and climbing stairs).
30
 Each activity 255 
is timed and rated from 0*4, a higher score indicating better physical performance. The test 256 
was not specifically developed for use in HD, but some of its clinimetric properties have been 257 
assessed in both pre* and manifest HD. Good test*retest reliability has been recorded in pre*258 
manifest HD (ICC = 0.76) and excellent reliability in manifest HD (ICC=0.95). The MDC 259 
was 3 points for pre*manifest HD and 5 points for manifest HD respectively.
6
 Convergent 260 
validity has been reported in manifest HD between the PPT and the UHDRS*TMS (r = *0.41 261 
n=63, p<0.01), the UHDRS*FAS (r = 0.59, p<0.01); and the UHDRS*TFC (r= 0.48, 262 
p<0.05).
7
A ceiling effect has been reported in pre*manifest HD.
6
 It has also been shown to be 263 
valid in patients with cognitive impairment.
31
 264 
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Recommendation: The PPT is “suggested” for assessing severity of impairment of physical 265 
function in performance of tasks that simulate activities of daily living.  266 
 267 
Sixcondition Romberg test  268 
The six*condition Romberg test is a 5*minute easy to administer performance*based measure 269 
of balance developed in the context of myelopathies and neuropathies with an associated 270 
sensory dysfunction. The amount of time the patient maintains the position without loss of 271 
balance for 6 standard conditions is recorded, for a maximum score of 180 seconds. Higher 272 
scores indicate better balance. The test has been used in some HD studies 
6, 10
 and the 273 
clinimetric data available document good test*retest reliability in both pre*manifest 274 
(ICC=0.73) and manifest HD (ICC=0.89).
6
 The six*condition Romberg test is a valid tool that 275 
can be used across all stages of HD provided that the patient is ambulatory as it is likely to 276 
have floor effects in non*ambulatory patients.
6
 It has not been shown to be sensitive to change 277 
in treatment.
10
 People with pre*manifest HD (158.8±22.2) have higher scores (better 278 
performance) than those with manifest HD (70.0±41.1).
6
 279 
Recommendation: The Six*Condition Romberg Test is “suggested” for assessing severity of 280 
balance impairment in HD 281 
 282 
2) Rating Scales 283 
 284 
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 “SUGGESTED”: 285 
The Unified Huntington's Disease Rating Scale (UHDRS)  Total Functional Capacity 286 
(TFC) 287 
The UHDRS*TFC is part of a multi*component rating scale originally designed to 288 
prospectively evaluate all patients with HD and individuals at risk for HD.
34
 It assesses 289 
capacity as opposed to actual performance, and consists of a 5*item interview between a 290 
clinician, and the patient and a person familiar with the patient’s functioning. It takes < 5 291 
minutes to complete and covers basic activities of living: occupation, handling finances, 292 
domestic responsibilities, ADLs such as eating, dressing, bathing, and level of care (home or 293 
facility).  A higher score indicates better functional capacity. The UHDRS*TFC has been used 294 
in pre*manifest and manifest HD populations in multiple observational studies and 295 
randomized controlled trials.
34*51
 The TFC total score can be categorized into Shoulson and 296 
Fahn HD stages.
35
 There is evidence of excellent inter*rater reliability, but only for a modified 297 
version of the UHDRS*TFC that is filled by patient or the caregiver (ICC = 0.96, 95% CI: 298 
0.92, 0.98).
52
 Data from multiple studies suggest good convergent validity with other 299 
components of the UHDRS assessing the functional domain and quality of life, and good 300 
divergent validity with motor disability, cognitive deficits and behavioral problems.
19, 29, 34, 53*
301 
60
 Extensive data from multiple observational studies and clinical trials suggest sensitivity to 302 
change over time.
34*51, 61*70
 There appears to be a ceiling effect for early stage HD and a floor 303 
effect for late stage HD.
41
 304 
Recommendation: The UHDRS*TFC is “suggested” for assessing severity of limitation in 305 
functional capacity in HD, because it lacks core clinimetric data, namely, test*retest reliability 306 
and internal consistency to reach a “recommended” status. 307 
 308 
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The UHDRS  Functional Assessment Scale (FAS) 309 
The UHDRS*FAS is an extensively*used checklist that is also part of the UHDRS. It is a 310 
clinician*administered questionnaire with 25 items which screen an individual’s capacity to 311 
complete specific tasks, enables the clinician to assess severity, and make longitudinal 312 
assessments.  The questionnaire takes 5*10 minutes to complete. It is considered an extension 313 
of the TFC and is more detailed in certain tasks.
34
 A total score is obtained by giving 1 point 314 
to all “yes” replies, and a higher score indicates better functioning.
34
 It has been used in 315 
multiple observational studies and randomized controlled trials in manifest HD populations.34, 316 
39, 43, 48, 49, 61, 62, 64, 68, 70-72 The UHDRS*FAS has been shown to have high internal consistency 317 
(Cronbach's α = 0.95).
34
 There are no available data on test*retest reliability or inter*rater 318 
reliability. Good convergent validity with other components of the UHDRS has been shown, 319 
as well as with motor disability, cogniti e and behavioral deficits.
34, 54, 58, 73, 74
 The UHDRS*320 
FAS has been shown to be sensitive to change over time in several studies.
34, 39, 42, 43, 48, 49, 61, 62, 
321 
64, 68, 70, 71, 75
 322 
Recommendation: The UHDRS*FAS is “suggested” for assessing severity of limitation in 323 
functional capacity in HD, because it lacks core clinimetric data, namely, test*retest or inter*324 
rater reliability data. 325 
 326 
The UHDRSIndependence Scale (IS) 327 
The UHDRS*IS is a clinician*rated tool which assesses the actual reduction of functional 328 
ability.
76
 It is rated from 100 (no special care needed) to 0 (tube*fed, total bed care) and takes 329 
approximately 5 minutes to complete. It has been used in many observational and randomized 330 
controlled trials in manifest HD populations.
34, 41*44, 46, 48*50, 61, 62, 64, 68, 70
 The clinimetric data 331 
available show that the UHDRS*IS has moderate inter*rater reliability but in a modified 332 
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version that compares caregiver report with patient self*report (ICC = 0.71, 95% CI: 0.48, 333 
0.85). 
59
 Good correlation with other components of the UHDRS, as well as motor disability, 334 
cognitive and behavioral deficits has been shown in various studies.
34, 54, 58, 59, 73, 76*79
 Data 335 
from clinical trials suggest sensitivity of the UHDRS*IS to change over time and across 336 
disease stages.
35, 41
 337 
Recommendation: The UHDRS*IS is “suggested” for assessing severity of limitation in 338 
functional ability in HD, because reliability data are missing, including test*retest, inter*rater 339 
(for clinicians) and internal consistency. 340 
 341 
HD Activities of Daily Living (HDADL) 17item 342 
The HD*ADL Scale, which was developed to be used specifically in HD, was modeled after 343 
the Scale for Instrumental Activities of Daily Living.
80
 It is a 17*item informant*completed 344 
instrument on which the informant rates the HD patient’s ability to perform specific activities, 345 
covering the domains of personal care, household care, work and money, social relationships, 346 
and communication. For each item, the patient is rated on a 4*point scale, from normal to 347 
severely limited. The total score of the HD*ADL scale ranges from 0 (normal) to 51 (maximal 348 
limitation). 
53
 With exception of one study,
19
 the scale has not been used outside the John 349 
Hopkins group who developed it. Clinimetric testing show that the HD*ADL has good 350 
internal consistency (α = 0.91*0.96).
53
 Principal Component Analysis showed that four factors 351 
account for 72*74% of the total variance.
53
 Convergent validity has been shown between the 352 
total score of the HD*ADL and the UHDRS*TFC (r= *0.89, p < 0.001), as well as all factors 353 
except for the domain “family relationships”.
53
 Multiple correlations have been reported with 354 
measures of cognitive impairment or disease duration.
53, 81, 82
 The HD*ADL failed to show 355 
differences in treatment compared to placebo.
83, 84
 356 
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Recommendation: The HD*ADL is “suggested” for assessing severity of limitation in ADL, 357 
because studies of the scale’s clinimetric properties are lacking, namely for any type of 358 
reliability. 359 
 360 
ActivitySpecific Balance Scale (ABC) 361 
The ABC is a patient*completed scale that measures balance confidence and fear of falling.  362 
The ABC can take anywhere between 6 and 30 minutes to complete depending on the patient. 363 
Although it is a self*administered scale, a face*to*face interview is recommended.
85
 Patients 364 
rate their balance confidence on a visual analogue scale ranging from 0 to 100 for each of 16 365 
tasks, with higher scores indicating greater confidence and lower fall risk. The ABC has been 366 
widely used in HD,
8, 17, 29
 including a modified ABC*UK version adapted for British culture,
86
 367 
but normative cut*off scores have not been established. The clinimetric data available show 368 
that the ABC has good test*retest reliability (ICC = 0.74 95% CI: 0.58, 1.0),
8
 the MDC has 369 
been reported to be 27.33.
8
 There is good convergent validity with the Mini*BESTest,
29
 and 370 
the modified ABC*UK can distinguish between non*fallers and fallers in HD (mean score: 371 
77.5 vs. 47.9).
86
 While the ABC has been shown to be sensitive to change in one study (after a 372 
9*month multidisciplinary rehabilitation program),
87
 no change was reported in two other 373 
studies.
8, 17
 374 
Recommendation: The ABC is “suggested” for assessing level of self*reported balance 375 
confidence in HD. The use of the ABC is challenged since the lack of insight is a feature of 376 
HD. 377 
 378 
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Rivermead Mobility Index (RMI) 379 
The RMI is an extension of the Rivermead Motor Assessment Gross Function Scale that 380 
assesses functional mobility and was initially developed for stroke. The RMI consists of 14 381 
questions about a patient’s ability to perform a wide range of activities, from turning over in 382 
bed to running, and one observation (standing for 10 seconds without any aid). Questions are 383 
answered as “able” (1 point) or “unable” (0 points) and summed to produce a total score, with 384 
a higher score reflecting better mobility.
88
 Test*retest reliability has been reported in HD (ICC 385 
in pre*manifest HD= 0.81; ICC in manifest HD = 0.94).
6
 A MDC of 2 points has been 386 
reported in manifest HD; ceiling effects are present in pre*manifest HD.
6
 There are no cut*off 387 
scores established in HD, which limits its use as a screening tool in HD. 388 
Recommendation: The RMI is “suggested” for the assessment of severity of restriction of 389 
mobility 390 
 391 
Discussion 392 
The current critique focuses on performance*based measures and rating scales assessing 393 
functional ability in HD. In the process of developing the protocol for the review, we found a 394 
variety of scale constructs and other instruments that could be associated with various aspects 395 
of function ability. We used the ICF
3
 as a conceptual framework related with function to 396 
guide us in the inclusion or exclusion of rating scales based on the adequacy of their 397 
constructs. Nevertheless, we realize that the measures included in this review represent a wide 398 
variety of concepts that apply across the components of the ICF. Many of these measures 399 
included multiple ICF components, raising challenges for conceptual clarity and subsequent 400 
evaluation of validity. For example, balance can be seen as a sheer impairment but it can 401 
overlap with activity/function, depending how it is captured in a given clinical measure. 402 
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Considering these aspects, we decided to be inclusive and included balance measures in this 403 
review. Ultimately, there is a need for clear definitions for future measures to better enable 404 
validation and application in HD populations. 405 
We identified and included a range of performance*based measures. We provide a 406 
“recommended” level of recommendation for both screening purposes related to balance, gait 407 
and/or risk of falling, and measurement of severity of impairment of specific motor tasks. 408 
There were however no “recommended” performance*based measures covering upper limb 409 
function. It is also important to emphasize that the majority of these performance measures 410 
were only used in ambulatory HD populations.  411 
We did not identify a rating scale that met the criteria for “recommended”. If further testing of 412 
the measurement properties is conducted, we agreed that UHDRS sub*scales related with 413 
function (TFC, FAS and IS) are in a good position to reach the higher level of 414 
recommendation in the future due to their widespread use, specific development in HD and 415 
known initial clinimetric development. For each one of these scales, important shortcomings 416 
in terms of clinimetric development were identified, namely incomplete reliability testing, 417 
which precluded a “recommended” level of recommendation. In addition, these scales have 418 
limiting ceiling effects that make them unattractive for use in earlier stages of HD. For 419 
example, the use of these UHDRS subscales in a clinical trial conducted with the purpose of 420 
capturing a disease*modifying effect in an ideal HD subgroup of individuals with a high level 421 
of functional ability would be performed at the cost of a prohibitively long trial duration to 422 
capture a meaningful change. Rating scales such as Functional Rating Scale Task force for 423 
pre*Huntington Disease 2 (FuRST*pHD)
89, 90
 are currently being developed and are expected 424 
to fill this gap in the future.  425 
The assessment of functional ability as a clinical outcome is deemed essential for therapeutic 426 
approval by regulatory agencies such as the FDA.1 In this regulatory context, it is important to 427 
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emphasize that there was no recommendation for the purpose of measuring change over time 428 
in individuals or groups of subjects in either a pure observational study or in an interventional 429 
context. In fact, formal testing for responsiveness was missing in all the included rating 430 
scales, and important measures of reliability such as test*retest had not been evaluated in 431 
many cases. Along the same lines, there is a need to assess the validity of each rating scale in 432 
different subgroups of patients with HD, as these data are presently lacking for most of the 433 
measures. The knowledge about responsiveness and its variation in important patient 434 
subgroups can determine sample size requirements and help with the interpretation of clinical 435 
trial results, respectively.1 436 
Looking towards the future, the committee concludes that there are well*validated 437 
performance*based measures that capture motor tasks such as walking or balance, but further 438 
clinimetric development is required for performance*based measures that capture other 439 
aspects of physical function such as upper limb function. For rating scales, including those 440 
evaluating activities of daily living, we are cannot endorse an existing scale at a 441 
“recommended” level and encourage the MDS to prioritize the development of such 442 
instruments for clinical care and research purposes. Further validation of HD*specific scales 443 
such as the UHDRS*TFC are warranted, as is the development of new scales designed to have 444 
greater sensitivity in capturing function in HD subgroups who have a relatively well 445 
preserved functional ability as measured by currently available rating scales.  446 
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